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Abstract  
Antiretroviral therapy (ART) drugs have increasingly been shown to contribute 
significantly to the morbidity of HIV positive patients exposed to them. This is more 
so with increasing survival of HIV patients since the introduction of ART. Individual 
ART drugs have been associated with specific organ related toxicities and clinical 
toxicity syndromes, such as Tenofovir disoproxil fumarate (TDF) association with 
risk of kidney injury. The pattern, pathogenesis, as well as key genetic and non-
genetic determinants of some these clinical ART drug-related toxicity syndromes 
remains uncertain.   
This thesis sets out to investigate the pattern/clinical/laboratory phenotype of ART 
drug related kidney toxicity, including the role of emerging biomarkers that define 
and most accurately diagnose these toxicity syndromes. I, and my co-reviewer (Dr 
Sudeep Pushpakom, University of Liverpool) then systematically reviewed, and 
carried out a metanalysis of current evidence with regards to the reported genetic 
association between TDF exposure, and risk of kidney related toxicity. I further 
explored a population cohort (MHRA) to ascertain the pattern/clinical phenotype of 
kidney injury following exposure to TDF in these cohorts of patients, and determine 
any discernible variation as it relates to what has been reported from clinical trial 
cohorts. Additionally, I examined the association between single nucleotide 
polymorphisms (SNPs) of genes encoding protein transporters involved in the bio-
disposition of TDF in HIV positive patients, with kidney injury following exposure 
to ART drugs.  
Specifically, in an attempt to explore the pattern of kidney injury in HIV patients 
exposed to TDF in observational databases, I reviewed 407 yellow card records of 
HIV positive patients on TDF who developed kidney injury and had them reported to 
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MHRA. One hundred and six (106) of these satisfied criteria for TDF related kidney 
injury, of which 53 (50%) had features of kidney tubular dysfunction (KTD), 35 
(33%) were found to have features of glomerular dysfunction, and 18 (17%) had 
Fanconi syndrome. The median TDF exposure was 316 days (IQR 120-740). The 
incidence of hospitalisation for TDF kidney adverse effects was high, particularly 
amongst patients with features of Fanconi syndrome. 
To define the clinical phenotype (including surrogate markers) of ART drug related 
kidney injury, I recruited and investigated the diagnostic utility of KIM-1/Cr 
(corrected for urinary creatinine excretion) in a 114 cross-sectional cohort of HIV 
positive patients (104 “on” ART, and 10 “off” ART drugs). HIV positive patients 
both “on” and “off” ART drugs had a higher baseline median (≥4.17ng/mg), upper 
quartile (≥8.6ng/mg), and urinary KIM-1/Cr levels compared to either non-HIV 
positive normal volunteers (0.39 ng/mg), or those with acute kidney injury in the 
general population (0.57 ng/mg). By ROC analysis, KIM-1/Cr (ng/mg) had a higher 
AUC (0.67) compared to either serum creatinine (0.64) or eGFR (0.31) in diagnosing 
patients with kidney injury. When median KIM-1/Cr (≥4.17ng/mg) was utilised as a 
marker of kidney injury, TDF exposure (per year increase) was significantly 
associated with risk of kidney injury in multivariate analyses (Odds ratio 1.4, CI 
1.02-1.82, P = 0.034). In a candidate gene based-based approach, I subsequently 
investigated the strength of association between the ABCC2 and ABCC10 sub-family 
genetic polymorphisms, and risk of kidney injury in HIV positive patients exposed to 
TDF. Patients with KTD had higher current CD4 cell counts, lower eGFR, and were 
less likely to possess the genotype CC at position 24 of the ABBC2 (MRP2, 
rs717620) gene. In multivariate analysis, genotype CC at position 24 of the ABBC2 
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gene (odds ratio =0.05, 95% confidence interval = 0.003-0.7, P = 0.027) was 
significantly associated with reduced risk of KTD. 
These findings support the observation that ART dugs are a leading cause of organ 
specific morbidity including TDF related kidney injury. Furthermore, we have 
demonstrated higher thresholds of low molecular weight proteinuria (including 
RBPCR and KIM-1/Cr) following TDF exposure, in HIV positive patients with 
normal kidney function (normal eGFR). 
Further work is required in prospective patient populations to validate some of the 
findings in our study including the potential diagnostic utility of low molecular 
weight proteinuria (KIM-1 and RBP) in these cohorts of patients. Additionally, there 
will be need to explore the clinical significance of possession of the ABCC2 24CC 
(rs717620) and ABCC10 SNP’s in an appropriately defined patient population 
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1.0 Introduction to HIV virus and antiretroviral drugs 
This is a review of the biology of HIV virus, and the spectrum of ART drugs 
currently in use as part of various treatment regimens.  
1.1 Historical context 
The clinical syndrome of acquired immune deficiency syndrome (AIDS) is caused 
by a retrovirus called human immune deficiency virus (HIV) (1). Since the initial 
characterisation of this disease in 1981 and subsequent discovery of the virus 
responsible for it in 1983, there have been unrelenting efforts at understanding of 
both the biology of the disease/virus and pharmaco-therapeutic targets to exploit for 
treatment. Despite initial conflicting reports as to the likely origin of the virus, the 
most accepted explanation is its transmission from chimpanzees to humans (2). 
Chimpanzees carry a virus (simian immunodeficiency virus) that bears some 
biological similarities with HIV and this was probably transmitted to humans 
following contact between hunters and infected simian blood (2).  
1.1.1 Global epidemiology of HIV/AIDS 
The World Health Organisation (WHO) 2013 Global Health Observatory data 
reported a case burden of about 78 million people have been infected with the HIV 
virus since the beginning of the epidemic, with a case mortality of about 39 million 
people thus far (3). It presents a global adult (15-49 years) prevalence of about 0.8 % 
(0.7-0.8%), with the highest prevalence rate in sub-Saharan Africa (4.5%). This 
accounts for about 71% of the case burden worldwide (3). Although the number of 
AIDS cases in the United Kingdom (UK) has fallen considerably since its peak 
between 1993-1995, the 2013 “HIV in the United Kingdom report” (4) puts the case 
burden of people living with the disease at 98,400 (93,500-104,300), figure 1.1. This 
gives an overall prevalence rate of about 1.5 per 1000 population (1.0 in women, and 
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2.1 in men). Of these, one in five (21,900, 22% [18%- 27%]) were undiagnosed and 
unaware of their infection (5). Figure 1.1 
 
Figure 1.1: People living with HIV (both diagnosed and undiagnosed): UK, 2012 [Adapted 
from HIV and AIDS Reporting Section, Centre for Infectious Disease Surveillance and 
Control] (5) 
1.1.2 HIV Transmission 
HIV is transmitted through a number of routes including sexual intercourse, infected 
needles, blood transfusion, vertically from infected pregnant mothers, and during 
delivery or breastfeeding (6). There is marked geographical variability in these 
various modes of transmission. In Europe/UK for example, migration of infected 
patients from sub-Saharan Africa contributes substantially to the case burden there, 
accounting for about 36% of all new cases in 2006 (5). In sub-Saharan Africa 
however, heterosexual transmission accounts for a significant number of new cases 
(7). Regardless of the mode of transmission, without treatment (in some individuals) 
the clinical syndrome of AIDS develops in about 10 years from index infection (7), 
with death supervening following opportunistic infections. It is noteworthy that 
despite a rise in number of new cases, the mortality due to HIV/AIDS has recently 
continued to witness a sustained decline (figure 1.2) 
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Figure 1.2: Annual new HIV/AIDS diagnoses and deaths: UK, 1981-2012 [Adapted 
from HIV and AIDS Reporting Section, Centre for Infectious Disease Surveillance 
and Control] (5) 
1.1.3 Pathophysiological mechanisms 
HIV is a lentivirus (retroviridae family) that exhibits tropism for immune-competent 
cells especially helper CD4+ T-lymphocytes, macrophages, and microglial cells (in 
the central nervous system) (8). Of the two characterised variants (HIV types 1 and 
2), HIV-1 cause most of the infections in Europe and has further sub-divisions into 
sub-types called clades (8). The latter is associated with significant and important 
geographical variation (9). HIV infection begins by initial entry of the virus into 
CD4+cells and other immune competent cells mediated by interaction of its 
glycoprotein envelope receptors (gp120) with receptors on surface of these cells (10). 
However, other variants including M-tronic strains of HIV-1 and non-syncytial 
inducing strains (R5 viruses) initiate infection by additionally utilising a membrane-
spanning β-chemokine co-receptor (CCR5) for this initial entry (11). Syncytial 
inducing viruses (X4 viruses) on the other hand utilise the α-chemokine co-receptor 
(CXCR4) for entry into both CD4+ T-cells and macrophages (11). Following fusion 
of the viral envelope proteins with receptors on immune competent cell, HIV 
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genomic RNA is released into the cell following uncoating of the viral core (12). 
Reverse transcription involves use of viral RNA polymerase to catalyse synthesis of 
viral DNA copies (utilising deoxyribonucleoside triphosphates [dNTPs] substrates) 
from genomic viral RNA (13). Reverse transcription leads to formation of viral pre-
integration complex (PIC) which is made of viral DNA copies as well as other host 
proteins (13). This then migrates to the nucleus where viral Integrase enzyme 
catalyses the integration of viral DNA into host DNA (14). Viral mRNAs are 
subsequently transcribed, and translocated to the protein assembly complex in the 
host cell cytosol. HIV viral structural polyproteins thus generated are cleaved by 
protease enzyme in the course of the maturation process. This result in formation and 
budding off of infective mature HIV virions to initiate new cycle of infection of other 
immune-competent cells (15). Figure 1.3 shows schematic representation of the HIV 
replication process.  
 
 
 
 
 
 
 
Figure 1.3: Schematic representation of pathogenetic mechanisms involved in HIV 
infection [adapted from Engelman A et al (16)]. 
1.2 Antiretroviral drug classes  
The various stages of HIV replication cycle present excellent therapeutic targets that 
have allowed for development of drugs that have evidently increased the life 
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expectancy of people infected with HIV (17). These groups of drugs are called 
antiretroviral therapy drugs, and are made of a number of drug classes used in 
various combinations/regimens (of 2 to 3 drugs). And as suggested by systematic 
studies, they have been adapted by national and international treatment guidelines 
(18). The choice of a particular drug class or regimen is dependent on a number of 
factors including ease of administration, adverse effects profile, genotype testing 
profile, associated co-morbidities, as well as food/drug-drug interactions amongst 
others (18). The following is a review of the pharmacokinetic, pharmacodynamics, 
and peculiar chemical characteristics of these drugs that may play a role or help to 
explain some of their reported adverse reactions. 
1.2.1 Nucleoside reverse transcriptase inhibitors (NRTI’s) 
These represent the first class of drugs approved for treatment of HIV/AIDS and 
continue to form an integral part of most national and internationally recommended 
treatment regimen (18). They include Zidovudine (AZT), Didanosine (DDI), 
Zalcitabine (DDC), Stavudine (d4T), Lamivudine (3TC), Emtricitabine (FTC) 
Abacavir (ABC), Adefovir, and Tenofovir disoproxil fumarate (TDF) (Figure 1.4). 
They are administered as pro-drugs but undergo cellular kinase mediated 
phosphorylation upon host cell entry to exert their anti-viral effect on HIV RNA viral 
synthesis (19). NRTI’s have no 3’hydroxy group at their 2’ deoxyribosyl sugar 
moiety (20). The implication of this is that the critical 3’5’ phosphodiester bond 
between them and incoming 5’ nucleosides triphosphates cannot be formed leading 
to chain termination. Both RNA-dependent DNA, and DNA-dependent DNA 
synthesis are affected resulting in inhibition of synthesis of both (positive and 
negative) strands of HIV proviral DNA (20, 21). They are competitive substrate 
inhibitors of HIV reverse transcriptase (22). Additionally, they also inhibit 
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mitochondrial DNA (mtDNA) polymerase gamma (γ) resulting in depletion of 
mtDNA precursor pool and a number of adverse effects including accumulation of 
lactic and pyruvic acids (23).  
 
 
 
 
 
 
 
Figure 1.4: Molecular structure of some nucleoside reverse transcriptase inhibitors 
(NRTI’s)  
 
Long-term experience with these agents meant that our understanding of their 
adverse effects profile is relatively better and more comprehensive than newer 
agents. Whilst no class effects have been attributed to any of their adverse effects, 
the underlying pathophysiological mechanism in all of them appears to be varying 
degrees of mitochondropathy (22). In a mechanistic study, Hein et al (24) showed 
that down-regulation of mitochondrial thymidine kinase 2 (TK2), and 
deoxyguanosine kinase (dGK) by NRTIs such as DDI might represent the 
mechanism through which they mediate their toxicity (24). This was thought to result 
in depletion of mitochondrial DNA (mtDNA) precursor pools, depletion of mtDNA, 
mitochondropathy, and long-term organ/system specific adverse effects (22, 24). 
Amongst reported adverse effects associated with this class of drugs includes 
  7 
pancreatitis, hepatitis, lactic acidosis, bone marrow suppression, myopathy 
Cardiomyopathy, and lipodystrophy (24).  
Reports thus far have linked NRTI associated pancreatitis mostly to exposure to DDI 
and D4T (25, 26). The underlying pathophysiological mechanism is still uncertain 
but a role for carriage of the cystic fibrosis trans-membrane conductance regulator 
(CFTR) has been suggested (27, 28). Indeed a pharmacogenetic study exploring this 
role in HIV positive patients showed that up to 40% of patients with 
hyperamylasemia and clinical pancreatitis were carriers of the CFTR gene (28). The 
overall incidence of clinically relevant pancreatitis related to NRTI’s is variable. An 
evaluation of patient level data of 20 clinical trials by Reisler et al reported an overall 
incidence of about 0.85/100 persons/year (29). The rates of pancreatitis were highest 
amongst patients on Indinavir/DDI/D4T regimen (29).   
1.2.2 Non-nucleoside reverse transcriptase inhibitors (NNRTI’s) 
Despite reported treatment-limiting adverse effects, these agents have formed an 
integral part of the backbone of most ART treatment regimen (18, 30) (Figure 1.5). 
They act primarily by prevention of HIV replication through non-competitive 
inhibition of the multifunctional HIV-1 reverse transcriptase (RT) enzyme (31). This 
subsequently affects the catalytic activity of the enzyme resulting in inhibition of 
viral replication (31). Other secondary modes of action have been suggested for 
NNRTI’s affecting various stages in the reverse transcription process including their 
effect on RT RNase-H (32). Rnase-H is part of the multifunctional complex of the 
RT enzyme, other functional units includes RNA-dependent DNA polymerase and 
DNA-dependent DNA polymerase activities. Despite their disparate chemical 
identities, NNRTI’s bind to the same site on reverse transcriptase enzyme, with each 
NNRTI interacting with different amino acid in the binding pocket (31). They show 
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diverse pharmacokinetic profiles resulting in differences in efficacy, differing levels 
of drug exposure (AUC), and marked inter-individual and intra-individual variability. 
They are generally well absorbed following oral administration (33, 34, 35).  
Nevirapine (NVP) is a dipyridodiazepinone (11-cyclopropyl- 5, 11-dihydro-4-
methyl-6H-dipyrido [3, 2-b: 2’, o; 3’-e] [1, 4] diazepin- 6-one) compound. It is 
rapidly and almost completely absorbed within 4 hours following oral administration 
of a 200mg tablet (33). Despite the effect of food on its absorption, NVP achieves a 
bioavailability of 93%, 63% of this is bound to plasma proteins particularly albumin 
(33). Kidney impairment have no significant effect on plasma NVP concentration, 
therefore no dose adjustment is advised in patients with mild, moderate or severe 
kidney failure (33). However in patients with end stage kidney disease on dialysis, 
there is a significant decrease in AUC of NVP. Consequently administration of a 
supplementary dose of 200mg of NVP is advised after each dialysis session in these 
cohorts of patients (33). Whilst caution is advised with administration of NVP in 
patients with mild to moderate liver injury, its use in those with severe liver injury 
(child-Pugh class C) should be avoided (33).  
Efavirenz (EFV) has excellent bioavailability and is extensively distributed in body 
fluids (34). It exhibits linear pharmacokinetics with a prolonged half-life of 40- 50 
hours at steady state (34). This makes administration of single daily oral dose 
possible, resulting in attainment of steady state within 2 weeks of initiation of 
therapy. An insignificant concentration of EFV (>1%) is excreted unchanged in 
urine. EFV causes mild transaminitis (2%), with caution advised when used as part 
of ART regimen in patients with mild to moderate liver injury (34). Its use is 
however contraindicated in patients with severe liver injury (child-Pugh class C) 
(34).  
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Etravirine (ETR) is a second generation NNRTI (diarylpyrimidine) which inhibits 
viral replication through binding directly to HIV reverse transcriptase disrupting the 
active site of the enzyme (35). Food significantly affects its absorption reducing its 
AUC by about 50%, therefore the drug is advised to be taken after meals (35). Owing 
to limited excretion in urine, dose adjustment is not advised in patients with kidney 
failure (35). Mild to moderate hepatic impairment results in about 18% reduction in 
some PK parameters including AUC and Cmin with no effect on its dosing regimen 
(35). However, its use in patients with severe liver impairment is contraindicated 
because of limited data (35). 
 
Figure 1.5: Molecular structure of some clinically useful non-nucleoside reverse 
transcriptase inhibitors 
 
Rilpivirine is a second-generation diarylpyrimidine NNRTI that has found increasing 
utility in ART naïve HIV positive populations (36). After oral administration, it 
reaches peak plasma concentration in about 45- hours with a prolonged terminal half-
life of 35-55 hours (37). Recent studies including report by Lamorde et al in 
Ugandan patients have demonstrated a definite food effect on the PK of this drug 
(38). Concomitant administration with low to moderate fat diet was shown in this 
study to result in enhanced serum level of the drug (38). Rilpivirine is metabolized 
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principally by CYP3A4, making it susceptible to significant drug interactions 
following co-administration with drugs that induce or inhibit activity of this enzyme 
(37, 38). This could affect the clearance of the drug with risk of virological failure. It 
is therefore advised to not be co-administered with avid CYP3A4 inducing drug 
classes such as the Rifamycins [Rifampicin, Rifabutin] (37). Despite its recent 
incorporation into national and international treatment guidelines, a number of 
treatment emergent adverse effects have been reported in patients exposed to it. It 
has been shown to cause increase in serum creatinine without demonstrable change 
in measured eGFR (by formulas utilising non-creatinine based variables) (39). 
Rilpivirine has been suggested to inhibit multidrug anion transport organic cation 
transporter 2 (OCT2), thereby blocking the transport of creatinine from kidney 
capillaries into kidney tubular cells (39).  
1.2.3 HIV Protease inhibitors 
Since their discovery in 1996 (40), HIV protease inhibitors (PI’s) have form a crucial 
part of most ART treatment regimen (18). They essentially target viral maturation by 
competitive inhibition of HIV protease enzyme (aspartyl protease) that plays a 
crucial role in cleavage of proteolytic precursors (Gag and Pol polyproteins) into key 
structural viral proteins (40). Consequently, this results in inability to combine these 
HIV viral particles into mature HIV virus (40). Despite early assurances regarding 
their efficacy and safety, a number of factors have limited the use of some of them as 
combination ART (cART). These include dose-dependent drug toxicities (41), 
relatively short half-life (requiring increasing dosing and high pill burden), and food 
interaction potentially impacting on their AUC with risk of virological failure (41), 
(42, 43). PI’s are highly bound to plasma proteins, with 99% of Ritonavir (RTV) (41) 
and 86% of Atazanavir (ATV) bound to plasma proteins (41, 42). Ritonavir (as a 
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booster), Darunavir, Atazanavir, and boosted Lopinavir (in resource-limited settings) 
are currently the most widely used PI’s in the HIV/AIDS therapeutics (41). Owing to 
factors highlighted above (including dose related adverse effects), RTV in particular 
is currently limited to use only as a booster for increasing serum concentration of 
concomitantly administered PI’s or other drugs (41, 43). It is a powerful inhibitor of 
CYP3A4 (a ubiquitous and highly polymorphic enzyme that metabolizes PI’s and a 
significant number of other drugs) (41). This subsequently results in increased 
(boosted) serum concentration of the co-administered drugs (41). The exploitation of 
this pharmacogenetic interaction in ensuring favorable virological outcomes 
unfortunately contributes significantly to some of the clinical phenotype of PI-related 
inadvertent treatment-limiting adverse effects. The range of PI related adverse effects 
are protean, but amongst the most widely reported toxicity syndromes includes, 
interstitial nephritis, Indinavir (IDV) induced hyperbilirubinemia, and dyslipidemias 
(44). Unlike the uniformity of their primary mechanism of action (i.e. Inhibition of 
cleavage of key structural proteins), the mechanism of PI related adverse effects is 
diverse. These range from inhibition of renal tubular transport proteins (such as 
OAT1, OAT3, MRP3, MATE) by RTV; to decrease solubility of ATV in urine 
(especially in setting of alkaline pH) resulting in interstitial nephritis; as well as 
significant pharmacogenetic interaction highlighted earlier (44, 45).    
1.2.4 Entry inhibitors  
HIV-1 primarily utilizes CD4 cell surface receptors as primary targets for entry into 
immune competent cells. Additionally, it also exploits a complex of other cell 
surface chemokine co-receptors, including C-C chemokine receptor type 5 (CCR5), 
and C-X-C chemokine receptor type 4 (CXCR4) amongst others (46).  This leads to 
release of HIV-1 viral core into the cytosol, and subsequent downstream processes 
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leading to viral replication (46). Fusion or entry inhibitors target and block the 
binding of HIV gp120 envelope to CCR5/CXCR4 chemokine receptors by 
allosterically inducing a conformational change in these receptors (46). Consequent 
upon this, HIV-1 viruses are therefore classified into CCR5 trophic (R5-trophic) or 
CXCR4 trophic (R4 trophic) viruses depending on whether they utilize the 
corresponding chemokine co-receptors to gain entry into immune competent cells. A 
tropism test to ascertain specific viral chemokine co-receptor preference is often 
advised before initiation of therapy with entry inhibitors (47). Amongst clinically 
characterized entry inhibitors includes Maraviroc (MVC) and Cenicriviroc (CVC). 
The latter is a dual CCR2/CCR5 inhibitor (48). Maraviroc (figure 1.6) is a potent, 
selective, CCR5 entry inhibitor, which has demonstrated excellent efficacy and 
safety profile in a number of clinical trials (49, 50). It is principally metabolized by 
CYP3A4 and therefore vulnerable to drug interactions, resulting in significant 
changes to its AUC and risk of therapeutic failure. Advisedly, its dose for example 
should be increased from 300mg twice daily to 600mg twice daily when co-
administered with EFV, due to the significant induction of its metabolism by EFV 
(51). MVC is increasingly evolving as a once daily elegant option for a cohort of 
HIV positive patients requiring a Nucleoside-sparing regimen (52). What has limited 
its utilization in this regard has been lack of robust pharmacokinetic data for such 
combination (53). A recent seminal report by Mora-Peris et al observed no short-
term efficacy/safety concerns for a once daily nucleoside-sparing regimen comprised 
of 800mg/100mg/150 mg of Darunavir/Ritonavir/Maraviroc respectively (54). It is 
noteworthy however that this study was limited by its relatively small sample size (N 
= 11). Caution and closer monitoring is advised when switching to MVC especially 
from EFV based regimen, owing to risk of reduced MVC serum concentration (from 
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CYP3A4 induction by EFV) (55) and consequent risk of therapeutic failure. This 
effect may be sustained for several days because of long half-life of EFV (40-55 
hours). Although clinical experience with MVC is still accruing, a range of adverse 
effects has been associated with it. These include upper respiratory tract infections, 
fever, rash, hepatotoxicity and reactivation of herpes infection (54, 55). Despite 
concerted attempts thus far, no specific CXCR4 inhibitor has been found to be useful 
in HIV pharmacotherapy.  
 
Figure 1.6: Molecular structure of Maraviroc 
1.2.5 Integrase strand transfer inhibitors (InSTI’s) 
Raltegravir and Elvitegravir were the first to be marketed amongst this class of novel 
ART agents in both ART naïve and treatment experienced HIV positive patients (56, 
57). It’s second in class (Dolutegravir) received market authorisation (MA) in 2013 
(58). They act principally by targeting Integrase, the key enzyme that catalyses 3’ 
end processing as well as DNA and strand transfer (59). This selective effect on 
strand transfer has been further clarified to involve an initial selective binding of 
Integrase to DNA-strand complex, and subsequent interaction with the two critical 
magnesium ions cofactors on both of the viral DNA/enzymes active sites (60). This 
dual but separate interaction with the Integrase enzyme, and the DNA of the virus 
makes the InSTI’s unique amongst other classes of ART drugs. There remains 
uncertainty regarding the absolute bioavailability of Raltegravir owing to its variable 
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PK, but maximal serum concentration is observed after approximately 3 hours with a 
terminal half-life of about 9 hours (61). It requires twice daily dosing (62), with 
concomitant food ingestion significantly reducing AUC of the drug. Brainard et al 
(61) reported a reduction in its AUC by as much as 46% in patients on fatty meals 
(62). Various reports have suggested uridine diphosphate glucoronyltransferase 1A1 
(UGT1A1) as the key enzyme involved in Raltegravir metabolism (63). UGTIA1 also 
play a major role in metabolism of Dolutegravir with limited additional metabolism 
by CYP3A4 (58). SNPs of both UGT1A1, and CYP3A4 have thus far been shown to 
have significant impact on AUC of Raltegravir. This effect is less so but still 
significant for Dolutegravir (58). 
Both Raltegravir and Dolutegravir have been shown to be safe and efficacious in a 
number of systematic studies involving various HIV cohorts including ART naïve, 
and treatment experienced patients (58, 62). The lack of comparable biological 
human homolog to the strand transfer step catalysed by HIV virus may account for 
some of the excellent tolerability of InSTI’s, as well as their limited adverse effects 
profile. Both Dolutegravir (64), and Cobicistat-boosted-Elvitegravir (65) have been 
associated with increase in serum creatinine with no effect in intrinsic kidney 
function. Dolutegravir and Cobicistat (COBI) have been shown to be non-
pathological inhibitors of the organic cation transporter 2 (OCT2), which is involved 
in uptake of creatinine from the kidney tubular capillaries into the tubule cells and 
subsequently secreted into the tubular lumen (65, 64, 66). This results in elevation of 
serum creatinine and decrease in creatinine clearance without change in true eGFR. 
Additionally, COBI is a well-established inhibitor of multidrug and toxin extruder 
protein 1 (MATE1). This transporter is located at the apical membrane, and is 
  15 
responsible for efflux of creatinine and other substrates from the proximal tubular 
cells into the tubular lumen and urine (67).  
1.3.0 Epidemiological perspectives of ART drug related adverse effects 
Reporting of ART related drug toxicities are influenced by patient’s socio-economic 
status, including study setting (observational or systematic studies), adverse events 
adjudication tools employed amongst other factors (68). These and other factors 
beyond the scope of this thesis have been suggested to account for marked variability 
in reported prevalence rates of ART drug related ADR’s (68). Even amongst 
systematic studies, reported prevalence rates of ART related drug toxicities show 
marked variability (69). Despite guideline recommendation for grading and reporting 
of ADRs (70), this variability in reporting and lack of standardization have persisted 
(70). This has been attributed to a number of factors including differing sponsor 
identities, and non-uniformity of study outcome measures employed (70). Current 
adjudication algorithms for ADR assessment and interpretation in the general 
population derived primarily from the seminal work of Naranjo et al (71), who 
pioneered the Naranjo ADR probability scale.  Proven efficacy and safety in 
randomised controlled clinical trials have always served as the standard for selection 
of various ART drugs into guideline recommended treatment regimen (18). Adverse 
effects reported from these studies and the controlled populations they study 
therefore represent an important component of the adverse events case burden of 
these drugs. It is however pertinent to note that post-marketing surveys (phase IV) 
captures other components of adverse effects morbidity not reported or limited by the 
relatively short observational period of systematic studies. Despite the inclusion of 
drug adverse effects reporting in the consolidated standards of reporting trials 
(CONSORT) statement (72), inadequate and partial reporting has been observed to 
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persist in a number of disease morbidities including HIV/AIDS. Consequent upon 
this, an extension of the CONSORT statement (73) was formulated specifically 
addressing issues with reporting of drug related adverse events (AE’s). How this 
change has impacted on overall reporting quality remains unclear. In an attempt to 
further clarify on these recommendations and improve on ADR reporting in HIV 
patients recruited into clinical trials, Carr et al (74) suggested a number of key 
monitoring algorithms for improvement of AEs reporting in these studies. Recent 
prospective studies have adopted some of these recommendations, but the overall 
impact of this is still unknown. Additionally, study design appears (by systematic 
bias) to influence the reporting of ADR’s. Randomised industry funded controlled 
clinical trials for example tended to report almost all spectrums of ADRs (including 
mild, moderate or severe), in contrast to non-profit studies that have emphasized on 
reporting serious adverse events only (69). The implication of this has been 
disproportionately higher burden of mild AE’s, with severe AE’s inappropriately 
reported with a lesser prevalence burden (69).   
The patho-physiology of adverse reactions attributable to ART drugs are a legion. 
They include drug-drug interactions, subject cytokine profile, immune hyper 
activation, genetic susceptibility as well intrinsic physiological changes induced by 
putative components of the drugs (75). Metabolism of some ART drugs such as PI’s 
by the ubiquitous and highly polymorphic cytochrome P450 enzymes systems makes 
drug-drug interactions an important contributor to the phenotype of PI related 
adverse events in patients exposed to them (41).    
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1.3.1.0   Factors impacting on prevalence and burden of ART drug related 
Toxicity 
1.3.1.1  Gender 
In the general population as in HIV positive patients on ART, gender has been 
reported as an important predisposing factor contributing to the development, 
severity, as well as the resulting clinical phenotypes of adverse reactions following 
exposure to these drugs (76, 77). Metanalysis of randomised controlled clinical trials 
of ART drugs in HIV patients including that by the food and drug administration 
(FDA) in the USA have failed to demonstrate any significant pharmacodynamic 
differences in response to these agents (78). However, despite the paucity of studies 
significantly powered ab initio to ascertain the role of gender in ART drug related 
adverse effects, data from both systematic and observational studies have reported 
higher prevalence rates of ART drug related ADRs in females than males (79). This 
is largely driven by data from studies exploring PK differences between males and 
females (80, 81). This is exhaustively summarised in table 1.1. Whilst the exact 
mechanism of gender in influencing the risk of ART related adverse effects remains 
unknown, total body weight, pharmacokinetics, and hormonal differences in men in 
comparison to women (amongst others) have been suggested as key determinants 
(81). Epidemiologically, there is likely to be underestimation of the exact prevalence 
rates of ART drug induced adverse events in women (82). This is so because until 
recently, women have represented relatively lower percentage of patients recruited 
into systematic studies to ascertain the efficacy and safety of ART drugs (82). In the 
AIDS Clinical Trials Group (ACTG) cohort of 11909 study participants for example, 
only 6.7% are women (82). Furthermore, despite changes to regulatory clinical trial 
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guidelines on gender enrolment into clinical trials, current enrolment of women into 
these studies still remains sub-optimal and has been estimated at about 20% (75).  
It is noteworthy that PK of second generation NNRTI’s such as Etravirine showed no 
significant gender related differences. Similarly, (perhaps largely driven by limited 
experience with these agents), no significant gender related PK differences have been 
reported with either InSTI, or entry inhibitors. The pharmaco-epidemiology of these 
agents however potentially could change as real-world experience with them 
becomes more established.
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Table 1.1: Studies exploring the role of gender in pharmacokinetics of antiretroviral therapy (ART) drugs 
 
Study 
 
ART drug 
class 
ART drug PK 
characteristics 
Gender difference Clinical toxicity phenotype Comment 
Anderson et al (83)  
NRTI 
Zidovudine (AZT) 
Lamivudine (3TC) 
Significantly higher concentration of both 
AZT and 3TC levels of intracellular 
triphosphate in females (reported ratios of 
2.3 and 1.3 for AZT and 3TC respectively).  
Risk of AZT and 3TC adverse drug 
reactions (ADR’s) 
It is noteworthy that unlike other ART drugs, 
for NRTI’s, intracellular phosphorylated 
triphosphate levels rather than plasma 
concentration correlates with risk of adverse 
effects.  
Stretcher et al (84) 
 
NRTI AZT  Reported higher intracellular levels of AZT 
triphosphate in females  
  
Moore et al (85) NRTI  Didanosine (DDI) Higher incidence of DDI related ADR’s in 
women. Additionally women have a higher 
likelihood of DDT adjustment or cessation 
of therapy than men  
  
Burger et al (86) NNRTI’s Efavirenz (EFV) drug 
levels 
60% Higher EFV serum levels than male 
cohorts (86) 
Increased susceptibility to EFV 
toxicity and virological failure (87). 
Also higher risk of discontinuation of 
therapy due to toxicity (88) 
Burger et al (86) reported EFV serum 
concentration of 4.0mg/L and 2.8mg/L in 
females and males respectively. Other studies 
including 2NN data support this finding (89) 
La Porte et al (90) NNRTI Nevirapine (NVP) Higher median NVP concentration (6.7mg/l) 
in females compared to males (5.5mg/l)  
 No conclusive sex related differences in the PK 
of NVP  
Regazzi et al (91)  NVP clearance  44% higher Cmax in females compared to 
males  
 The consistently higher NVP serum 
concentration and lower clearance reported in 
women partly explains the disproportionately 
higher incidence of NVP ADR’s in women 
compared to male counterparts.  
Sanne et al (92) NNRTI NVP Women with low BMI had a higher risk of 
hepatotoxicity compared with male 
counterparts 
Combined risk of NVP 
hypersensitivity which manifest as 
either rash or hepatotoxicity or both 
The risk of hepatotoxicity in Sanne et al’s 
report was higher in women with higher CD4 
count. This perhaps informs the suggestion by 
some treatment guidelines for NVP containing 
regimen not be commenced in women with 
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CD4 count of >250 cells/mm3.  
Hodder et al (93) NNRTI  
 
Rilpivirine clearance 13.6% lower apparent clearance in females 
compared to males  
  
Burger et al (94) Protease 
inhibitor (PI) 
Boosted Lopinavir 
level (LPV/r) 
Higher LPV and LPV ratio in females 
compared to male counterparts 
 Other PK studies including Ofotokun et al (95) 
failed to show any gender related difference in 
PK of LPV/r. it is probable that the lower body 
weight reported in Burger et al’s study (94) 
may have accounted for this discordant 
outcomes 
Fletcher et al (96) PI Saquinavir (SQV) 
serum concentration 
Significantly higher median Saquinavir 
Cmin and AUC in females. Additionally, 
women had a lower weight-adjusted 
clearance of SQV 
 There was a larger proportion of females with 
suppressed RNA viral copies (<500cells/ml) in 
this study, perhaps a consequence of SQV 
serum concentration 
Burger et al (97) PI Indinavir serum levels No gender related difference in IDV levels 
(see comment) 
 However more women had IDV TDM assays 
because of concerns for drug toxicity. 
Additionally there were more adverse event 
related dose adjustments in females (9.7%) 
than males (1.1%) 
Arasteh et al (98) 
 
PI Darunavir (DRV) Population PK analyses from POWER 1 & 2 
studies (n =68) showed that females had a 
higher AUC24h for DRV compared to male 
patients 
 The difference in DRV AUC24h in this report 
was not deemed to be clinically significant. 
Currier et al (99) PI  Ritonavir (RTV) More incidence of RTV related neurological 
and gastroenterological adverse events in 
females (61%) than males (27%) 
  
Pai et al (100) 
 
PI SQV Higher SVQ AUC0-24H in females compared  Potential for SQV adverse events  
Flexner et al (101) 
 
PI Atazanavir (ATV) Higher mean serum concentration in women.    
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1.3.1.2  Pharmacogenetics 
Inter-individual variation in both efficacy and adverse events associated with ART 
drugs represents a significant morbidity of HIV patients on treatment (86). Whilst 
extraneous factors such as drug concordance and gender amongst others may 
contribute to this, pharmacogenetics increasingly has been identified as a significant 
determinant of this variation (102). Single nucleotide polymorphisms (SNPs) 
represent the most common genetic variation in the human genome (102). By 
definition they are referred to as nucleotide sequence variation in human DNA with 
an allele frequency of greater than 1% (103). This is to differentiate them from 
variation with allele frequency of less than 1%, often referred to as gene mutation.   
Since the groundbreaking work of the Human genome project and subsequent 
elucidation of the genetic code, increasing body of evidence links SNPs with various 
HIV comorbidity phenotypes and adverse drug toxicities (102). A significant 
proportion of these studies have largely utilised a candidate gene approach. Recently 
however, there has been increasing attempts at exploring relevant genotype-
phenotype correlation using genome wide association studies in HIV positive 
patients exposed to ART drugs (104, 105). SNPs have been shown to occur about 
every 200-300 base pairs along the 3 billion letters of the genetic code (103). 
Specific genes regulate various proteins involved in the bio-disposition of ART 
drugs including their absorption, distribution, metabolism and elimination from the 
body. Variation in these genes represented as SNPs do impact on the bio-disposition 
of these drugs resulting in either reduced efficacy (including virological failure) due 
to decreased tissue exposure or clinical toxicity (103).   
 It is often difficult to conclusively associate a single SNP with a particular clinical 
phenotype or drug related adverse event. This is so because of the multiplicity of 
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other factors associated with such adverse event. However, where a cluster of SNPs 
called haplotypes consistently reports association with a particular ART adverse 
event, causality in this case is more robust and clear. Amongst the various ART 
related drug toxicities explored by pharmacogenetic studies includes hypersensitivity 
syndromes (106), kidney tubular dysfunction (107, 108, 109,110), liver injury, 
peripheral neuropathy, and various central nervous system related adverse effects 
amongst others (106). The ultimate goal is to utilize these data in identifying 
population at risk of developing these adverse events based on their possession of the 
relevant SNP thereby avoiding exposure to the incriminating ART drug in the first 
place. Unfortunately, the quality of studies reported thus far (with a few exceptions), 
and data generated from most pharmacogenetic studies exploring ART drug 
toxicities are not robust enough to allow their utilization as surrogate genetic markers 
or point of care assays yet. In a few reported cases what initially appears as 
significant associations between a particular SNP and a clinical ADR phenotype in 
candidate gene analysis doesn't prove significant in further genetic evaluation 
including GWAS. A pertinent example is the reported association between the 
possession of UGT1A1 promoter (TA)n repeat (rs8175317), and risk of Atazanavir 
induced hyperbilirubinemia (111). Further exploration of this association in 
pharmacogenetic studies including correction for UGT1A1 (rs8175317) carriage 
failed to replicate this finding (112). Table 1.2 summarizes key pharmacogenetic 
studies exploring ART drug exposure and various clinical drug toxicity phenotypes
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Table 1.2: Summary of pharmacogenetic studies exploring association between anti-retroviral therapy (ART) drug exposure and risk of ART 
related adverse drug reactions 
Study  Study design  ART class ART drug  Candidate 
gene/genotype/haplotype 
explored 
Clinical ADR phenotype Comment  
Mallal et al (106) Case control  NRTI Abacavir (ABC) HLA B*5701 ABC hypersensitivity. 
People from Indian sub-
continent have the highest 
carriage rates of this 
haplotype (15%) 
This represent the first and perhaps the only candidate 
gene in the whole of HIV/AIDS therapeutics to be 
exploited in order to guide clinical therapy 
Saag et al (113) for 
SHAPE trial  
Randomised 
controlled trial 
(RCT) 
NRTI ABC HLA B*5701 Risk of ABC 
hypersensitivity  
Both SHAPE and PREDICT represent the first RCT’s to 
established a clinical role for this genotype in the triage 
of HIV patients potentially at risk of ABC 
hypersensitivity 
Mallal et al (114) 
for PREDICT trial 
group 
RCT NRTI ABC HLA B*5701 Risk of ABC 
hypersensitivity 
 
Izzedine et al (109) Case control  NRTI TDF ABCC2 1249 G>A 
(rs2273697) 
ABCC2 Haplotypes: 
CGAC and CATC 
Risk of Kidney tubular 
dysfunction (KTD) 
Strong allelic link between ABCC2 1249 G>A and risk 
of KTD. Conversely ABCC2 haplotypes CGAC, and 
CATC were found to be protective and increased risk of 
KTD respectively 
Rodriquez-Novoa et 
al (107) 
Case control NRTI  TDF ABCC2 24CC (rs717620; 
MRP2) 
KTD Possession of genotype CC at position 24 of the ABCC2 
gene has seminally been reported by this study to be 
associated with increased risk of KTD 
Nishijima et al 
(2012) (108) 
Case control  NRTI TDF 
 
ABCC2 24CC (rs717620; 
MRP2) 
KTD  
Pushpakom et al Case control NRTI TDF ABCC10 (MRP7; KTD The first study to both ascertain MRP7 as a putative 
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(110) rs2125739, rs9349256) 
ABCC2-ABCC1O 
extended haplotype 
(GGC-CGTC) 
TDF transporter and link possession of intronic SNPs of 
ABCC10 and their extended haplotype with risk of KTD 
Nishijima et al 2015 
(115) 
Case control NRTI TDF ABCC2 24CC (rs717620; 
MRP2) 
Decrease in eGFR Neither allele C or genotype CC were associated with 
risk of KTD 
Likanonsakul 2015 
(116) 
Case control NRTI TDF ABCC2 
-24CT 
1249GA 
Urinary β2-microglobulin 
thresholds 
No significant association with KTD 
Hulgan et al (117) Case control  NRTI Didanosine 
(DDI) 
7028C>T, 10398G>A, 
and (118)68G>A (within 
haplotype T of mtDNA) 
Peripheral Neuropathy  
Canter et al (119) Case control  NRTI DDI 4216C and 4917G (within 
haplotype T of mtDNA) 
Peripheral neuropathy This is irrespective of age and HIV RNA viral load 
levels amongst other co-variates  
Felley et al(28) Case control  NRTI DDI CFTR mutations and 
SPINK-1 
Polymorphisms 
Suggested association with 
risk of hyperamylasemia 
and pancreatitis 
Further studies still awaited to ascertain these findings 
Holzinger et al 
(120) 
Case control NNRTI Efavirenz (EFV) CYP2B6 516G>T 
(rs3745274) 
Associated with high EFV 
serum concentration.  
Potentially increased risk of CNS adverse effects. 
Increased frequency of this allele in patients of African 
ancestry  
Wyen et al (121) 
 
Case control  NNRTI EFV CYP2B6 983 T>C 
(rs28399499) 
Increased EFV serum levels  
Saitoh et al (122) Case control  NNRTI  Nevirapine 
(NVP) 
CYP2B6 516G>T  Increased NVP AUC  Potential for risk of NVP ADRs including rash and liver 
toxicity Associated with  
Carr et al (123) Case control  NNRTI NVP HLA-C*04: 01 Increased risk of Steven-
Johnson syndrome 
This study was carried out in Malawian patient cohort  
Martin et al (124) Case control  NNRTI NVP HLA-DRB1*01:01 High CD4 count and Predominantly Australian patient cohort  
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increased risk of Liver 
injury and skin rash 
Gatanaga et al (125) Case control NNRTI NVP HLACw*08 Risk of NVP rash Japanese cohort 
Ritchie et al (126) Case control  NNRTI NVP MDR1 3435 C>T Protective of risk of NVP 
drug related liver injury 
(DILI) 
 
Haas et al (127) RCT NNRTI NVP MDR1 3435 C>T Reduced risk of NVP 
related DILI 
First RCT to ascertain protective effect of this genotype 
in a clinical trial setting 
Rodriquez-Novoa et 
al (128),  
Rotger et al (129) 
 
Case control PI Atazanavir 
(ATV) 
UGT1A1 (*6*6, *7*7, 
*6*7) 
Increased risk of 
hyperbilirubinemia with 
possession of these 
genotypes  
This association was consistent across diverse ethnic 
populations.  
Rodriquez-Novoa et 
al (128) 
Case control  PI ATV MDR1 3435 C/C Increased risk of ATV 
induced hyperbilirubinemia 
with possession of this P-
glycoprotein genotype 
 
Fauvel et al (130) Prospective 
cohort 
PI-based 
regimen  
 SNPs of APOC3 Increased risk of 
dyslipidaemias  
 
Foulkes et al (131) Prospective 
cohort 
PI-based 
regimen  
 APOC3 and APOA1 
genotypes 
Risk of hyperlipidaemias   
Tarr et al (132) Prospective 
cohort (Swiss 
HIV cohort data) 
PI-based 
regimen  
 SNPs of APOC3 and 
APOE  
Patients with all 3 SNPs of 
APOC3 and APOE were 
associated with increased 
risk of hypertriglyceridemia 
This study also suggested association between these 
studied SNPs and risk of lipodystrophy 
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1.3.1.3  Ethnicity 
There have been notable, well-established racial differences in PK (133,134), PD 
(134, 118), and pharmacogenetic (134, 118) profiles of patients from diverse study 
settings. Unfortunately, this is not without morbidity, as it has increasingly been 
shown to impact adversely and contribute to the burden of ART drug related 
toxicities (135). Amongst the most extensively studied race-related ART drug 
toxicity has been those exploring EFV (86) and NVP in varied ethnic populations. 
The PK of EFV is associated with extensive inter-individual variability (133, 118). 
This has been shown to result in downstream effects including treatment failure (sub-
therapeutic levels) with concentration less than1μg/ml, and CNS toxicity when serum 
concentrations exceed 4μg/ml (136, 137, 138). Ethnicity amongst other factors 
including body weight, and concomitantly administered drugs (such as Rifampicin), 
significantly impact on EFV serum concentration (133). In an earlier report, Stohr et 
al for example showed that black ethnicity was significantly associated with about 
59% higher EFV serum concentration than comparable cohorts (133), with a 
potential concern for risk of EFV associated CNS adverse effects. EFV as 
highlighted earlier is metabolised predominantly by CYP2B6 and to a limited extent 
by CYP3A4 (34). Studies of polymorphisms of these enzymes vis-à-vis EFV adverse 
effects in various ethnic populations have reported varying risk profile. Carriage of 
the genotype CYP2B6 516G>T for example has consistently been shown to correlate 
with higher EFV concentrations across a broad range of ethnic populations (139). A 
number of studies (124, 140) have also recently explored the pharmacogenetic 
underpinning behind cutaneous hypersensitivity syndromes/liver injury following 
exposure to NVP in diverse ethnic populations. NVP rash is a well-established 
treatment limiting AE reported in a wide cohort of patients with an overall incidence 
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estimated to be about 2.8 times higher in Thai than comparable white patient cohorts 
(141). In a study exploring the role of environmental and genetic factors in the 
pathogenesis of NVP hypersensitivity in Malawians, Carr et al reported association 
between HLA-C*04: 01 carriage and development of Stevens-Johnson syndrome in 
HIV infected Malawian patients exposed to NVP (123). Earlier report in 
predominantly white Australian population have suggested a causal link between the 
HLA-DRB1*01:01 genotype, higher CD4 T-cell, and risk of liver/skin rash in cohort 
of patients exposed to NVP (124). Conversely, studies in Japanese patients reported 
more of association with HLACw*08 genotype (125) than other previously suggested 
genotypes. A recurrent theme of reports discussed thus far has been the consistent 
phenotype-genotype linkage in specific ethnic populations. This perhaps helps 
explain the defining role of genetics as one amongst a number of determinants of 
ART drug induced ADR in various ethnic populations.  
What has limited the clinical utility of the afore-mentioned surrogate genetic markers 
here and elsewhere in this thesis as point of care assays to date, includes limited 
sample size of these studies and their relatively low predictive values amongst 
others. 
1.4.0 Specific antiretroviral therapy (ART) drug related toxicity syndromes  
1.4.1 Tenofovir induced Kidney tubular dysfunction (KTD)  
Tenofovir either given as one of its available salts i.e. Tenofovir disoproxil fumarate 
(TDF), or Tenofovir alafenamide fumarate (TAF) is a pro-drug which undergoes 
rapid bio-activation to its active moiety Tenofovir (TDF) with a terminal half-life of 
about 30 hours (142) (figure 1.8). It is metabolized and cleared from plasma through 
a combination of glomerular filtration and active secretion from kidney tubules 
(143). TDF is the most widely used of the NRTI’s in HIV therapeutics, largely due to 
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its well-established efficacy and safety profile from a number of studies (144, 145). 
It has however continued to generate concerns owing to its propensity to cause 
kidney injury in HIV positive patients exposed to it (145). The EUROSIDA 
investigators for example reported that for every 10 year exposure to TDF, there was 
about 16% risk of decline in eGFR, with the magnitude of decline highest in patients 
on ATV/r regimen (22%) compared to other PI based regimen (8%, and 11% for 
LPV/r and Indinavir respectively) (146). Contemporaneous use of both PI/TDF 
regiment was associated with a faster rate of decline (41%) in kidney function in the 
study (146). Despite this case burden, the exact pattern (clinical phenotype), 
diagnostic markers, and mechanism of kidney involvement is still uncertain. Kidney 
tubular dysfunction and Fanconi syndromes were amongst the most widely studied 
and reported clinical and laboratory phenotypes from both longitudinal and 
systematic studies (144, 145). The reported prevalence of clinically significant TDF 
related kidney injury is variable, but it is estimated to range between 2-11% 
(147,148, 149). Organic Influx transporters such as organic anion transporter 1 
(OAT1) encoded by SLC22A6, and OAT3 (SLC22A8) located at the basolateral 
membranes are suggested to mediate the entry of TDF into kidney tubular cells 
(KTC). Efflux transporters such as multi-resistant protein 4 (MRP4, encoded by 
ABCC4), and MRP7 (encoded by ABCC10) located on apical membrane are involved 
in secretion of TDF from KTC into the tubular lumen (110, 150, 151) (figure 1.7). 
Both transporters have been reported to be polymorphic, with single nucleotide 
polymorphisms (SNP) of genes encoding them (particularly MRP2 (ABCC2), and 
MRP7 (ABCC10) proposed to confer increased risk of KTD in HIV positive patient 
exposed to TDF (107, 110).  
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Figure 1.7: Relative disposition and kinetics of known Tenofovir Kidney 
transporters [adapted from Moss DM et al] (152) 
 
Recently, three studies with different study methodology, patient populations, and 
surrogate markers of kidney injury, established associations between polymorphisms 
of ABCC2 genes (MRP2, rs717620), and risk of TDF related KTD (107, 108, 109). 
In a seminal report, Izzedine et al showed a strong allelic association between 
carriage of the CATC haplotype (represents combination of SNPs at position 1249, 
3563, 24, and 3972 within the ABCC2 gene) and risk of KTD (OR 6.11 [95% CI, 
1.19–31.15]; P <0.02). Conversely, the possession of the CGAC haplotype in this 
report was found to confer a protective effect on risk of kidney injury through a 
higher TDF secretion from the PCTs (109). All three reports were limited by their 
retrospective case control designs. This is so because early onset KTD may have 
been missed by these analyses and this limits ability to establish causality. In another 
report, Rodriquez-Novoa et al in pharmacogenetic analyses of the Liverpool 
therapeutic drug monitoring (TDM) registry data, reported association between 
possession of genotype CC at position 24 of ABCC2 gene (rs717620), and risk of 
TDF-induced KTD in multivariate analysis (107). Older age, and low body weight 
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were additional factors found in this study to be associated with an increased risk of 
KTD in cohorts of HIV positive patients exposed to TDF (107). Conversely, a recent 
pharmacogenetic study (115) in a prospective cohort of HIV positive patients failed 
to establish association between the ABCC2 24CC (rs717620) SNP, and risk of KTD. 
This further highlights the lack of agreement regarding the relationship between 
possession of this SNP (ABCC2 24CC), and risk of KTD in these cohorts of patients. 
Nevertheless, the findings from previously highlighted reports (linking increased 
KTD risk with ABCC2_24CC genotype) (107, 108, 109) presented an unresolved 
mechanistic paradox. Studies thus far have failed to associate MRP2 (ABCC2) with 
transport of TDF, rather mechanistic reports thus far have consistently associated 
MRP4 (ABCC4), and MRP7 (ABCC10) as putative TDF transporters (110, 150, 151). 
How possession of ABCC2 24CC genotype mediates kidney tubular dysfunction 
therefore remains uncertain. Suggested mechanisms for this paradox includes 
decreased secretion of TDF by ABCC2-24CC homozygotes; transport by MRP2 of 
yet to be identified factor that influences TDF toxicity on the kidneys; also proposed 
is the suggestion that ABCC2-24CC might be in linkage disequilibrium with yet to be 
identified SNPs that influence TDF secretion by the kidneys (107) 
A  B  
Figure 1.8: Molecular Structure of Tenofovir disoproxil fumarate (A), and Tenofovir 
alafenamide fumarate (B) 
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TDF is a well-established substrate for MRP4 (ABCC4). Pharmacogenetic 
exploration of the various SNPs and Haplotypes of ABCC4 have thus far only 
reported conflicting data regarding the risk of KTD with any specific SNP or 
haplotype associated with this gene. The ABCC4 3463G SNP for example has been 
associated with decreased kidney clearance of TDF (153). In his seminal report, 
Izzedine et al (109) first reported allelic association between the possession of the 
ABCC4 669C>T genotype and risk of KTD. Subsequent pharmacogenetic reports 
including those by Nishijima et al (108) and Rodriguez-Novoa et al (107) failed to 
establish this association. How differences in the study methodology, patient 
populations, and surrogate markers of kidney dysfunction deployed explain these 
contradictory findings is still open to debate. 
In a recent mechanistic/pharmacogenetic report, Pushpakom et al (110) both 
established MRP7 (ABCC10) as a TDF transporter and subsequently demonstrated 
increased risk of KTD with possession of two ABCC10 SNPs (MRP7, rs2125739, 
rs9349256) and their haplotypes (OR 2.1, P = 0.05) in HIV positive patients. In this 
study, possession of the ABCC10 SNP (rs9349256) was also associated with 
increased urinary phosphate excretion (a surrogate marker of TDF induced kidney 
tubular dysfunction) (110).  
P-glycoprotein (PGP) has been shown to influence the absorption of TDF through 
the enterocytes but has no effect on its systemic kinetics including its kidney 
transport (154). Pharmacogenetic studies so far have failed to demonstrate any 
association between the polymorphisms in P-glycoprotein MDR-1 gene 
(including1236 C>T, 2677G>T/A, and 3435C>T) and risk of TDF-induced KTD 
(107, 109). 
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Recently, a new formulation of Tenofovir called Tenofovir alafenamide fumarate 
(TAF) is generating intense mechanistic interest (155). Its absorption across 
intestinal epithelium as TAF is influenced by p-glycoprotein. It circulates within the 
blood steam as, and subsequent transport into cytosol of immune competent cells as 
TAF (156). Intracellularly, it is converted by cellular kinases into Tenofovir 
diphosphate (156). Its preferentially high intracellular disposition (in form of 
Tenofovir-diphosphate), and relatively limited plasma concentration meant there is 
reduced systemic exposure to this drug. The implication of these salutary properties 
is a probable reduction in risk of kidney related adverse effects. Indeed a recent 
seminal study have reported reduced incidence of KTD (as evidenced by 
hypophosphatemia and proteinuria), as well as bone mineral density when TAF was 
part of a regimen comprised of Cobicistat (COBI), Elvitegravir (EVG), Emtricitabine 
(FTC) (157). Additional reports including the recent 48-week follow-up switch data 
from Pozniak et al, have suggested increased renal safety with regimen consisting of 
TAF in patients with mild to moderate kidney impairment (158). As more studies 
continue to explore the pattern and definitive clinical phenotype of TDF-related 
kidney injury, emphasis remains on current point of care measures aimed at reducing 
this risk. These includes, close monitoring of kidney function with conventional 
markers of kidney injury in HIV positive patients commencing the drug, avoidance 
of TDF in HIV patients with established chronic kidney disease (CKD) amongst 
other measures. 
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1.5.0   Adjudication of ART drug related Kidney adverse effects  
1.5.1    Determination of kidney dysfunction 
As in the general population, the exact burden of ART drug related adverse effects is 
very difficult to established (80). This has been attributed to a number of factors 
described in other sections of this thesis.  These include lack of uniformity of 
reporting methods and algorithms, differences in patient’s population, variable ADR 
adjudication process, and marked discrepancy in monitoring process (68, 69). The 
lack of agreement in the accepted surrogate markers of kidney dysfunction for 
example has contributed significantly to uncertainty regarding the prevalence and 
pattern of TDF related kidney tubular dysfunction. Whilst both observational and 
clinical trial data have suggested varying degrees of kidney dysfunction, traditional 
markers of kidney injury such as eGFR and urinary ACR/PCR have so far been 
suggested to miss early/sub-clinical forms of TDF related kidney injury (147, 149). 
Consequently, having a biomarker reporting early/subclinical forms of ART drug 
related injury will be important as it has the potential to reduce morbidity associated 
with these drugs and serve as an effective monitoring tool. Recently, some low 
molecular weight proteinuria (LMWP) such as kidney injury molecule 1 (KIM-1), N-
acetyl-beta-D-Glucosaminidase (NAG), neutrophil gelatinase associated lipocalin 
(NGAL), retinol binding protein (RBP), interleukin-18 (IL-18), and L-type fatty acid 
binding protein (L-FABP) have increasing been shown to correlate with sub-clinical 
forms of various ART drug related kidney injury (159, 160, 161, 162). Whether such 
associations are consistent enough to allow their use as diagnostic/monitoring 
surrogate markers is still unknown. 
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1.5.1.1   Kidney injury molecule 1 (KIM-1) 
KIM-1 (kidney injury molecule 1) is a putative, inducible, type-I trans-membrane 
tubular adhesion glycoprotein facultatively expressed on the surface of kidney 
tubular cells (163). Its trans-membrane domain undergoes proximal membrane 
cleavage, releasing the ectodermal KIM-1 that is excreted and quantifiable in urine 
(163). It is not usually expressed in normal kidney tubular cells. However, in 
response to a variety of insults including ischemic reperfusion injury and 
metabolic/infective stress, its expression is markedly increased (163) where it 
functions as a scavenger receptor (163). Recent reports from a variety of 
experimental and observational studies have suggested KIM-1 as a potential early 
surrogate marker of kidney tubular injury (159, 160) (figure 1.9). In a seminal report 
determining its diagnostic utility in Humans, Han et al reported high levels of 
normalised urinary KIM-1 in patients with clinically adjudicated acute kidney injury 
(AKI) (164). In this report, one unit rise in normalized KIM-1 levels was associated 
with a twelve fold increased odds of ischaemic acute tubular necrosis (164). Other 
subsequent studies explored the relationships between elevated KIM-1 levels and 
actuarial kidney survival. In the Multi-Ethnic Study of Atherosclerosis (MESA) for 
example, elevated KIM-1 and IL-8 values were significantly associated with 
increased risk of kidney function decline independent of urine albumin or eGFR 
(165). Furthermore, other studies associate higher levels of KIM-1 with increased 
mortality risk or need for dialysis in AKI patients presenting to accident and 
emergency departments (166). However, there is limited data pertaining to its use in 
assessment of kidney function in HIV positive patients on ART drugs. In a recent 
report by Peralta et al in HIV positive patients, higher KIM-1 values were associated 
with doubling of mortality risk in demographically adjusted model. This effect was 
  35 
however completely attenuated and found to be insignificant with full adjustment 
(167). Despite the multiplicity of biomarkers so far suggested to predict or detect 
kidney injury earlier than traditional assays (eGFR, urine PCR/ACR), KIM-1 data 
from a wide variety of sources have supported its potential role as tubular biomarker 
following exposure to ART drugs.  
 
  
Figure 1.9: A schematic representation of time course of standard and novel kidney 
biomarkers [Adapted from Mcllroy DR et al] (168) 
 
1.5.1.2   Retinol Binding Protein (RBP) 
This is a low molecular weight single polypeptide produced by liver as well fat cells. 
It primarily transports retinol (vitamin A) in plasma and it is freely filtered, and 
completely reabsorbed by kidney tubules (169). This, in addition to pH stability of 
RBP, as well as its ease and reliability of measurements has suggested a potential 
role for it as a surrogate marker of kidney tubular dysfunction (169). It is expressed 
as RBPCR, corrected for urinary creatinine excretion (161). In a cross-sectional 
study exploring the diagnostic utility of low molecular weight proteinuria (LMWP), 
Hall et al reported a higher normalised urinary RBP in cohorts of patients on TDF 
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based regimen (161). This study explored the diagnostic utility of a number of 
LMWP including RBP, NAG, and normalised urine albumin (urine ACR) in HIV 
positive patients on various ART regimens (161). NAG levels were elevated in all 
cohorts of patients regardless of ART exposure whereas normalised urinary RBP 
levels were only raised in patients on TDF based regimen. Inhibitory effect of TDF 
on tubular transport of LMWP including RBP has been suggested to account for this 
increased urinary kinetics (161). Other reports whilst exploring the same diagnostic 
utility of RBP in HIV patients on ART, reported a higher proportion of tubular 
proteinuria in these cohorts of patients (162). Notably, those with no overt evidence 
of kidney disease had normalised urine RBP within the reference range. This has 
been suggested to underlie a potential role for RBP as surrogate marker of kidney 
function in these cohorts of patients (162). In a recent mechanistic study, Calcagno et 
al reported significant association between urinary TDF concentration and urinary 
RBP levels (170). It is pertinent to note that the relationship between serum 
Tenofovir concentration and risk of kidney dysfunction have remained contentious.  
Previous studies including report by Ray et al have failed to establish any significant 
association between TDF concentrations and risk of kidney injury (171).  
Establishing RBP as a diagnostic marker of clinical, and sub-clinical injury in HIV 
positive patients on ART drugs will contribute immensely in ascertaining both the 
prevalence as well as the clinical phenotypes of some these toxicities.  
1.5.1.3   Neutrophil gelatinase associated lipocalin (NGAL) 
These are diverse groups of proteins called lipocalins, the hallmark of which is the 
possession of a three-dimensional structure as a unifying characteristic (172). They 
are comprised of a 178-amino acid (25-kilo Dalton) glycoprotein expressed by 
neutrophils and most epithelial cells including kidney tubular cells (172). Their exact 
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function is still unclear, but they are suggested to be involved in kidney tubular 
regeneration (172). NGAL expression by kidney tubular cells has been shown to 
increase following exposure to metabolic, inflammatory, and infective stress (173). 
NGAL as a prospective kidney injury marker has been extensively studied in varied 
clinical settings in both HIV cohorts and the general population (173). Paragas et al 
working on transgenic mouse model reported a higher expression of NGAL in 
kidney biopsies of HIV positive patients with HIVAN compared to those other 
kidney morbidities (174). Following on from this, both diagnostic and prognostic 
kidney biomarker roles has been suggested for NGAL by a number of studies 
including metanalysis of these studies by Hasse et al (175). In a recent study 
evaluating LMWP in a hospital-based cohort, Campbell et al reported 67% of studied 
participants having NGALCR (corrected for urinary creatinine excretion) above 
diagnostic thresholds published by NGAL manufacturers (162). NGAL’s ability to 
correlate and track early kidney tubular injury in both the general population and 
limited HIV cohorts on ART, as well as its ease of laboratory measurement at point-
of-care potentially could suggest a role for it as a surrogate marker of KTD in these 
cohorts of patients on ART. The totality of available data thus far remains 
insufficient to suggest application of NGAL as point of care assay in HIV positive 
patients on ART.  
1.5.1.4   N-acetyl-β-D-glucosaminidase (NAG) 
This is a 150kDa glycolytic lysosomal protein expressed by tubular epithelial cells as 
well as in other diverse tissues (176). It is widely distributed amongst kidney tubular 
cells (176,  177), with increased expression and urinary excretion following exposure 
to infective, metabolic and ischaemic stress (177). In an evaluation of prevalence of 
sub-clinical kidney tubular injury in a cohort of HIV patients on various ART 
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regimens, Hall et al reported higher urinary levels of NAG/C (corrected for urinary 
creatinine excretion) in patients on TDF based regimen compared to those on 
alternative regimen (161). In spite of this, NAG/C in common with other LMWP 
evaluated in this study (including RBPCR) failed to detect significant degrees of sub-
clinical kidney tubular dysfunction reported. The multifactorial nature of ART 
related kidney morbidities suggest that multiple biomarkers utilised as a cluster, may 
be required to robustly report clinical and subclinical degrees of kidney injury 
following exposure to these drugs. Indeed a recent report by scherzer et al, showed 
that NAG, KIM-1, and alpha-1 microglobulin utilised as a cluster were as effective 
as an 8-panel biomarker in predicting incident chronic kidney disease in HIV 
infected women (178). As with other novel biomarkers, NAG is still undergoing 
further clinical evaluation to prospectively determine its role as diagnostic surrogate 
marker of early kidney tubular dysfunction in HIV positive patients exposed to ART 
drugs.  
1.5.1.5    L type-fatty acid binding protein (L-FABP) 
This is usually found in the cytosol of proximal tubular cells, where it primary binds 
and transports fatty acids into the mitochondria for subsequent β-oxidation as part of 
the body’s energy generation pathway (179). A number of reports from the general 
population have suggested its potential utility as an early marker of kidney tubular 
dysfunction in varied clinical settings including patients with acute kidney injury and 
solid organ transplant cohorts (167). In HIV population, it has been shown to be 
markedly elevated in patients on EFV compared with healthy controls (180). In 
further characterisation of probable diagnostic role of L-FABP, Peralta et al studied 
association of L-FABP (amongst other markers such as urine ACR, KIM-1, NGAL, 
IL-18) with a 10-year all-cause mortality risk in a cohort of 908 HIV positive women 
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(180). There was a J-shaped relationship between L-FABP and mortality, with IL-18 
showing the most consistent relationship with mortality in this study. These 
associations were independent of either thresholds of urine ACR, or eGFRcys (eGFR 
corrected for Cystatin C excretion used as a surrogate marker of kidney dysfunction) 
in this study (167). Whilst a possible inference from these reports is potential utility 
of L-FABP to identify early kidney injury in these cohorts of patients following ART 
exposure, there is need for more robust prospective data to validate its use in this 
setting.  
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CHAPTER 2 
SYSTEMATIC REVIEW AND METANALYSIS OF 
GENETIC DETERMINANTS OF TENOFOVIR 
INDUCED KIDNEY INJURY IN HIV POSITIVE 
PATIENTS 
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2.0  Background  
2.1.1 Tenofovir and kidney disease 
Over the past few years, there has been an increasing interest in the role of genetics 
in the pathogenesis of TDF induced kidney tubular dysfunction (KTD) (107, 108, 
110). Comprehensive narrative review of the role of SNP’s encoding proteins 
involved the biodisposition of TDF, and risk of Kidney injury is provided in chapter 
one of this thesis. However, despite these reported associations, it remains uncertain 
if the variability associated with these polymorphisms is robust and significant 
enough to recommend them as point of care assays or reliable risk stratification tools. 
In this chapter, we have attempted for the first time to systematically analyse current 
pharmacogenetic data with regards to the reported SNPs to in order to ascertain the 
strength of association with risk for KTD in HIV positive patients exposed to TDF.  
2.1.2 Aim of systematic review 
This is to attempt a systematic review of available pharmacogenetic data (including 
SNP’s of ABCC2, ABCC4, ABCC10, and ABCB1 genes) linking TDF exposure with 
risk of kidney injury from a wide variety of sources. This was in order to ascertain 
any degree of agreement between them, as well as consistency, and robustness of 
such association. 
2.2.0 Materials and Method 
2.2.1 Search strategy 
We adopted a broad search strategy (encompassing all languages, all studies, and 
available years (up to 30/08/2016). We did a comprehensive search of pre-specified 
databases including PUBMED, MEDLINE, Cochrane database of systematic 
reviews, Web of Science, (dbSNP), PharmGKB, clinical trials.org, CROI, and 
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EMBASE to identify studies using the following medical subject heading (MeSH) 
terms: ((“Tenofovir Disoproxil Fumarate”[MeSH Terms] OR “Tenofovir”[All 
Fields] OR “TDF”[MeSH Terms]) OR “TDF”[MeSH])) AND ((“proximal kidney 
tubular dysfunction”[MeSH Terms] OR “kidney Tubular Dysfunction”[All Fields] 
OR “KTD”[MeSH Terms]), OR (Renal Tubular Dysfunction)) AND 
((“polymorphism, single nucleotide”[MeSH Terms] OR (“polymorphism”[All 
Fields] AND “single”[All Fields] AND “nucleotide”[All Fields]) OR “single 
nucleotide polymorphism”[All Fields] OR (“single”[All Fields] AND 
“nucleotide”[All Fields] AND “polymorphism”[All Fields]))ORSNP[All Fields])) 
We selected manuals, publications (including abstracts) meeting the inclusion 
criteria. The systematic review was conducted in keeping with PRISMA guidelines 
(181).   
2.2.2 Eligibility criteria 
For inclusion in the review, studies must provide methods of mutational screening 
for SNPs, the target SNPs explored, rationale behind selecting those SNPs including 
if linkage disequilibrium was evaluated or not. Additionally, studies must clearly 
state a pre-specified outcome of ascertaining potential associations between TDF 
exposure, and risk for KTD as a factor of various SNPs of transport proteins involve 
in the bio-disposition of TDF. In this review, we included all studies regardless of 
their design, although all studies evaluated in this review (except one) had a case 
control design. Studies were excluded if they provide no detailed pharmacogenetic 
data, and failed to meet other inclusion criteria as outlined above.  
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2.3 Study quality evaluation  
This was determined by a checklist and algorithm for methodological assessment of 
pharmacogenetic studies suggested by Jorgensen et al and this is discussed elsewhere 
(182). 
2.4. Statistical analysis 
In order to ascertain quality of studies under review, HWE was assessed in both 
cases and controls using the chi-squared tests. A P-value of <0.05 was considered 
statistically significant, and studies with deviation from HWE were defined as low-
quality studies. Data pooling was performed with and without these studies to test the 
robustness of reported estimates. Heterogeneity of reviewed studies was ascertained 
by chi-squared tests. Overall, odd ratios for reviewed studies were determined using 
both fixed and random effect models. The Q-statistics considered in our analyses 
measures the heterogeneity across studies. Whilst I2 quantifies the heterogeneity of 
these studies, and is expressed as a percentage of variability of effect sizes between 
studies. Where there was marked heterogeneity (as evidenced by high I2), random 
effect models were considered. This ensures that the inevitable within, and between 
study variability were captured. We choose a random effects model because of 
heterogeneity of our data. 
2.5.0 Results  
2.5.1 Study selection  
A comprehensive literature search retrieved eleven citations, out of which six met the 
inclusion criteria for analyses. There were no other previous systematic studies for 
comparison. We excluded the following referenced studies (183), and (184) because 
they were not designed to explore TDF-kidney toxicity association, and did not 
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report on this. da Rocha et al (185), and Manosuthi et al (186) reports provided 
incomplete allele and genotype frequency data, and were excluded from pooled 
analyses. The fifth report by Kiser JJ et al (187), explored TDF pharmacokinetic 
outcomes only and was excluded from pooled analyses. See figure 2.1 for flow 
diagram of reviewed studies.  
2.5.2 Target single nucleotide polymorphisms 
There were varied reasons expounded by investigators of the reviewed studies for 
evaluating specific SNPs. Izzedine et al (109) whose seminal work first established 
the probable role of genetics in TDF-related KTD, targeted various ABBC2 (MRP2), 
and ABCC4 (MRP4) SNPs based on the role they played in the pathology of other 
substrate transporters (109) 
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In addition, their location within the basolateral membrane of the kidney tubules lent 
credence to their probable role in causation of TDF related KTD. In addition to this, 
other studies (107, 108, 110, 115) targeted the SNPs they evaluated based on 
functional significance, minor allele frequencies >5% in their respective populations. 
These includes reported protective effect of some haplotypes for example ABCC2 
4544G>A (exon 32) which has been reported to be under-represented in patients with 
TDF-associated kidney toxicity (107). Additionally, ABCC4 3463A>G, and ABCC4 
4131T>G were targeted because of their association with decreased renal TDF 
clearance (153) and high frequency in White populations (107) respectively. The 
ABCC4 669C>T SNP was studied owing to its high frequency of expression among 
patients with TDF-associated kidney toxicity (107). For this systematic review, we 
have focussed on the SNPs of the following transporter SNP’s: ABCC2 (MRP2), 
ABCC4 (MRP4), ABCC10 (MRP7 rs2125739, and rs9349256), and ABCB1 (p-
glycoprotein).  
2.5.3 Study design and outcome definition  
There was distinct concordance in the definition of KTD amongst four of the 
reviewed studies (107, 108, 110). They utilised a composite of serum and urinary 
parameters described extensively elsewhere (107) as surrogate markers of KTD. 
From the criteria utilised by the reviewed studies to estimate tubular injury, it is 
evident that the robust algorithm they employed for case adjudication and 
ascertainment supports their selection and consideration for this review. TDF 
induced KTD is currently a developing field and its current definition rely on utility 
of the composite criteria highlighted earlier (107). Five of the included reports 
utilised this, whilst the sixth report utilised the current validated point-of-care gold 
standard for the determination of kidney injury in HIV patients irrespective of ART 
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exposure (eGFR). The latter decision is based on current uniformity of eGFR 
<60mls/min/1.72m2 as one of the internationally accepted surrogate markers of 
kidney dysfunction in both the general population as well as HIV positive patients on 
ART (its stated limitations not withstanding in these cohorts). We selected the six 
SNP’s, and Table 2.1 gives a summary of various definition of KTD by the reviewed 
studies 
2.5.4 Data Analysis 
Data was abstracted by two independent reviewers (I, and Dr Sudeep Pushpakom of 
the Wolfson Centre for Personalised Medicine, the University of Liverpool) from 
studies included in the review, and entered into a Microsoft excel spreadsheet. 
Variables considered includes author, study design, sample size (including cases and 
controls), patients cohorts, effect size (OR), year of publication, target SNP, reported 
allelic or haplotypic associations, and Hardy Weinberg equilibrium (HWE). Effect 
size was determined from Pooled odd ratios (ORs) and confidence interval (CI) of 
selected studies. Dr Ben Francis (University of Liverpool) provided additional 
statistical input. Five of the reviewed studies had a case-control design with a 
uniform definition of cases and controls in four studies (107, 108, 110, 109) (utilising 
diagnostic criteria of Fanconi syndrome (107). Cases were defined as HIV positive 
patients on TDF who developed two of the following parameters (one of which must 
be a parameter for Fanconi syndrome) (107), with those not having any of these 
features classified as controls.  
• Non-diabetic glucosuria (urine glucose level >300 mg daily)  
• Total excretion of phosphorus (urine phosphorus × urine volume) >1200 mg 
daily  
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• Fractional tubular re-absorption of phosphorus (1 − [(urine phosphorus × 
plasma creatinine)/(plasma phosphorus × urine creatinine)]) <0.82 
• Hyper-aminoaciduria (any amino acid in urine, with the exception of 
histidine, glycine and serine),  
• β2-microglobulin (urinary β2-microglobulin > 1mg daily) 91   
• Fractional excretion of uric acid ([(urine uric acid × plasma creatinine)/ (urine 
creatinine × plasma uric acid)] × 100) >15%.   
Fanconi syndrome encompasses glycosuria in non-diabetic patients, hyper 
aminoaciduria (except histidine, lysine and serine) and phosphaturia. 
The fifth study (116) utilised thresholds of urinary median β-2 microglobulin 
(corrected for urinary creatinine excretion) in ascertainment of cases (KTD) and 
controls. β-2 microglobulinuria is an integral component of the diagnostic criterion 
for KTD/Fanconi syndrome discussed elsewhere in this thesis (107). Nishijima et al 
(115) utilised three thresholds of eGFR to classify kidney dysfunction into three 
distinct groups (>10ml/min/1.73m2 fall in eGFR relative to baseline, >25% fall in 
eGFR, and eGFR <60ml/min/1.73m2). We considered the third definition of kidney 
dysfunction i.e. eGFR <60mls/min/1.72m2 in this review.  
We estimated the population attributable risk of developing KTD following exposure 
to TDF (with possession of index SNP’s) following pooling of data from the various 
studies that evaluated specific SNP’s using the following formula: 
PAR% = 100 × p (OR-1)/(p [OR-1]+1) 
Where,  
 P is the percentage attributable population risk 
 p: Frequency of the index SNP allele in the control population cohort 
 
 OR: odds ratio 
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Table 2.1: Definition of kidney Tubular Dysfunction (KTD) in studies included in 
the review  
Study 
 
Definition of kidney Tubular Dysfunction 
 
Rodriquez-Novoa et al (2009) 
(107) 
Presence of 2 abnormalities 1, one of which must be a Fanconi 
criteria (107) 
Pushpakom et al (2011) (110) Presence of 2 abnormalities 1, one of which must be a Fanconi 
criteria (107) 
Izzedine et al (2006) (109) 
 
Presence of 2 abnormalities1, one of which must be a Fanconi 
criteria  
Nishijima et al (2012) (108) Presence of 2 abnormalities 1, one of which must be a Fanconi 
criteria (107) 
Nishijima et al (2015) (115) 1. Decline in eGFR of >10 ml/min/1.73 m2 relative to the 
baseline; 2. >25% decrement in eGFR relative to the baseline; 3. 
eGFR <60ml/min/1.73 m2. 
(As determined by CKD-EPI equation) 
Likanonsakul et al (116) Median β-2 microglobulin (corrected for urinary creatinine 
excretion) 
 
1.KTD abnormalities: non-diabetic glycosuria (urine glucose level, 1300 mg daily); total excretion of 
phosphorus (urine phosphorus x urine volume) >1200 mg daily; fractional tubular reabsorption of 
phosphorus (1 x [(urine phosphorus x plasma creatinine)/ (plasma phosphorus x urine creatinine)]) 
<0.82; hyperaminoaciduria (any amino acid in urine, with the exception of histidine, glycine, and 
serine), β2-microglobulinuria (β2-microglobulin level, >1 mg daily), and fractional excretion of uric 
acid ([(urine uric acid x plasma creatinine)/(urine creatinine x plasma uric acid)]x 100) >15% 
2. Fanconi abnormalities: glycosuria in nondiabetic patients, hyperaminoaciduria, or 
hyperphosphaturia 
2.5.5 Sample Size 
The combined sample size of the study population was (N = 1426). This is made up 
of 250 cases and 1176 controls, with a median sample size of 152 (IQR 94, 380). 
None of the reviewed studies provided a pre-specified sample size/power calculation, 
potentially confounding the reported associations or lack of, between possession of 
these SNPs and risk for KTD following exposure to TDF. However, considering the 
minor allele frequency (MAF) of the SNP’s evaluated in the studies, it is probable 
that they were underpowered to detect any significant associations.   
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2.5.6 Patient Populations/Stratification 
Only one of the reviewed studies (115) provided stratification data beyond genotype 
model. Nishijima et al (115), additionally provided stratification based on dominant, 
recessive and additive models. None of the other studies reviewed in this review 
determined any potential confounding for cryptic populations. There were also a 
notably small number of black patients in all the six studies. This may have to do 
with centres where these studies were carried out (Europe Japan and Thailand). Two 
of the studies reported exclusively on Japanese patients (108, 115), and Thai patients 
only (116). 
2.5.7 Reliability of Genotyping methods 
There was uniformity in the genotyping assays employed across all studies. All 
reviewed studies utilised pharmacogenetic assays employing allelic discrimination 
using TaqMan 5-nuclease assays with standard protocols (107, 108, 110). There was 
however, no reference in the five reports (107, 108, 110) as to whether all study 
personnel were blinded to either the genotype or the outcome status. Similarly, 
despite the uniformity of genotyping methods, there were no comments regarding 
any attempts at determining genotyping quality control in any of the reviewed 
studies. These limitations represent an important source of potential confounding.  
2.5.8 Hardy Weinberg equilibrium (HWE) 
All studies performed statistical analyses for HWE of all evaluated SNP’s (including 
ABCC2, ABCC4, and ABCC10) with no discernible deviation apparent or reported.  
 
2.5.9 Mode of Inheritance 
Apart from Nishijima et al (115), none of the other studies reported any 
determination of mode of inheritance of evaluated SNP’s. 
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2.5.10 Adjustment for multiple comparisons 
We did not carry out correction for multiple comparisons (Bonferoni) because of 
potential risk of type two errors given our small sample size.  
2.6.0 Association between specific SNP variants and risk of Tenofovir induced 
Kidney tubular dysfunction in HIV positive patients 
We systematically reviewed the influence of ABCC2, ABCC4, ABCC10, and ABCB1 
SNP’s from various reports of HIV positive patients on TDF. Tables 2.2 to 2.4 give a 
summary of key determinants of variability of SNP’s explored by various 
pharmacogenetic reports.  
2.6.1 Influence of ABCC2 24CC (MRP) Polymorphisms on risk for KTD  
A number of polymorphisms of the ABBC2 (MRP2) gene have been evaluated in 
recent published reports. Possession of the ABCC2 24CC genotype (MRP2, 
rs717620) was consistently associated with the risk for KTD in two of the evaluated 
studies (107, 108), Conversely, Nishijima et al (2015) (115) found no association 
between possession of this genotype and risk of TDF related KTD in these cohorts of 
patients. We found heterogeneity across all studies that explored ABCC2 24CC 
(MRP2, rs717620) SNP (I2 = 51.2%, Q statistics = 8.19, P = 0.08). The pooled odds 
ratio (DerSimonian-Laird) for random effects model was 0.08, (95% CI = 0.05-0.13, 
P = <0.0001). This denotes association between possession of the ABCC2 24CC 
(rs717620), and risk for KTD in these cohorts of patients. It is noteworthy, that the Q 
statistics was lower than the key threshold of 16.9 (threshold for nine degrees of 
freedom). Table 2.3 gives the summary of fixed and random models of the studies in 
this report 
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Study, year 
(Country) 
Ethnicity  
 
Design 
(numbers 
per group) 
Sample size 
justification 
Provided 
Definition of 
case group 
Definition of 
comparison 
group 
Exclusion 
criteria 
Tenofovir 
exposure 
Covariates  Genes 
investigated 
SNPs 
investigated 
HWE 
assessed 
at each locus 
Statistical 
analysis 
Izzedine et al 
(109), 2006 
(France) 
Caucasian Case control 
13 cases, 17 
controls 
No  Cases and 
controls were 
defined as 
discussed in 
section 2.5.4 
Cases and controls 
were defined as 
discussed in 
section 2.5.4 
Not stated  One month  Duration of 
HIV, Age, 
and Male 
sex 
ABCC2 
ABCC4 
ABCB1 
 
ABCC2 24CC 
ABCC2 1058 
ABCC2 1249 
ABCC2 3563 
ABCC2 3972 
ABCC2 4544 
ABCC4 559 
ABCC4 669 
ABCC4 912 
ABCC4 951 
ABCC4 969 
ABCC4 1497 
ABCC4 3310 
ABCC4 3348 
ABCC4 3609 
Yes Logistics 
regression  
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Rodriquez-
Novoa et al 
(107), 2009 
(UK) 
 
 
Caucasian 
(90%) 
 
Case control 
19 cases, 96 
controls 
No  Cases and 
controls were 
defined as 
discussed in 
section 2.5.4 
Cases and controls 
were defined as 
discussed in 
section 2.5.4 
Not stated  
 
Median of 
34 months  
Age, TDF 
exposure, 
Body 
weight, 
SNPs of 
genes 
encoding 
TDF 
transporter
s 
 
 
 
ABCC2 
ABCC4 
ABCB1 
SLC22A6 
SLC22A11 
 
ABCC2 24CC 
ABCC2 1249 
ABCC2 3563 
ABCC2 3972 
ABCC2 4544 
ABCC4 669 
ABCC4 3463 
ABCC4 4131 
ABCB1 3435 
ABCB1 1236 
SLC22A6 
SLC22A11 
Yes Logistics 
regression 
Pushpakom et 
al (110), 2011 
(UK) 
 
Caucasian 
90%  
Case control 
(19 Cases, 96 
controls) 
No  Cases and 
controls were 
defined as 
discussed in 
section 2.5.4 
Cases and controls 
were defined as 
discussed in 
section 2.5.4 
Not stated Median of 
34 months 
Age, TDF 
exposure, 
Body 
weight, 
SNPs of 
genes 
encoding 
TDF 
transporter
s 
ABCC10 
 
ABCC10 
(rs2125739) 
ABCC10 
(rs9349256) 
 
 
Yes Logistics 
regression  
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Nishijima et al 
(108), 2012 
(Japan) 
 
 
Japanese 
(100%) 
 
 
Case-control 
(19 cases, 171 
controls) 
No Cases and 
controls were 
defined as 
discussed in 
section 2.5.4 
Cases and controls 
were defined as 
discussed in 
section 2.5.4 
(1) Active 
infection, 
(2) 
malignancy
, (3) 
diabetes 
(4) alanine 
aminotrans
ferase 2.5 
times more 
than the 
upper limit 
of normal. 
(5) 
Estimated 
glomerular 
filtration 
rate 
(eGFR) 
<50 
mL/minute
s. (6) 
Patients 
without 
consent to 
the study 
  
71.5 weeks 
 
Sex, Age, 
Gender, 
body 
weight, 
duration of 
TDF 
exposure, 
SNPs of 
genes 
encoding 
TDF 
transporter
s 
 
ABCC2 
ABCC4 
ABCC10 
ABCB1 
SLC22A6 
 
ABCC2 24CC 
ABCC2 1249 
ABCC2 2366 
ABCC2 2934 
ABCC4 559 
ABCC4 912 
ABCC4 2269 
ABCC4 3348 
ABCC4 4135 
ABCC4 4976 
ABCC10 
rs2125739 
ABCC10 
rs9349256 
ABCB1 2677 
T>A 
SLC22A6 
rs11568630 
 
Yes Logistics 
regression 
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Danjuma et al, 
in press 
(UK) 
 
Caucasian 
(73.7%) 
 
Case-control 
(15 case and 
43 controls) 
No  Cases were 
defined by 
urinary 
RBPCR >17 
Controls were 
defined as patients 
with RBPCR <17 
Not stated  583 days Age, 
weight, 
duration of 
TDF 
exposure, 
SNPs of 
genes 
encoding 
TDF 
transporter
s  
ABCC2 
ABCC4 
ABCC10 
SLC22A6 
SCL22A11 
ABCC2_24CC 
ABCC4 669 
ABCC4 3463 
ABCC10 
(rs2125739) 
ABCC10 
(rs9349256) 
SLC22A6 
SLC22A11 
Yes  Logistics 
regression 
Nishijima et al 
(115) 2015 
(Japan) 
Japanese 
(100%) 
Prospective 
cohort 
No Cases were 
defined as 
patients with 
eGFR >10m 
l/min/1.73m2 
decrement in 
eGFR relative 
to baseline, 
>25% 
decrement in 
eGFR, and 
eGFR 
<60ml/min/1.
73m2 
Controls were 
patients with 
eGFR greater the 
thresholds defined 
earlier  
Exclusion 
criteria 
provided  
3.66 years Age, 
weight, 
BMI, HIV 
VL, CD4 
count, 
duration of 
TDF 
exposure, 
SNPs of 
genes 
encoding 
TDF 
transporter
s 
ABCC2 
 
ABCB1 
24C>T 
1249G>A 
2677T>A 
Yes  Logistic 
regression  
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RBPCR: urinary retinol binding protein creatinine ratio (corrected for urinary creatinine excretion 
Table 2.2: Summary of demographic and pharmacogenetic characteristics of evaluated studies  
 
Likanonsakul 
et al (116)  
Thailand 
(2016) 
Thai 
(100%) 
Case control; 
n = 273 
(cases = 54, 
controls = 
219) 
No  Cases and 
controls were 
defined based 
on urinary β-
microglobulin 
thresholds 
Cases and controls 
were defined 
based on urinary 
β-microglobulin 
thresholds 
 At least 12 
months 
Age, 
weight, 
duration of 
TDF 
exposure, 
and genes 
encoding 
TDF 
transporter
s 
ABCC2 
 
 
 
 
ABCC4  
-24CT 
1249  
 
 
T4976C  
Yes Logistic 
regression  
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As reported by previous published mechanistic/pharmacogenetic studies (107, 108, 
109), MRP2 (ABCC2) is not a transporter for TDF. Rather, putative transporters for 
TDF include MRP4 (ABCC4), and MRP7 (ABCC10) (110). Probable suggestions for 
this mechanistic dissonance have already been dealt with in section 1.4.1 of this 
thesis. Regardless of pharmacogenetic mechanism for this paradox, the consistency 
of association across these reports suggests a potential predictive role for the ABBC2 
24CC (rs717620) genotype. Other evaluated SNPs of ABCC2 (MRP2) include 
ABCC2 1249GA (rs2273697) (107), (108),(109), ABCC2 3563TA (rs8187694) (107), 
(109). It is noteworthy, that no consistent association has been reported with these 
SNPs. Figure 2.2 depicts a forest plot of studies evaluating the ABCC2 24CC 
(rs717620) SNP.
  58 
Table 2.3: A random and fixed effects model summary of evaluated studies 
 
Pharmacogenetic and statistical consideration 
 
 
 
 
Random Effects Model 
 
Fixed Effects Model 
 
SNP ID Target 
Genotype
/Allele 
Genotype/Allele 
Frequency 1 
  
I2 (%) Q-statistics Effect 
Size 
Confidence 
interval 
(95%) 
P Effect Size  Confidence 
interval (95%) 
P 
ABBC2 24CC 
(MRP2 
rs717620) 
 
 
CC 135 51.2 8.19 
 
0.08 
 
0.05-0.13 <0.0001 0.08 0.06-0.11  <0.0001 
ABCC10 
(MRP7, 
rs9349256)  
 
 
GG 56 0 0.93 0.04 0.03-0.06 <0.0001 0.04 0.02-0.06 <0.0001 
ABCC10 
(MRP7, 
rs2125739) 
 
 
CC 27 0 0.93 
 
0.12 
 
0.07-0.20 <0.0001 
 
0.12 
 
0.07-0.19 <0.0001 
1. Combined target genotype/allele frequencies of the reviewed studies  
I2 = measure that aims to quantify heterogeneity of the studies. The higher the value, the more heterogeneous the studies are.
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Figure 2.2: Forest plot of studies exploring association between ABCC2 24CC single 
nucleotide polymorphism and risk of TDF induced kidney tubular dysfunction in HIV 
positive patients 
2.6.2 Role of ABCC10 (MRP7) gene polymorphisms in Tenofovir induced 
Kidney tubular dysfunction 
Three of the reviewed studies in this report explored the potential association 
between possession of ABCC10 SNPs (rs9349256 and rs2125739) and risk for KTD 
following TDF exposure in HIV positive patients (108), (110), and (115). There was 
no significant heterogeneity in the evaluated ABCC10 SNPs (MRP7, rs9349256 and 
rs2125739) in regards to their effect sizes (I2 = 0%, Q statistics of 0.93, P = <0.62 vs. 
I2 = 0%, Q statistics = 0.93, p = <0.65 respectively). There was significant 
association between possession of the intronic G allele of the ABCC10 (rs9349256), 
and C allele of the ABCC10 (rs2125739) and risk for KTD (Mantel-Haenszel pooled 
odds ratios for the fixed effects models = 0.04, CI = 0.02-0.6, p = <0.0.0001; 0.12, 
Odds ratio meta-analysis plot [random effects]
0.01 0.1 0.2 0.5 1
ABCC2 24_CC (rs717620) Nishijima et al 2015 0.09 (0.06, 0.12)
ABCC2 24_CC (rs717620) Izzedine et al 2006 0.23 (0.05, 0.97)
ABCC2 24_CC  (rs717620) Danjuma et al 2014 0.04 (0.01, 0.12)
ABCC2 24_CC  (rs717620) Nishij ima et  al 2012 0.06 (0.03, 0.11)
ABCC2 24_CC  (rs717620) Rodriguez-Novoa et al 2009 0.14 (0.07, 0.28)
combined [random] 0.09 (0.06, 0.13)
odds ratio (95% confidence interval)
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and CI = 0.07-0.19, p = <0.0001 respectively) figures 2.3 and 2.4. Table 2.3 gives the 
estimate of the predictive models including the random effects model. In a recent 
combined mechanistic/pharmacogenetic seminal report, Pushpakom et al (110) first 
established the association between possession of ABCC10 genotypes and combined 
ABCC2-ABCC10 haplotypes with the risk of TDF induced KTD. There was an over-
representation of the intronic G allele (rs9349256) in the KTD cohort (OR 2.3; CI, 
1.1–5.3; P = 0.02), compared with non-KTD controls. Conversely, the exonic non-
synchronous SNP (ABCC10 rs2125739) was found to be only marginally associated 
with risk for KTD (OR, 2.0, P = 0.05).  
 
 
Figure 2.3: Forest plot of studies evaluating single nucleotide polymorphisms of ABCC10 
(MRP7, rs9349256) gene and risk of Tenofovir induced kidney tubular dysfunction in HIV 
positive patients 
 
Odds ratio meta-analysis plot [fixed effects]
0.001 0.01 0.1
ABCC10 (rs9349256) Nishijima et al (2012) 0.049 (0.026, 0.090)
ABCC10 (rs9349256) Danjuma et al (2014) 0.027 (0.007, 0.090)
ABCC10 (rs9349256 Pushpakom et al (2011) 0.040 (0.019, 0.086)
combined [fixed] 0.042 (0.028, 0.064)
odds ratio (95% confidence interval)
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 Figure 2.4: Forest plot of studies evaluating single nucleotide polymorphisms of 
ABCC10 (MRP7, rs2125739) gene and risk of Tenofovir induced kidney tubular 
dysfunction in HIV positive patient 
2.7.0 Discussion  
There has been considerable interest regarding the association of TDF with 
development of KTD in HIV positive patients. Whilst the exact clinical and 
laboratory phenotypes have continued to be subjects of intense debate, possession of 
certain single nucleotide polymorphisms of genes encoding proteins involved in TDF 
transport seems to confer increased risk for KTD (107, 108, 110). In separate reports, 
Rodriquez-Novoa (107) et al, and Pushpakom et al (110) first reported the 
association between possession of the ABCC2 24CC (MRP2, rs717620) and 
ABCC10 (MRP7, rs2125739, rs9349256) SNPs respectively with increased risk for 
KTD in these cohorts of patients. Subsequent reports have since suggested varying 
degrees of association between the ABCC2 24CC, the two ABCC10 SNPs 
(rs2125739 and rs9349256), and KTD risk in these cohorts of patients.
Odds ratio meta-analysis plot [fixed effects]
0.01 0.1 0.2 0.5
ABCC10 (rs2125739) Danjuma  et  al (2014) 0.12 (0.04, 0.35)
ABCC10 (rs2125739) Nishijima et al (2012) 0.09 (0.03, 0.22)
ABCC10 (rs2125739) Pushpakom et al (2011) 0.16 (0.07, 0.33)
combined [fixed] 0.12 (0.08, 0.20)
odds ratio (95% confidence interval)
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Table 2.4: ABCC2 and ABCC10 SNP frequencies and distribution amongst KTD cohorts in HIV positive patients exposed to TDF 
Studies Design Population N 
Gender 
(male) 
% 
ABCC2 Genotype 
Frequencies 
ABCC10 Genotype frequencies 
rs9349256 rs2125739 
 
GG       GA       AA  CC       CT  TT 
Rodriguez-Novoa 
et al (2009) (107) 
Case control HIV positive 
patients (Hospital 
Cohort) 
115 78.9 16 2 1 - - - -            - - 
Nishijima et al 
(2012) (108) 
Case control HIV positive 
patients (Hospital 
Cohort) 
190 94.7 18 1 0 4  9 6 15 6 0 
Pushpakom et al 
(2011) (110) 
Case control HIV positive 
patients (Hospital 
Cohort) 
115 98 16 2 1 - 22 -        - 
Nishijima et al 
(2015) (115) 
Prospective 
cohort § 
 
HIV positive 
patients (Hospital 
cohort) 
703 95.6 83 38 5 -- -- -- 
Danjuma et al (in 
press)  
Case control HIV positive 
patients (Hospital 
Cohort) 
81 43 24  7 13        17 7 15 
Izzedine et al 
(2006) (109) 
Case control HIV positive 
patients (Hospital 
Cohort) 
30 92 9 3 1 - - -- -- 
 
§. We considered the third out of the three outcomes used to define kidney injury in this study (i.e. eGFR<60mls/min/1.72m2)
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It is noteworthy however, that in recent pharmacogenetic analyses of a large 
prospective cohort of HIV positive patients on TDF based regimen Nishijima et al 
(115) reported no significant association between possession of the ABCC2 24CC 
genotype and risk for KTD. How the relatively large sample size of this study and its 
mode of adjudication of kidney dysfunction (eGFR rather than novel markers of 
tubular dysfunction) affect this outcome remains uncertain. Additionally, the 
percentage variability (attributable to possession of these SNP’s) in risk of 
developing KTD following TDF exposure in light of other potential confounders 
(including concomitant medications, and HIV disease process itself) remains 
unsettled. Utilising pooled estimates from constituent studies, we found an 
attributable risk of about 9.9% of developing KTD with possession of the ABCC2 
24CC genotype following exposure to TDF in HIV positive patients.  Overall, there 
appears to be over representation of the male population amongst carriers of the 
ABCC2 24CC genotype (107). About 78-98% of the KTD cohorts for example in the 
Six published studies evaluating this SNP were males (107, 108, 115). Whether this 
male over representation has to do with previously suggested mitochondropathy as a 
mechanism for TDF induced kidney injury is open to debate. Mitochondrial DNA is 
highly mutagenic, and its inheritance is sex-linked (exclusively from the mother). 
How SNPs of these impacts on TDF suggested mitochondropathy should perhaps be 
considered as additional themes in future pharmacogenetic work in this area. It is 
noteworthy that none of the reviewed studies other than Nishijima et al (2015) (115) 
in this systematic review reported on correction/stratification for cryptic populations. 
However, despite stratification, none of the four genetic models showed any 
significant association between possession of the ABCC2 24 CC SNP, and risk of 
TDF induced KTD (115). Most of the studies were carried out in predominantly 
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white populations with two of the studies reporting on exclusively Japanese and Thai 
patients respectively. How much of the variability in susceptibility of this patient 
population to TDF induced kidney dysfunction is explained by possession of these 
SNPs of transport proteins remains unknown. The consistency of these reported 
associations would suggest an underlying effect, the magnitude of which is currently 
difficult to ascertain. Issues with sample size, and methodological qualities of these 
reports may have either blunt or accentuate these effects/associations. In a recent 
report, Jorgenson et al (182) have attempted to address the obvious flaws of these 
reports in common with most recent pharmacogenetic reports. Some of the 
recommendations from this report includes, a checklist of key methodological and 
genotypic issues that needs to be addressed by would-be trialists in the design of 
future pharmacogenetic studies exploring TDF exposure with risk for KTD. 
Similarly, uncertainty would continue to remain until an all-encompassing, readily 
available, and accessible point-of-care outcome mode of adjudication of KTD is 
agreed upon.  
2.7.1 Limitations  
Our analysis is limited by the relatively small sample size of the studies 
systematically reviewed. This perhaps reflects the fact that this is an emerging field 
of ART pharmacogenetics. Additionally, the absence of emphasis on the genotyping 
quality and non-blinding of study personnel as to the various genotypes and study 
outcomes undoubtedly represent a significant source of confounding. Furthermore, 
all the reviewed studies considered a candidate gene-based approach to establishing 
association between TDF exposure and risk of kidney injury in these cohorts of 
patients. What has not been explored thus far is the strength and robustness of these 
associations utilising a genome wide association study (GWAS). From studies in 
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both the general population as well as HIV positive cohorts, GWAS has been shown 
and does have the potential to identify other putative genetic markers that may have 
been missed by hypothesis-based candidate gene approach due to SNP selection bias. 
Furthermore, the lack of a standardised, uniform, acceptable definition of cases and 
controls may have under or overestimated the strength of reported associations  
2.7.2 Conclusion  
We have shown from this systematic review that despite limitations highlighted 
earlier, possession of ABCC2 24CC (rs717620), ABCC10 (rs2125739, and 
rs9349256) SNPs were associated with risk for KTD in HIV positive patients 
exposed to TDF. 
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CHAPTER 3 
THE DETERMINATION OF THE PATTERN OF 
TENOFOVIR INDUCED-KIDNEY INJURY IN 
HIV POSITIVE PATIENTS: AN EXAMINATION 
OF THE MEDICINES AND HEALTHCARE 
PRODUCTS REGULATORY AGENCY (MHRA) 
OBSERVATIONAL COHORT 
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3.0 Introduction 
I set out to conduct a descriptive analyses of yellow card records of HIV positive 
patients on TDF based regimen who developed adverse events, and had them 
reported to medicines and healthcare products regulatory agency (MHRA). 
3.1.1 Methods  
3.1.2  Study design  
This is a descriptive analysis of yellow card records submitted to the MHRA. The 
Yellow Card scheme is the pharmaco-vigilance tool employed by the MHRA to 
encourage spontaneous and voluntary reporting of all suspected adverse drug 
reactions by healthcare providers, the pharmaceutical industry, and patients (since 
2005) in the United Kingdom (188). This data is subsequently classified into an 
online repository called the adverse drug reaction on-line information tracking 
(ADROIT) database and updated on a regular basis as additional reports are 
submitted (188). Periodic evaluation of this data is carried out to identify any adverse 
events signals or potential hazards associated with medicines currently in clinical 
use. Where adverse signals are ascertained or suspected, they are communicated to 
both healthcare providers and patients to prevent any further harm and protect public 
health (188).  
For this study, category II Yellow Card reports of HIV-positive persons taking TDF 
as part of their ART regimen and spontaneously reported to the MHRA and 
Commission on Human Medicines (CHM) between 2001 and 2010 was obtained and 
analysed. Category II data refers to data with potential patient/reporter identifiers. 
They include patient’s medical history, dates of drug administration, reported 
reaction as well as pre and post exposure blood test results. Utilisation of these data 
therefore require prior authorisation. An application to obtain and analyse these data 
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was submitted to independent scientific advisory committee (ISAC) of the MHRA. 
Following exhaustive review, approval was granted to obtain and analyse these data. 
Data was received in form of Microsoft excel spread sheets with key variables such 
as adverse drug reaction number (ADR), duration on TDF, route of administration, 
description of the drugs adverse event, action taken by the reporting team, ADR 
outcome, weight, age, unclassified laboratory data (including serum creatinine, urea, 
serum phosphate, serum calcium, HIV viral load, and CD4 count). Urinary 
parameters accompanying the data include urinary amino acids (where available), 
urine protein creatinine ratio (PCR), results of urine dipstick including glycosuria 
and proteinuria. Not all patients had complete laboratory dataset before commencing, 
whilst taking, and after TDF exposure. Before classification, the data was cleaned to 
remove duplicate entries. Cases that were adjudicated by original reporting source to 
be “Fanconi syndrome”, “acute kidney injury” (reported as “increased creatinine” 
“reduced GFR”, “acute renal failure”) or chronic kidney disease/injury were 
analysed. In addition reports with outcomes such as “nephrogenic diabetes 
insipidus”, proteinuria, glycosuria and amino aciduria (with or without other 
components of Fanconi syndrome) were classified as suspected kidney tubular 
dysfunction (KTD) and analysed as a sub-group. Where numerical eGFR was 
reported as the marker of kidney dysfunction, I further standardised this by 
estimation with the CKD-EPI equation and presented as mls/min/1.73m2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
3.1.3 Definition of Tenofovir associated kidney Injury 
I utilised the definition of kidney tubular dysfunction (KTD) and Fanconi syndrome 
as variously discussed elsewhere in literature (107).  
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Additionally, CKD was defined as estimated glomerular filtration rate 
(eGFR)/creatinine clearance (estimated by Cockcroft-Gault equation) 
<60 mls/min/1.73m2 over a 3-month period.  
Cases where alternative causes for kidney impairment were reported (including 
nephrotoxic drugs and intrinsic kidney disease amongst others) were excluded from 
the analyses.  
Resolution of kidney dysfunction was defined as eGFR/creatinine clearance 
>60 mls/min/1.73m2 from baseline, or normalisation of makers of KTD/Fanconi 
syndrome (highlighted above) on follow up assay.   
3.2.0 Patient recruitment and screening 
3.2.1 Inclusion criteria  
 HIV positive 
 On TDF based regimen  
 Any stage of kidney disease 
3.2.2 Exclusion criteria 
Yellow card reports without evidence of TDF exposure 
3.2.3    Statistical Methods and Data handling 
Demographic, laboratory, and clinical characteristic were compared using Student T- 
and Chi-squared tests for parametric and non-parametric variables as appropriate. 
Descriptive results of variables were presented as Median ± interquartile range, 
Mean ±standard deviation as appropriate. All statistical analyses were carried out 
with SPSS software 22 (version Inc. Chicago, Illinois, USA). 
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3.3.0 Data management  
As discussed in earlier section of this chapter, data were received unclassified from 
MHRA in form of a Microsoft excel spreadsheet. This was classified as earlier 
described and stored in the secured computers of department of clinical 
pharmacology, the University of Liverpool. Access to these records are logged and 
restricted to the principal and co-investigators only.  
3.4 Ethics approval  
An initial application for authorization to utilize ADROIT data in order to carry out 
this analysis was submitted to the MHRA. This was reviewed by ISAC and a 
provisional approval granted subject to compliance with suggested amendment to the 
study protocol. Following implementation of suggested amendments, a further 
review by ISAC resulted in full authorization to proceed with data acquisition from 
information technology unit of MHRA. 
 
 
Figure 3.1: Classification of MHRA data into various kidney phenotypes 
3.5.0 Results 
The demographic and clinical characteristics of the study population are given in 
Table 3.1. Over a 9-year period (2001-2010), a total of 407 category II Yellow Card 
reports of patients with suspected kidney related ADRs due to TDF were reviewed. 
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One hundred and six (106) satisfied the definition of acute kidney injury (33%), 
Fanconi syndrome (17%), and kidney tubular dysfunction (50%), figure 3.1. There 
was significant correlation between eGFR (estimated by the EPI-CKD equation) and 
age in this patient cohort (r = -0.41, P = 0.01).  
Out of the 106 reports analysed, 33 (31.4%) patients required hospitalisation due to 
TDF-related kidney adverse events, with a mortality of 18.2% (6 out of 33 patients), 
figure 3.2. There was a statistically significant difference (P = 0.01) in the rates of 
hospitalisation between the 3 TDF related kidney phenotypes. Patients classified as 
Fanconi syndrome had the highest frequency of hospitalization (55.6%). Fanconi 
syndrome represents the extreme phenotype of TDF related kidney toxicity. 
 
 
Figure 3.2: Morbidity of various TDF Kidney phenotypes amongst MHRA patient 
cohorts 
3.5.1 Amino Aciduria and TDF exposure 
About 2.8% of the studied cohort had urinary amino acid abnormalities. However, 
the nature of amino acids excreted in urine in these patients was not reported. In all 
cases, cessation of TDF was associated with normalization of adverse kidney 
parameters (including amino aciduria). 
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3.5.2 Proteinuria and TDF exposure 
Two patients had significant Nephrotic range proteinuria out of the 106 patient 
cohorts examined. The first patient had 4.5gram/24hours proteinuria thirteen months 
after commencing TDF. There were no records of normalisation of kidney function, 
and or persistent proteinuria following cessation of TDF in this patient. Whilst the 
second patient had 2.59 grams proteinuria in 24 hours, with kidney function 
(including 24 hour urinary protein excretion) returning back to normal following 
cessation of TDF. In both cases, the diagnostic threshold for significant proteinuria 
was attained.
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Table 3.1: Demographic and clinical characteristics of the study population (N = 
106) 
Characteristics All patients AKIa (N=35) KTD b (N=53) 
 
Fanconi Syndrome 
(N =18) 
 
 
P 
Age (years) 
Mean (±SD c) 
 
41 (±13) 44.1 (±14.1) 39.1 (±12.1) 45 (±11.7) 0.16 
Gender (Male) 
(N) 
77 27 38 12 0.6 
Ethnicity (White) 
N 
4 - 2 2 0.41 
Hepatitis BsAg 
(Positive) 
N  
2 - 2 - -- 
CD4 cell count (cells/mm3) 
Median (IQRD) 
 
192 (117, 
259) 
200 (55, 241) 200 (117, 259) 232 (113, 305) 0.86 
HIV RNA viral load (copies/ml) 
Median (IQR) 
 
 
1165 (244, 
2710) 
4676 (63.8, 
29355) 
811 (811, 811) 0.90 
Duration on TDF (Days) 
Median (IQR) 
316 (120,740) 
374.5 (51.5, 
813.7) 
277 (122.5, 
521.5) 
419 (246, 1000) 0.46 
Protease Inhibitors (PI) exposure 
N (%) 
4 (3.3) 0 3 1 0.36 
Weight (Kilograms) 
Median (IQR) 
61 (50, 73) 63 (51.5, 76) 60 (50, 70) 55 (48, 74.3) 0.59 
eGFR (ml/min/1.73m2) 
Median (IQR) 
34 (12.2, 
58.2) 
29 (25, 75) 44 (12, 64) 41 (18, 61) 0.58 
Serum Creatinine (μmol/L) 
(Median, IQR) 
183 (127, 
371) 
 
221 (146, 
379) 
133 (123, 500) 145 (110, 523) 0.48 
Urine PCRe (mg/mmol) 
Median (IQR) 
62 (4.4, 
113.5) 
62 (62, 62) 48.9 (4.1, 114.4) -- 1.0 
Alkaline phosphatase (IU/L)        
(Median, IQR) 
265 (196, 
330) 
286 (187, 
329) 
324 (228, 324) 204 (164, 204) 0.29 
Data presented are median (interquartile range) for quantitative variables and number of patients (percentage) for 
qualitative variables as appropriate. a: acute kidney injury; b: Based on  RBPCR > or < 17 µg/mmol; c: Standard 
deviation; d: Inter-quartile range; e: Urine protein creatinine ratio
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Figure 3.3. TDF exposure (in months) amongst various Kidney phenotypes in the 
MHRA cohort 
 
There were limited data available for HIV protease inhibitor exposure (3.5 %). Only 
four patients of the entire series examined had data on PI exposure. Of these, patients 
on boosted Atazanavir (n = 2) had KTD, whilst those on boosted Lopinavir and 
Indinavir had Fanconi syndrome and KTD respectively. The median time between 
TDF exposure and onset of kidney related adverse effect was 316 days (IQR, 
120,740). See figure 3.3 
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Nearly half (48.1%) of a total of 106 Yellow Card reports of TDF related kidney 
adverse effects analysed reported resolution following withdrawal of the drug. None 
of the patients fulfilled criteria for CKD before exposure to TDF but four patients 
(6.2%) out of the total number of reports had eGFR <60mls/min/1.73 m2 consistent 
with CKD even after withdrawal of TDF. The report of TDF kidney related adverse 
effects from various community and clinical sources to the MHRA peaked between 
2005-2006 as shown in figure 3.4. 
3.6.0 Discussion  
This represents the first attempt at interrogation of MHRA records to ascertain the 
pattern of kidney injury in HIV-positive persons exposed to TDF. Despite the likely 
under reporting of cases, this study provides additional insight into the pattern of 
kidney involvement amongst HIV positive persons exposed to TDF, and supports 
this association reported from observational and randomised clinical trials. TDF has 
well-established efficacy and safety profile for the treatment of HIV patients, but a 
propensity to cause various kidney syndromes have continued to be a subject of great 
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concern as expounded in other areas of this thesis (144, 145). The high number of 
TDF related ADRs evident between 2005-2006 in this study (as shown in figure 3.3), 
and subsequent fall thereafter would suggest periods of increasing awareness, 
increased monitoring, and resultant caution with the use of TDF. Alternatively, it 
may reflect the enthusiasm sometimes seen with early experience with a new drug, 
and the associated tendency to report on any new untoward adverse effects (AE’s). 
However, as often is the case, with more clinical experience with it, there is a waning 
tendency to report less on these AE’s. I was unable to ascertain the impact of 
protease inhibitor (PI) exposure on the pattern of TDF-related injury in this cohort 
owing to missing data on this variable. Overall, only 4 patients of the entire series 
had data on PI exposure. Nevertheless, patients who were on boosted Atazanavir (n = 
2) had KTD, whilst those on boosted Lopinavir and Indinavir had Fanconi syndrome 
and KTD respectively. The role of PI exposure in the pathogenesis of TDF-related 
injury has continued to be a subject of intense mechanistic and therapeutic debate 
(154, 153, 171). In a recent report exploring the Swiss HIV study cohort database, 
contemporaneous administration of TDF with boosted Atazanavir or Lopinavir was 
associated with a greater initial decline in e-GFR compared to TDF/EFV regimen 
(189). Similarly Cao et al (190), recently reported a greater rate of decline in renal 
function in Chinese patients on TDF+PI/r based ART regimen compared with their 
cohorts on non-TDF regimen at 48 weeks. Amongst suggested mechanisms for the 
role of PIs in the TDF-related kidney injury includes PI-mediated increase in plasma 
concentration of TDF (191). In contrast to earlier reports, this study showed no 
preponderance of the KTD/Fanconi phenotype in male sex. The fact that only about 
50% of patients in this study were reported to have regained normal kidney function 
is very interesting. Four patients out of the examined cohort had CKD. The 
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underlying primary/secondary kidney disease in the patients with CKD in the reports 
was unstated. The mean duration of restoration of kidney function following 
cessation of TDF is variable (192). All of the reported mortality in this study were 
due other HIV related complications and not attributable to progressive kidney 
disease or TDF exposure. Similarly though 6 out of the 33 patients hospitalized for 
TDF related adverse effects died in this report, it still remains uncertain if these were 
mainly as a result of TDF kidney adverse effects only, or if concomitant burden of 
associated comorbidities largely drove this. Two patients had Nephrotic range 
proteinuria, there were no further data or information as to the definitive cause of 
this. TDF has been associated with varying degrees of proteinuria, but association 
with frank Nephrotic syndrome is still yet to be established. One patient died of 
intractable metabolic acidosis with no additional details to support the role of TDF 
exposure or other alternative diagnoses. Another patient had associated limb 
weakness with muscle biopsy demonstrating COX negative fibres suggestive of 
drug-induced mitochondrial toxicity. The third patient had acute pancreatitis with 
severe metabolic acidosis.  
3.6.1 Limitations 
The limitation of this study reflects problems encountered by previous attempts at 
exploring such data schemes. These include its descriptive design, difficulties with 
accurately estimating the prevalence of TDF related kidney injury, certainty in 
establishing causality between TDF exposure and kidney injury, and incomplete 
records of reported events amongst others. The significance of under reporting of 
yellow cards as a limitation of this study needs to be emphasized, as it remains an 
important confounder to the outcome of this study. Not all professionals statutorily 
required to send yellow card reports of patients on TDF who develop ADR were well 
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informed about the need for this. And even where there was an understanding of 
need, often the report sent was not exhaustive and fails to support the clinical 
circumstances underlying the ADR. Additionally, very often with early experience of 
a new drug, there is a tendency for increased yellow card reports, which then wanes 
as more clinical experience with the drug becomes established. This may have 
explained the varying time-related reporting pattern with TDF in our report. In 
addition the absence of a universally accepted validated definition of what constitutes 
tubular dysfunction in HIV-positive persons on TDF makes objective adjudication of 
the Yellow Card reports difficult.  
3.6.2 Conclusion and future perspectives  
The pattern of TDF associated kidney adverse effects observed in this population 
series mirrors that reported in both hospital cohorts, and randomized clinical trials. 
Cessation of TDF was associated with complete restoration of kidney function in up 
half of the patient population in this report. 
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4.0 Background 
4.1 Tenofovir transport  
TDF is excreted by the kidneys through a combination of glomerular filtration, and 
active tubular secretion into the kidney tubular lumen. Two groups of drug 
transporters have been identified to facilitate TDF kinetics. Influx and efflux 
transporters such as organic anion transporters (OAT), and multi drug resistance 
proteins (MRP) transports TDF in and out of kidney tubular cells respectively (150, 
155), figure 4.1.  
 
Figure 4.1: Schematic representation of TDF transport proteins (MRP2 is 
represented in red as it has not been established as a TDF transporter despite genetic 
association SNP’s of gene encoding it)   
 
4.1.1 Organic Anion Transporters (OAT) 
Organic anion transport (OAT) (150, 155) proteins are expressed at the basolateral 
aspect of kidney tubular cells (KTC) and have been established from a number of 
mechanistic studies to transport TDF into these cells from blood capillaries. Multi-
drug resistant (MRP) proteins mediate the transport from KTC’s into the tubular 
lumen(155). Influx transporters OAT1 and OAT3 (encoded by the SLC22A6 and 
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SLC22A8 genes respectively) have thus far been shown to be the key transporters 
involved in TDF transport into KTC’s (193). To date no single nucleotide 
polymorphisms (SNPs) of their genes have been shown to either impact on TDF 
transport, therapeutics, or toxicity.   
4.1.2 Multi-drug resistant protein (MRP) transport systems 
This class of drug transporters is comprised of about seven members, and are 
involved in organic anionic transport of a varied number of drugs and other 
xenobiotics across intracellular and extracellular membranes (194). They are 
principally found in the liver, kidneys, and intestinal wall (194). Widely distributed 
in various ethnic populations as depicted in table 4.1, their production is encoded by 
a superfamily of genes called antigen-binding cassettes (ABC) (194). These are 
designated subfamily C, member 2 for ABBC2, member 4 (ABCC4), and member 10 
(ABCC10) etc. They have been shown to transport a number of ART drugs, notably 
TDF (MRP4/ABCC4 (143), MRP7/ABCC10 (110). Mutations in these genes have 
been reported from a number of pharmacogenetic studies to impact on the transport 
of ART drugs as expounded in other sections of this thesis. Figures 4.2, and 4.3 
shows a schematic representation of the ABCC2, ABCC4, and ABCC10 genes.
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Table 4.1: ABCC2, ABCC4, and ABCC10 subfamily common (minor allele frequency > 1%) variant alleles in different ethnic groups and 
functional consequences relevant to Tenofovir disoproxil fumarate metabolism. 
 
Gene (alleles) 
 
Chromosome  
 
Exon/Intron 
 
Nucleotide 
change 
 
Protein variation 
 
Risk of KTD 
 
    *MAF in different populations (%) 
Caucasians Asian Mixed 
ABCC2 
24CC (rs717620) 
1249 G>A (rs2273697) 
2366 C>T, rs56220353 
3563 T>A (rs17222723) 
2934 G>A (rs3740070) 
 
 10 
 10 
 10 
 10 
 10 
 
   Exon 1 
Exon 
Exon 
Exon 
-- 
 
24C>T 
1249 G>A, 
2366 C>T 
3563 T>A 
2934 G>A 
 
-- 
Val417Ile 
Ser789Phe 
Val956Glu 
Ser978Ser 
 
Increased  
Increased  
-- 
Decreased 
-- 
 
0.81 
-- 
-- 
-- 
0.01 
 
0.79 
0.046 
-- 
-- 
0.07 
 
0.89 
0.42 
-- 
0.01 
-- 
ABCC4 
669 C>T (rs899494) 
3463 A>G (rs1751034) 
4131 A>C (rs3742106) 
 
 
 13 
 13 
 13 
  
Exon 
Exon 
Exon 
 
 
669 C>T  
3463 A>G  
4131 A>C  
 
 
Arg144Cys 
Lys1116Lys 
 
-- 
 
 
 
No association 
Lower TDF 
clearance 
Lower TDF 
clearance 
 
 
0.83 
0.85 
 
0.47 
 
 
0.75 
0.67 
 
0.47 
 
 
--- 
-- 
 
-- 
 
ABCC10 
526G>A (rs9349256) 
2759T>C (rs2125739) 
 
 6 
 6 
 
Exon 
Exon 
 
 
526G>A  
2759T>C  
 
 
-- 
Ile948Thr 
 
 
Decreased  
Increased  
 
 
0.44 
0.25 
 
 
0.6 
0.1 
 
 
-- 
-- 
 
* MAF: minor allele frequency. Data compiled from (References (107, 108, 109, 110). Insufficient data is indicated by a hyphen
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Figure 4.2: Schematic representation of polymorphisms of the ABCC2 and ABCC4 genes in 
HIV positive patients on Tenofovir disoproxil fumarate [adapted from Izzedine et al]  (109) 
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Figure 4.3: A schematic representation of the ABCC10 gene [adapted from Hopper 
et al] (195)  
4.2   Pharmacogenetics of TDF induced kidney tubular dysfunction   
Despite increasing reports of association between TDF exposure and risk of KTD, 
uncertainty remains as to the most appropriate diagnostic modality for adjudication 
of KTD. In recent studies (107, 108, 110), KTD has been defined by a composite of 
urinary and serum parameters that perhaps highlight the variable nature of TDF/KTD 
clinical phenotype, and thus preclude easy applicability of these composite markers 
in clinical practice. There has been increasing interest from several reports regarding 
the potential diagnostic utility of LMWP in patients with clinical and sub-clinical 
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forms of TDF induced KTD (162). Retinol-binding protein (RBP) is a low molecular 
weight (LMW) protein that is excreted in increased amounts in patients with KTD 
(162). In the pivotal ASSERT study, patients randomised to TDF experienced 
significant increases in urinary RBP excretion (196). Additionally, in a cross 
sectional report, Campbell et al showed that patients exposed to TDF (when 
administered with a ritonavir-boosted protease inhibitor) were more likely to have 
substantially elevated urinary RBP concentrations (162). Whether KTD as defined by 
LMW proteinuria correlates with SNPs of genes encoding transport proteins 
involved in the disposition of TDF is unknown. I examined association between 
adjusted RBPCR (as a marker of kidney injury) with SNPs of ABCC2, ABCC4, 
ABCC10, SLC22A6 and SLC22A8 genes in HIV positive patients exposed to TDF in 
this hospital cohort. 
 
4.3.0   Study design and patient recruitment  
4.3.1   Study aims 
This study principally investigated the impact of specific SNPs of genes encoding 
proteins involved in TDF transport, and risk of KTD in HIV positive patients 
exposed to it. These include SNPs of ABCC2 (MRP2), ABCC4 (MRP4), and 
ABCC10 (MRP7). These SNPs were selected based on their minor allele frequencies 
(www.pharmgkb.org; www.cypallelles.ki.se) and reported associations with KTD 
from earlier studies amongst other factors (107, 108, 110).  
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4.3.2   Study design 
HIV positive patients attending King’s College Hospital, London, United Kingdom 
between August 2006 to August 2007 were invited to participate in a cross sectional 
study to examine the prevalence of kidney disease and its associated factors.   
 
 
 
Figure 4.4: Study design and patient enrolment (King’s college cohort) 
 
4.4.0   Patient enrolment, screening and sampling 
Patients who provided consent and agreed to participate in the study were initially 
screen and enrolled into the study cohort. A single blood (10mls) and urine (10mls) 
samples were collected and stored at -70C until completely used.  
4.4.1 Patient recruitment 
4.4.2 Inclusion criteria 
 Age ≥18 years  
 HIV positive “on” or “off” ART drugs 
 Any CD4 count or HIV viral load 
 Able to give informed consent 
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4.4.3 Exclusion criteria 
 Inability to give informed consent  
4.4.4 Case definition 
In this study kidney injury (as a standard for subsequent comparison with other novel 
biomarkers including LMW proteinuria) was defined as: 
 eGFR <60mls/min/1.73m2 
 Urine PCR ≥20mg/mmol (this definition was based on the work of Campbell 
et al (162) in a cross section of HIV positive patients attending outpatients 
clinic at King’s College Hospital London) 
 RBPCR ≥ 17μmol/mmol 
4.4.5 Ethics and data management 
The protocol for the initial cross sectional study was reviewed and subsequently 
approved by NHS research ethics committee. For this subsequent pharmacogenetic 
sub-study, an amendment was sent to North Manchester research ethics committee 
for approval to carry out additional genetic analyses on the repository serum samples. 
Following review of this amendment, approval was granted for commencement of 
pharmacogenetic assays and further analysis of stored serum samples.   
4.5.0 Genetic analyses 
To ensure reliability of the process, and validity of our results, separate DNA 
processing steps were carried out in designated areas in keeping with best laboratory 
(lab) practices. Sample preparation was carried out in a category II lab, whilst DNA 
extraction was done in a designated area of our lab earmarked for nucleic acid work. 
Preparation of PCR reaction plates including genotyping was carried in a category III 
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lab under a safety hood in keeping with local GCP and manufacturers’ protocol. All 
DNA work was carried out in the molecular labs of the University of Liverpool 
4.5.1 DNA extraction  
Genomic DNA was extracted from stored serum samples using the QIAamp DNA 
extraction kit. This was to allow rapid purification of DNA from our serum sample. I 
carried this out as follows: 
 Frozen serum samples were thawed by placing in preheated water bath for 
one hour. 
 20µl of QIAGEN protease provided from the manufacturer was pipette into a 
2ml Eppendorf to ensure lysis of DNA in the sample.  
 200µl of thawed serum sample was added into this. 
 200µl of AL buffer was added to this mix 
 The resulting mixture was pulse vortexed for 15 seconds (s) to ensure 
adequate mixing of the constituents (buffer, sample, and QIAGEN protease) 
 I incubated the mixture at 56o C for 10 minutes. This represents the optimal 
time for DNA yield, as longer incubation periods have no impact on quality 
of DNA. 
 The mixture was centrifuged at 1000 rotations per minute (RPM)  
 200µl of 96% ethanol was pipette into the mix, and pulse vortexed for 15s to 
remove drops from the lid. 
 I then pipette out the mixture unto a QIAamp Mini spin column (provided 
with 2mls collection tubes), without wetting the rim of the column. This was 
centrifuged at 8000 RPM for purification involving four steps below. 
 The QIAamp spin column was transferred unto a clean 2mls collection tubes, 
and the old collection tubes containing the filtrate was discarded 
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 Centrifuge again at 8000RPM for 1 minute (min) 
 I carefully opened the QIAamp spin column and pipette in 500µl of AW1 
buffer with adequate care taken not to wet the inside of the rim of the spin 
column. With the spin column cover closed, it was centrifuged at 8000RPM 
for 1 min.  
 The QIAamp spin column was transferred into a clean 2ml collection tube, 
with the one containing the filtrate discarded.  
 I then opened the lid of the QIAamp spin column and added 500µl of AW2 
buffer (took adequate care not to wet the inside of the rim of the spin 
column). With the lid closed, the spin column columns were centrifuged at 
12000 RPM for 1min to ensure all residual AW2 buffer is extruded into the 
collection tubes.  
 With the collections tubes discarded, the QIAamp spin column was 
transferred into a clean 1.5ml micro-centrifuge tube. 200µl of AE buffer was 
then added and incubated at room temperature for 5min (to increase DNA 
yield, considering that we were utilizing serum samples rather than whole 
blood, and therefore needed to maximize our DNA yield).  
 The QIAamp spin column was centrifuged at 8000 RPM for 1min. 
 Extracted DNA was stored in -25oC fridge prior to, and during genotyping.  
4.5.2 Quantification of DNA  
DNA concentration of individual samples was estimated through absorbance at 
250nm using spectrophotometer (NanoDrop® spectrophotometry). 
The spectrophotometer was initially calibrated with distilled water and DNA 
concentration. Extracted DNA concentration for individual samples as estimated are 
given in appendix C)  
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4.5.3 Genotyping individual SNP’s 
Made to order primer-probe mix were utilised for genotyping of the seven identified 
SNP’s highlighted earlier. This was made up of sequence-specific forward and 
reverse primers designed to amplify the SNP sequence of note (table 4.2). 
Additionally it contains 2 Taqman® MBG probes with NFQ: 
1. One VIC® labeled probe (to detect allele sequence 1) 
2. One FAMTM labeled probe (to detect allele sequence 2) 
 
Table 4.2: A summary of the VIC/FAM allele context sequences explored  
SNP ID VIC-labeled context sequence  FAM-labeled context sequence 
ABCC2 24CC 
(rs717620) 
ACAATCATATTAATAGAAGAGTCTT[C] 
[T]GTTCCAGACGCAGTCCAGGAATCAT 
ABCC4 3463A>G 
(rs1751034) 
TGCATACCTGAGGTATGATTGACAT[C] 
 
 
 
 
 
 
[T]TTCTTCCTTAAATCGTGAAGTCCAA 
ABCC4 (rs899494) CCATCCAGAGTAGGGCAGTCACTGC[A] 
 
[G]ATCGCCTGCAGTGGTCCTGCCCACA 
ABCC10 
(rs9349256) 
GAGTTTTCACTCTCTCCTGACCTTT[A] [G]TCCAACCCTGTGCCCCACAGCTCAA 
ABCC10 
(rs2125739) 
ACAGCCCCCTCCTCACCACCCAGCA[C] 
[T]CCCAGTGTTCCCACTGCCCAAAGCT 
OAT1 (relative to 
accession 
numberAJ249369 
CCCACTCGGGCCATGGTGCTGCCCA[C] [T]TCCCATGCCTGTCTGCCTGCAGGGC 
OAT4 (rs11231809) AATTCATTCATTCAACAAACATGTA[A] 
[T]TGAGTCCTTACAAACGATACGTCTG 
 
4.5.3.1 Preparation PCR reaction Mix  
Table 4.3 gives a summary of the PCR reaction constituents and volume  
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 Frozen pre-prepared made-to-order primer-probe mix was thawed by placing 
on ice. Fully thawed, it was further re-suspended by vortexing and 
centrifuging at 3000 RPM for 1 min 
 To minimize the usual freeze-thaw cycles, the 80X cDNA primer-probe mix 
was diluted with 1X TE buffer (composed of 10 mM Tris-HCl, 1 mM 
EDTA, pH 8.0, in DNase-free sterile filtered water) to a 20X working stock. 
This was subsequently aliquoted into 1.5ml micro-centrifuge tubes and sored 
at -25oC. 
 I utilised the 96-well plate for running PCR reaction for each SNP, I 
therefore ensured that the total reaction volume was 25µl. This was made up 
of 12.5µl of the 2X TaqMan® Master Mix, 1.25µl of 20X made-to-order 
assay Working Stock, and nuclease free water. Total volume per well was 
5µl.  
Table 4.3: Summary of PCR reaction constituents and volume 
Reaction reagent/DNA Volume (µl) 
ABgene master mix 12.5 X number of samples 
Primer probe mix 12.5 X number of samples 
Sigma water 8 X number of samples 
cDNA 2  
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4.5.3.2 Preparation of the reaction plate  
 5µl of the reaction mix was pipette carefully into each well (60 of the 96-well 
plate). We avoided the outer wells to reduce the risk of contamination (see 
figure 4.5 for plate setup).  
 Reaction plate was carefully sealed with a MicroAmp® Optical adhesive 
film, taking care to expel air bubbles. 
 I centrifuged the plate at 1000 RPM for 1 min to further spin down the 
contents of each well and expel air bubbles.  
 The plate was loaded into a PCR cycler (Opticon® 2 DNA engine, version 3.1 
Bio-Rad laboratories, Inc., Hercules, Ca., USA) utilising standard 
methodology. This was set at 95oC for 15mins, then 40 cycles of 95oC, and 
60oC for 1min. Following upload of the 96-well reaction plate, preparation of 
reaction in the PCR machine was done as follows: 
 A reaction file is opened on the accompanying Opticon® LCD monitor 
 The corresponding FAM/VIC dyes are confirmed and one blank removed. 
 
 
 
 
Figure 4.5: PCR reaction plate setup depicting avoidance of the outer wells to reduce 
risk of sample contamination 
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4.5.3.3   Reading the plates  
Sigmoid curves generated by allelic discrimination of the PCR process, and relevant 
VIC and FAM dye disposition of the SNP’s on the PCR curve were “called” as 
homozygous, heterozygous, or wild type (Figures 4.6, and 4.7). The excel files 
containing raw “called” VIC and FAM dye disposition of various SNPS are given in 
appendix D)  
 
 
 
Figure 4.6: Sigmoid amplification plots showing florescence for different study 
samples. I set the threshold above the detection limit, but above the plateau phase 
during which amplification slows down according to manufacturer’s protocol 
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Figure 4.7: Clustering of “called” SNP PCR amplification data into, blanks (orange), 
homozygous (red), heterozygous (green), and wild type (blue)  
 
4.5.4 Selection of single nucleotide polymorphisms and genotyping  
I selected seven SNPs for mutational screening of genes encoding transport proteins 
involved in the disposition of TDF. The selected SNPs were considered this study 
based on their previously reported association with risk of KTD from earlier studies 
[(107, 108, 110) as well as a minor allele frequency of > 5% in the general 
population. Selected SNPs for analysis in this study includes ABCC2 24CC (MRP2; 
rs717620), ABCC4 3463 (MRP4; rs1751034), ABCC4 669 (MRP4; rs899494), 
SLC22A8 (OAT4; rs11231809), SLC22A6 (OAT1; accession number AJ249369), 
and ABCC10 (MRP7; rs9349256, rs2125739).  
4.6.0 Statistical analysis and Bio-analytical methods 
4.6.1 Statistical analysis 
Genotypic frequencies in the study population were compared by Fisher’s exact test. 
All SNPs were tested for deviation from the Hardy-Weinberg equilibrium (HWE) by 
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Chi squared test using Haploview software (Broad Institute, Cambridge, 
Massachusetts, USA). Both bivariate and multivariate analyses were carried out to 
identify predictor variables. Co-variates with p<0.1 in univariate analysis were 
entered into multivariate logistic regression models. P values <0.05 were considered 
statistically significant. All other data analyses were carried out using StatsDirect 
version 2.7.9 (StatsDirect Ltd, Altrincham, Cheshire, UK). 
4.6.2 Additional bio-analytical methods  
Retinol binding protein (RBP) was quantified by enzyme-linked immunosorbent 
assay (ELISA; Immundiagnostik, Bensheim, Germany; reference range 0.01-
0.54 mg/L) and expressed as ratio to creatinine concentration (RBPCR). Urinary 
RBP corrected for creatinine (mg/mmol) excretion were estimated by laboratory staff 
at King College Hospital laboratories, London. KTD was defined by an upper 
quartile RBPCR (>17 µg/mmol) (162). This definition was based on the seminal 
work of Campbell et al in a cross sectional analysis exploring diagnostic utility of 
various urinary biomarkers (162). 
4.7.0 Results 
4.7.1 Patient characteristics 
Eighty-one (81) of the 220 patients in this cross sectional cohort received TDF at the 
time of sampling. Of these, 23 had missing RBPCR values and were not included in 
analyses. Fifteen (25.9%) of the remaining 58 patients had KTD (as defined by 
RBPCR ≥17 µg/mmol), whilst the remaining 43 (74.1%) patients served as controls. 
The median duration of TDF exposure was 583 days. Patients with KTD had higher 
current CD4 cell counts, lower estimated glomerular filtration rates (eGFR), and 
higher albumin creatinine ratios (ACR), this is shown in Table 4.4. 
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Table 4.4: Demographic and clinical characteristics of the study population (N = 58) 
 
Characteristics 
 All patients 
 
KTD a 
(N =15) 
 
 
Controls 
(N = 43) 
 
P 
Age (years) 
 
Mean (±SDb) 42.2 (±8.2) 46 (±8.3) 41.3 (±8.5) 0.06 
Gender (Male) 
 
N (%) 60 (73.2) 
 
12 (80) 
 
31 (72.1) 
 
0.55 
Ethnicity (White) 
 
N (%) 41 (50) 10 (66.7) 19 (44.2) 0.079 
Hepatitis C co-infection 
(Positive) 
N (%) 7 (8.5) 1 (6.7) 5 (11.6) 0.57 
CD4 cell count 
(cells/mm3) 
 
Median (IQRc) 
 
398 (246, 526) 491 (417, 598) 361 (227, 492) 0.006 
HIV RNA (copies/ml) 
 
Median (IQR) 
 
50 (50, 50) 50 (50, 50) 50 (50, 50) 0.59 
Duration on TDF (Days) 
 
Median (IQR) 583 (195, 1035) 794 (210, 1370) 576 (175, 1022) 0.35 
Co-exposure to protease 
inhibitors (PI) 
N (%) 29 (35.4) 8 (53.3) 13 (30.2) 0.11 
Weight (Kilograms) 
 
Median (IQR) 73 (66, 81.8) 76.7 (53, 23) 74.4 (55, 121) 0.57 
Hypertension (Yes) 
 
N (%) 6 (7.3) 2 (13.3) 4 (9.3) 0.75 
eGFR (ml/min/1.73m2) 
 
Median (IQR) 
 
85.7 (75.5, 94.6) 78.2 (50.6, 87.9) 88.9 (77.8, 100.7) 0.006 
Urine PCRd (mg/mmol) 
 
Median (IQR) 
 
9.4 (6.9, 15.9) 11.2 (6.9, 21.1) 11.1 (1.8, 31.9) 0.112 
Urine ACRe (g/mmol) 
 
Median (IQR) 1.1 (0.7, 2.1) 2.8 (0.16, 12.6) 1.35 (0.094, 6.31) 0.019 
Serum phosphate 
(mmol/L) 
 
Median (IQR) 0.96 (0.84, 1.1) 0.92 (0, 1.35) 0.98 (0.65, 1.36) 0.09 
TmPO4/GFR
f 
 
Median (IQR) 1.0 (0.9, 1.1) 80.8 (62.4, 94.6) 87.8 (66.9, 98.3) 0.08 
Data presented are median (interquartile range) for quantitative variables, and number of patients (percentage) for qualitative 
variables as appropriate. a: Based on  RBPCR > or < 17 µg/mmol; b: Standard deviation; c: Inter-quartile range; d: Urine 
protein creatinine ratio; e: urine albumin creatinine ratio; tubular maximum capacity for renal phosphate re-absorption to 
glomerular filtration rate (GFR) ratio 
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4.7.2 Association of KTD with single nucleotide polymorphisms of genes 
encoding TDF transport proteins 
The distribution of genotypes of various SNPs is shown in Table 4.5. All evaluated 
SNPs achieved HWE (<0.05). There was a lower expression of the genotype CC at 
position 24 of the ABBC2 (MRP2, rs717620) gene in patients with KTD compared 
with CT and TT genotypes (odds ratio [OR] 0.29; 95% confidence interval [CI] 0.08-
0.96, p= 0.04), Figure 4.8. There was a trend towards reduced risk of KTD with the 
intronic G allele of ABCC10 (MRP7, rs9349256; OR = 0.4, 0.2-1.0, P = 0.08), and 
increased risk with the A allele of the influx transporter gene SLC22A11 (OAT 4, 
rs11231809, OR 2.3, 0.9-5.8, P = 0.07).  
 
 
 
Figure 4.8: Graphical representation of the ABCC2 24CC (rs7171620) allele 
frequencies in the study cohort 
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Table 4.5: Allelic frequencies of single nucleotide polymorphisms of genes encoding 
Tenofovir transport proteins in HIV positive patients with and without kidney tubular 
dysfunction (KTDa)  
 
SNPb ID 
 
Patients with KTD a 
N = 15 
 
Controls 
N = 43 
 
OR (95% CI) 
 
P-value 
ABCC2 24  (rs717620) MRP2 
(Chromosome 10) 
  
Homozygous variant               TT 
1 (6.7%) 0 
Heterozygous                          CT 5 (33.3%) 7 (16.3%) 
Homozygous wild type           CC 9 (60.0%) 36 (83.7%) 
C 23 (76.7%) 79 (91.9%) 
T 7 (23.3%) 7 (8.1%) 
ABCC4 3463 (rs1751034) MRP4 
(Chromosome 13) 
  
Homozygous wild type          TT 8 (57.1%) 26 (60.4%) 
Heterozygous                         CT 3 (21.4%) 15 (34.9%) 
Homozygous variant              CC 3 (31.4%) 2 (4.7%) 
T 19 (67.9%) 67 (77.9%) 
C 9 (32.1%) 19 (22.1%) 
ABCC4 669 (rs899494) MRP4 
(Chromosome 13) 
  
      Homozygous wild type    CC -- -- 
      Heterozygous                   CT 3 (20%) 10 (23.3%) 
      Homozygous variant        TT 
12 (80%) 33 (76.7%) 
C 
3 (10%) 10 (11.6%) 
T 
27 (90%) 76 (88.4%) 
SLC22A11 (OAT 4) rs11231809 
(Chromosome 11)   
Homozygous wild type        TT 8 (53.3%) 30 (69.8%) 
Heterozygous                       AT 3 (20%) 9 (20.9%) 
Homozygous variant           AA 4 26.7%) 4 (9.3%) 
T 19 (63.3%) 69 (80.2%) 
A 11 (36.7%) 17 (19.8%) 
SLC22A6 453 GA (OAT1) c 
(Chromosome 2) 
  
Homozygous wild type        CC 12 (80%) 29 (67.4%) 
Heterozygous                       CT 3 (20%) 12 (27.9%) 
Homozygous variant            TT 0 2 (4.7%) 
C 27 (90%) 70 (81.4%) 
T 3 (10%) 16 (18.6%) 
ABCC10 (rs9349256) MRP7 
(Chromosome 6) 
  
Homozygous variant              AA 7 (46.7%) 8 (19%) 
Heterozygous                         AG 3 (20%) 17 (38.1%) 
Homozygous wild type          GG 5 (33.3%) 18 (42.9) % 
A 17 (56.7%) 33 (38.4%) 
G 13 (43.3%) 53 (61.6%) 
ABCC10 (rs2125739) MRP7 
(Chromosome 6) 
  
Homozygous variant                TT 6 (54.5%) 9 (29.0%) 
Heterozygous                           CT 3 (27.3%) 17 (54.8%) 
Homozygous wild type            CC 2 (18.2%) 5 (16.1%) 
T 15 (68.2%) 39 (62.9%) 
C 7 (31.8%) 23 (37.1%) 
Note: Data are number of Alleles/Genotype with percentages in bracket a: As defined by RBPCR >17 µg/mmol; 
b. Single nucleotide polymorphisms; c. Relative to accession no: AJ24936 
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4.7.3 Diagnostic performance of retinol binding protein/creatinine ratio 
(RBPCR) 
I generated AUC/ROC curves to evaluate the performance of upper quartile RBPCR 
(>17μg/mmol), adjusted NGAL/CR, serum creatinine (mmol/L), and eGFR 
(mls/min/1.73m2) in differentiating patients with kidney tubular injury from those 
with normal kidney function. Utilising urine PCR ≥20mg/mmol as cut-off for kidney 
dysfunction, AUC-ROC of upper quartile RBP/CR (>17μ/mmol) was 0.67, (CI = 
0.55-0.81, p = 0.01). This is shown in figure 4.9. 
 
Figure 4.9: AUC-ROC of upper quartile retinol binding protein/creatinine (RBPCR) 
as a diagnostic marker of kidney injury in HIV positive patients on TDF-based 
regimen 
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It is noteworthy that out of the six evaluated surrogate markers of kidney injury, 
eGFR had the least AUC-ROC (0.37, CI = 0.22-0.53, P = 0.07). Conversely, urine 
ACR had the highest AUC-ROC compared with other diagnostic markers for kidney 
injury in these cohorts of patients. RBPCR had the next highest AUC-ROC 
compared to established surrogate markers of kidney injury. The areas under the 
curves as well as sensitivities and specificities of other biomarkers are shown in 
figure 4.10 and table 4.6.    
 
Figure 4.10: ROC curves comparing diagnostic performance of various Kidney 
biomarkers in HIV positive patients on TDF-based regimen. The more leftward the 
plots, the higher their reliability as diagnostic markers of kidney injury in these 
cohorts of patients 
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Table 4.6:  Area under the curve (AUC) and confidence intervals of comparative 
performance of biomarkers of kidney injury in HIV positive patients exposed to 
TDF-based regimen.  
Kidney biomarkers 
 
 
 
      AUC 
 
      P 
95% confidence interval 
 
Lower bound 
 
Upper bound 
Urine ACR (g/mmol) 1 
 
0.79 0.001 0.69 0.90 
Serum creatinine (mmol/l) 
 
0.61 0.105 0.46 0.76 
TMPO4/GFR (mmol/L) 2 
 
0.58 0.246 0.41 0.75 
eGFR (mls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
/min/1.73m2) 
0.37 0.078 0.21 0.52 
 
RBPCR (μg/mmol) 
0.67 0.014 0.53 0.82 
 
Adjusted NGAL/Creatinine 
0.56 0.366 0.42 0.70 
1. ACR; urine albumin creatinine ratio; 2. TMPO4/GFR: Tubular maximum capacity for renal phosphate 
reabsorption to glomerular filtration rate (GFR) ratio 
 
4.7.4 Independent predictors of kidney tubular dysfunction in HIV positive 
patients exposed to Tenofovir disoproxil fumarate 
Table 4.7 shows factors associated with risk of KTD in HIV positive patients 
exposed to TDF. Univariate odds ratios were calculated for each of the SNPs of 
interest. Possession of genotype CC at position 24 of the ABCC2 gene (MRP2, 
rs717620) was the only SNP significantly associated with reduced risk of KTD. This 
SNP remained significantly associated with KTD after adjustment for age, and eGFR 
(adjusted OR = 0.05; 0.003-0.71, P = 0.027) 
 
 
 
  102 
Table 4.7: Factors predicting risk of kidney tubular dysfunction (KTD) 1 in HIV 
positive patients exposed to TDF  
Parameter  
Univariate analysis 
 
Multivariate analysis 
OR (95% CI) 
 
 
 
P OR (95% CI) P 
Age (Years) 
 
0.9 (0.99-1.0) 
 
 
 
0.07 1.0 (0.91-1.1) 0.53 
 
ABCC2 24CC (rs717620) 
MRP2 
 
 
 
Genotype CC  0.24 
(0.06-0.93) 
 
 
0.04 0.05 (0.003-0.71) 0.027 
ABCC10 (rs2125739) MRP7 
 
 
C allele 3.0 (0.54-16.8) 
 
 
0.21 
 
-- -- 
ABCC10 (rs9349256) MRP7 
 
 
G allele 0.42 (0.1-.1.7) 
 
 
0.2 
 
  
ABCC4 669 (rs899494) MRP4 
 
 
T allele 0.83 (0.19-3.5) 
 
 
0.78 -- -- 
ABCC4 3463 (rs1751034) 
MRP4 
 
 
C allele 2.5 (0.31-20.4) 
T allele 2.1 (0.29-14.7) 
0.39 
0.46 
-- -- 
SLC22A11 (rs11231809)  
OAT4 
 
 
A allele 0.28 (0.03-1.31) 
 
 
0.11 -- -- 
 
SLC22A6 (453 GA)  
OAT1 2  
 
A allele 1.93 0.46-7.9 
 
 
0.36 -- -- 
1. Kidney tubular dysfunction; 2. Relative to accession no: AJ249369 
 
 
  103 
4.7.5 Haplotype analyses  
Exploratory haplotype analyses of the ABCC2-ABCC4 SNPs encoding genes 
involved in the bio-disposition of TDF, showed no significant association between 
KTD and any of the tested haplotypes.  
4.8.0 Discussion  
A number of genes encoding transport proteins involved in the bio-disposition of 
TDF have been known to be polymorphic (107, 108, 110). This is the first study 
exploring the potential relationship between SNPs of genes encoding transport 
proteins involved in the bio-disposition of TDF, and risk of kidney tubular injury in 
HIV positive patients as defined by LMW proteinuria (RBPCR). Since its approval 
in 2001, TDF continuous to be widely used and its efficacy and safety has been well 
established in numerous studies (144, 145). Nonetheless, a small proportion of 
patients develop severe kidney tubular toxicity (including Fanconi syndrome), with a 
variable proportion of patients (6-22%) reportedly having subclinical KTD (145, 
147, 149). Previous studies have suggested possession of genotype CC at position 24 
of the ABCC2 (MRP2, rs717620) gene (107, 108, 109), ABCC10 (MRP7, rs9349256, 
and rs2125739) (110) including the extended haplotype ABCC10-ABCC2 (GGC-
CGTC) (110) in addition to age, and low body weight (107) as potential determinants 
of KTD in these cohorts of patients. In these studies, KTD was defined by a 
composite of serum and urinary parameters. In this report, I confirm the association 
between ABCC2 24CC and KTD, and observed a non-significant association for 
polymorphisms in ABCC10 and OAT3 genes.  
This study finding of reduced KTD risk with the ABCC2 24CC (rs717620) SNP is 
not consistent with reports from previous studies (107, 108, 109). These reports 
showed increased risk of KTD with possession of this genotype. It is noteworthy 
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however that these studies utilised a different surrogate marker of kidney tubular 
injury (discussed elsewhere in this report) than the one used in this study (RBPCR).  
How the mode of case ascertainment of KTD explains the difference in outcome 
between this report and previous reports (107, 108, 109) is still uncertain. The 
novelty of this report is both in its finding of significant association between ABCC2 
24CC (rs717620) and LMWP-defined KTD, as well as possible protective effect of 
this genotype in this cohort of patients. In a recent study evaluating association 
between ABCC2 24CC SNP and risk of KTD in a prospective cohort of HIV positive 
patients on TDF, Nishijima et al (2015) (115) failed to establish any link between 
possession of this SNP and risk of KTD. 
Kidney tubular dysfunction comprises a spectrum with Fanconi syndrome 
representing the extreme phenotype, and its definition to date has relied on a 
composite of several urine and serum parameters (107, 108, 110). The use of RBP as 
a single biomarker provides a convenient way to assess KTD in clinical practice. It is 
also noteworthy that on further evaluation of the diagnostic performance of various 
kidney biomarkers (utilising threshold of urine PCR as standard), RBPCR had a high 
AUC-ROC. This will suggest its potential utility as a surrogate marker of kidney 
dysfunction in this cohort of patients.  
4.8.1 Limitations  
Despite its novel attempt, this study is limited firstly, by lack of robust power to 
demonstrate an independent association with KTD. Secondly, the quality of DNA 
extracted from serum rather than whole blood may have affected potential 
associations between the evaluated SNPs and LMW proteinuria. Additionally, a 
candidate gene-based approach may represent a limited attempt at exploring potential 
genetic associations compared to genome wide association study (GWAS). With the 
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latter evaluating the whole genome, thereby highlighting potential associations.  
Owing to these limitations, I suggest that the findings of this study are interpreted in 
the context of previous published work in this area. 
4.8.2 Conclusion 
In conclusion I have demonstrated that possession of genotype CC at position 24 of 
the ABCC2 (MRP2 rs7171620) gene was associated with reduced risk of KTD (as 
defined by an elevated RBPCR level) in HIV positive patients exposed to TDF.  
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5.0   Introduction  
I set out to conduct a biomarker association study in an outpatient population of HIV 
positive patients attending clinics in an urban tertiary centre. This is to determine 
potential association between low molecular weight proteinuria (LMWP), and risk of 
kidney injury in these cohorts of patients exposed to antiretroviral therapy (ART) 
drugs. 
5.1.0   Methods  
5.1.1   Clinical trial design  
This study cohort is comprised of two separate sub-studies all recruited from patients 
attending outpatient HIV clinics at the Royal Liverpool University Hospital (RLUH). 
Sub-study one is the cross-sectional arm that was scheduled to recruit HIV positive 
patients (N = 200) “on” ART drugs for cross sectional comparison with HIV positive 
patients “off” ART drugs (N = 100). See figure 5.1. The second arm is a prospective 
sub-study that was scheduled to recruit 75 HIV positive patients just starting ART for 
longitudinal follow-up at designated time points. At the time of analyses, a combined 
total of 127 patients have been recruited into both studies. Figure 5.1 gives the 
patient recruitment summary. 
5.1.2   Cross-sectional sub-study 
All consecutive HIV infected patients either “on” (cases) or “off” (controls) ART 
drugs that met inclusion criteria for the study and who attended HIV outpatient 
clinics in designated recruitment centre were approached, counselled, consented, and 
enrolled in the study. We scheduled to recruit a study cohort of HIV-positive patients 
(N =200) on ART drugs for cross sectional comparison with a randomly selected 
control cohort of HIV-positive patients (N = 100) off ART (both ART naive and 
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previously experienced). However, at the time of analyses, 114 patients have already 
been recruited into this arm of the study. Figure 5.2 gives a summary of various 
patients cohorts recruited at the time of analyses. Patients were consented and this 
includes a separate consent to participate in genetic research.  Clinical, demographic, 
and laboratory parameters were abstracted from patient’s case notes and electronic 
online records. 
5.1.3   Prospective longitudinal sub-study 
All consecutive HIV infected patients starting ART drugs that met inclusion criteria 
for the study, and who attend HIV outpatient clinics in designated recruitment 
centres were approached, counselled, consented, and recruited into the study. Study 
cohorts of HIV-positive patients (N = 75) starting ART were scheduled to be 
recruited into this arm of the DETIKI clinical cohort. However owing to problems 
with logistics and recruitment attrition, the total number of participants enrolled into 
this arm of the study at the time of analyses were eleven (N = 11). These patients 
were consented including a separate consent to participate in genetic research (see 
appendix 1). At screening demographic, clinical, and laboratory parameters were 
abstracted from patient’s case notes and electronic records. In addition, whole blood 
and random urine samples were collected for the determination of parameters as 
shown in table 5.1. An observational follow-up of study participants was scheduled 
at 4 and 24 weeks. At each study week visits, blood and freshly voided random urine 
samples were collected and stored for the determination of parameters as stated in 
table 5.1.  
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5.2.0   Clinical trial setting and patient recruitment  
Study participants were recruited from HIV outpatient clinics at the RLUH.  
 
 
Figure 5.2: Flow chart of DETIKI study cohort showing patient accrual into various 
study arms 
5.3.0   Study population and recruitment sites 
Study population were entirely comprised of HIV positive patients that met inclusion 
and exclusion criteria and who attend HIV outpatient clinics at RLUH.  
5.4.0   Definition and adjudication of clinical cases and controls 
1. As a standard for comparison, proteinuria in this study is defined as urine 
protein/creatinine ratio (PCR) ≥20mg/mmol. This was based on seminal work 
of Campbell et al detailed in previous section of this thesis (162).  
2. Exposure to various ART drugs were categorised as ART naive, protease 
inhibitor (PI) based regimen (ART/PI), Tenofovir/Protease inhibitor based 
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regimen (TDF/PI), and “other ART regimen” (including NNRTIs, fusion 
inhibitors, Integrase strand transfer inhibitors).   
3. Kidney failure/injury/dysfunction was defined as any one or a combination of 
the following: 
 eGFR <60mls/min/1.73m2  
 Urine PCR ≥20mg/mmol (162) 
4. Patients with normal kidney function (as determined from 3 above) were 
classified as controls. 
Table 5.1: Study flow chart (Prospective Longitudinal sub-studies)  
Activity 
 
Baseline 
 
4weeks 24 weeks 
Medical history X   
     Physical examination X   
e-GFR1 X X X 
Serum biochemistry 2 X X X 
TMPO4/GFR 3 X X X 
Urine ACR/PCR4 X  X 
KTD biomarkers 5  
 
 
Biomarkers 
X  X 
Urinalysis X   
Weight (kilograms) X  X 
Height (meters) X   
CD4 count/Viral load X  X 
Hepatitis B and C status X   
Genetic analysis X   
Informed consent X   
1. Calculated from simplified 4-variable MDRD equation. 2. Includes Creatinine (Cr), Urea, alkaline 
phosphatase, liver function test (LFTs), glucose, corrected calcium, inorganic phosphate, uric acid, thyroid 
function tests (TFTs), serum lipids 3. Tubular maximum capacity for renal phosphate reabsorption to glomerular 
filtration rate (GFR) ratio. 4. Albumin creatinine ratio/protein creatinine ratio. 5.  Kidney injury molecule-1 
(KIM-1): Cystatin C (Cys C), N-acetyl-D-glucosaminidase (NAG): Neutrophil gelatinase-associated lipocalin 
(NGAL); Fatty acid binding protein (FABP) 
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5.5.0   Cohort recruitment  
5.5.1   Inclusion criteria (cross sectional) 
1. Age ≥18 years  
2. Any CD4 count or viral load 
3. HIV-positive patients “on” or “off" ART drugs 
4. Able to provide informed consent 
5.5.2   Inclusion criteria (prospective) 
1. Age ≥18 years  
2. Any CD4 count or viral load 
3. HIV-positive patients starting ART drugs 
4. Able to provide consent  
5.5.3   Exclusion criteria (cross sectional and prospective arms) 
Unable to provide informed consent 
5.6.0   Sample collection, storage and estimation  
For both sub-studies, 10 millilitres (mls) of whole blood and random urine samples 
(10mls) were collected for the determination of pre-specified study parameters at 
baseline. Additionally, for patients on the prospective arm at 4 and 24 weeks follow-
up, blood and freshly voided random urine samples were collected and stored for 
determination of parameters as stated earlier (figure 5.1) until completely used. In 
addition, some of the whole blood sample (5mls) will be stored for mutational 
screening of SNPs of genes encoding transport proteins involved in the bio-
disposition of ART drugs. 
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5.6.0 Bio-analytical methods 
5.6.1 The determination of KIM-1 and urinary creatinine concentration 
Following initial introduction to the technique of urinary KIM-1 and creatinine 
estimations by the Dr. Steve McWilliams (Post-Doctoral Fellow, Wolfson Centre for 
personalized medicine, University of Liverpool) on an initial trial set of my study 
samples, I carried out the estimation of the entire cohort of my study samples myself.  
5.6.2 Principle of KIM-1 assay 
The MSD platform provides for rapid detection and estimation of protein target from 
a small volume of a given sample. The KIM-1 assay I utilised is a form of MSD 
platform assay that takes the form of sandwich immunoassay. The MSD plate is 
provided from the manufacturers (Meso Scale Discovery® [MSD], MD, USA), pre-
coated with capture antibody adhered to a working electrode at the base of each well. 
Into each well, the investigator is required to add the sample of interest (blood, 
serum, urine, etc.), and a solvent containing detection antibodies tagged with 
electroluminescence labels (MSD SILFO-TAGTM), with varying incubation periods 
at each stage. KIM-1 (as in our case) or any analyte of interest binds to the capture 
antibodies adhered to the working electrode. Attraction and binding of labeled (MSD 
SILFO-TAGTM) detection antibodies completes the reaction sequence or “sandwich”. 
The addition of an MSD read buffer provides the chemical milieu necessary for 
elctrochemiluminescence to be expressed. Loading the MSD plate unto an MSD 
SECTOR® imager, ensures that when a voltage is applied to the MSD plate 
electrodes, the captured labeled antibodies “complexed” to the analyte (KIM-1) emits 
light. The intensity of this light as measured by the imager gives a quantitative 
estimation of the analyte (KIM-1) in the sample, figure 5.3.  
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Figure 5.3: Principle underlying KIM-1 assay on MSD platform (adapted from Meso 
Scale Discovery® [MSD], MD, USA),  
 
As a standard we took the lower limit of quantitation (LLOQ) is greater than two 
standard deviations above the background value for the assay (which is the 
concentration of the diluent 37) 
5.6.3 KIM-1 assay procedure   
Urinary KIM-1 was estimated from stored urine samples according to manufacturers’ 
protocol (Meso Scale Discovery® [MSD], MD, USA), as set out in steps below: 
Step one: Preparation of standard calibration curve solution  
 
Stored urine (at -80oC) was thawed, mixed, and centrifuged at 3000 RPM for one 
minute.  
The stock calibrator was thawed on ice and an 8-point standard calibration curve 
solution was prepared. I prepared calibration standard solution curves for three 
replicates as follows: 
 I initially prepared the highest standard by adding 15µl of stock calibrator to 
285µl of diluent 37 
 I then prepared the next standard by transferring 60µl of the highest standard 
to 180µl of diluent 37 
 The above process (4 serial dilutions) was repeated five times to generate 
seven standards (solutions)  
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 Diluent 37 was used as the 8th blank calibrator (standard)  
Step two: MSD plates  
Manufacturers 96-well MSD plates were supplied pre-coated with capture antibodies 
(MSD SULFO-TAGTM) 
Step three: Assay protocol 
 I pipetted 150µl of blocker A to each well of the 96-well MSD plate 
  I washed the plate 3 times with 300µl/well of PBS-T buffer solution ensuring 
that there were no residual buffer solutions adhering to the bottom of the 
wells. 
 50µl of sample solution was added to each well and incubated at room 
temperature with vigorous shaking (at 1000RPM) for 30mins 
 The plate was sealed with adhesive film tightly, and incubated (at room 
temperature) for 2 hours with vigorous shaking at 700 RPM  
 The plate was washed thoroughly with 300µl of PBS-T buffer 3 times  
 25µl of 1X SULFO-TAGTM labeled detection antibody was added to each 
well, and the plate was sealed with adhesive film and incubated at room 
temperature for 2 hours with vigorous shaking (700RPM).  
 The MSD plate was thoroughly washed with 300µl of PBS-T buffer solution 
3 times ensuring that no residual buffer remained in the wells. 
 I then added 150µl of 2X read buffer to each well of the 96-well MSD plate  
 The plate was analysed on the MSD sector imager. 
 MSD DISCOVERY WORKBENCH® software generates a standard curve, 
which is used to calculate the concentration of KIM-1 in the sample. Accurate 
quantification of KIM-1 values were obtained by generating a standard curve 
for each plate utilising atleast 2 replicates from the calibrator (see figure 5.4 
for KIM-1 standard and unknown (sample) curves for this study) 
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5.6.4 Estimation of KIM-1 
The upper and lower limits of quantitation (ULOQ, LLOQ respectively) on a seven-
point calibration curve were 5000, and 1.22 pg. /ml respectively. Intra and inter-
assay precision were <6, and <7% respectively, on three plates on different occasions 
with recovery of spiked samples at 104–107%. Dilutional linearity was shown at 
1:10, 1:100, and 1:1000 dilutions in the assay diluent. The LLOQ was about two 
standard deviations greater than the background value of the diluent alone, the LLOQ 
was taken as the limit of detection. Subsequently derived KIM-1 values were 
normalized to urinary creatinine (determined spectrophtometrically) and expressed as 
KIM-1/Cr (ng/mg). 
.  
 
Figure 5.4: Standard and DETKI cohort KIM-1 estimated concentrations 
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5.6.5 Estimation of urinary creatinine  
Urinary creatinine was estimated initially by preparation of seven-creatinine curves 
standard solution in keeping with manufacturers protocol (Jaffe assay method, 
Roche/Hitachi Cobas C system Roche diagnostics, Indianapolis, IN, USA). The 
plates were spectrophotometrically read at 490nm (with and without a creatinine 
quencher to determine the final absorbance values, which are the definitive urinary 
creatinine values of the sample (figure 5.5).  
 
 
 
 
 
Figure 5.5: Urinary Creatinine assay standard curve  
 
5.6.6 Estimation of urinary KIM-1/Creatinine 
KIM-1 (pg/ml) corrected for urinary creatinine excretion (mg/gram) was expressed 
as KIM-1/Cr (ng/mg). 
5.7   Withdrawal from the study 
All study participants were free to withdraw from the study at any time. Following 
this, their samples were removed and destroyed in keeping with regulatory 
requirements. 
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5.8.0   Study outcomes 
This study met the criteria outlined by the medical research council (MRC) 
guidelines for complex interventions. This is borne out of the impact incorporation of 
pharmacogenetic outcomes will potentially have on the overall determinants 
(including clinical and biochemical) of kidney injury in this cohorts of patients.   
5.8.1   Primary outcome 
 The primary outcome measure is elevated median of KIM-1/Cr at baseline 
and 24 weeks. I described DETIKI patient cohort with the view to validate 
the utility of LMWP as biomarkers for monitoring of renal function in HIV 
positive patients exposed to ART drugs.  
5.8.2   Secondary outcomes 
 Correlation between SNP’s/haplotypes of genes encoding transport proteins 
involved with the bio-disposition of ART drugs, and LMWP. 
 Correlation between KIM-1/Cr and other traditional markers of kidney injury 
(eGFR, Urine PCR, etc.)  
 Prevalence of kidney injury in HIV positive patients on ART drugs 
5.9   Safety consideration  
The safety of ART drugs in HIV-positive patients has been widely described. As this 
is not an interventional trial, study subjects recruited to both arms underwent their 
usual point of care monitoring for concurrent ART drug treatment consistent with 
national and local guidelines. 
5.10   Sample size estimation  
There are few robust studies in literature to enable objective estimation of sample 
size, largely because this is a developing field. This study was conducted as a pilot, 
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therefore I estimate that assuming a coefficient of variation (CV) of about 5% in 
median KIM-1(159), a sample size of 200 patients (cases), and 100 controls for the 
cross sectional sub-study, and 75 for the prospective longitudinal sub-study will give 
us about 80% power to detect 20% difference in KIM-1 population mean. 
5.11   Data management  
All data collected in course of the study was recorded in an individualised subject 
specific case report form (CRF). In order to maintain confidentiality, only subject 
number and initials on the CRF were used to identify study subjects.  
5.12   Ethics and study sponsorship 
The study protocol, patient information, consent forms, available safety information, 
study participants recruitment procedures, information about payments, and 
compensation available to the subjects as well as documentation evidencing the 
Investigator’s qualifications was submitted to the North Manchester research ethics 
committee for ethical review and approval according to local regulations, prior to 
commencement of the study. Following initial review of the study protocol, a 
provisional approval was granted with suggested changes to study documentation. 
An amendment to this effect was re-submitted to ethics committee, following which 
a final approval was granted for commencement of the study.  
5.13.0   Results  
5.13.1   Patient’s demographics and clinical characteristics 
Table 5.2 gives a summary of baseline characteristics of the study population (cross-
sectional cohort). About 73.7%, and 81% of patients recruited into the cross sectional 
and prospective arms of the study respectively were Caucasians. This perhaps 
reflects the demography of the main enrolment site (Royal Liverpool University 
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Hospital, the United Kingdom). Amongst 114 cross-sectional patient cohorts, mean 
age was 43.1 years (SD ±9.9), with about 70.2% male population. Proteinuria 
(defined as urine PCR ≥20mg/mmol) was present in about 20.9% of cross sectional 
patient cohort with a higher proportion in older patients compared with their gender-
matched cohorts (49.3mg/mmol vs. 41.4mg/mmol, respectively P = 0.002). Median 
TDF exposure was 36 months (IQR 22.5, 72). KIM-1/Cr had a non-parametric 
distribution as shown in figure 5.6. Median KIM-1/Cr was 4.17ng/mg (IQR 1.5, 8.2) 
with an upper quartile threshold of ≥8.6ng/mg. 
 
Figure 5.6: Probability plot of the distribution of KIM-1/Cr amongst DETIKI cross 
sectional patient cohorts.  
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Table 5.2: Demographic and clinical characteristics of DETIKI cross-sectional 
cohort (N = 114) 
Variable  Number available 
for analyses  (N) 
Age (years)                              Mean (SD)  43.1 (9.9) 114 
Male Gender                            N (%) 80 (70.2) 114 
White Caucasian                     N (%)  84 (73.7) 114 
Duration of HIV in years         Med (IQR) 8 (4, 12) 113 
KIM-1/Cr (ng/mg)                    Med  (IQR) 3.7 (1.5, 8.2) 114 
Serum Creatinine (mmol/l)       Med (IQR)  83.5 (69, 93) 114 
eGFR (mL/min/1.73 m2)          Med (IQR) 85 (74, 90) 114 
Urine PCR (mg/mmol)             Med (IQR) 11 (8, 17) 68 
Serum Phosphate (mmol/l)       Med (IQR)  0.96 (0.86, 1.06) 112 
Total Cholesterol (mmol/l)        Med (IQR) 5 (4.5, 5.7) 110 
HDL Cholesterol (mmol/l)         Med (IQR) 1.3 (1.1, 1.7) 108 
Triglycerides (mmol/l)               Med (IQR) 1.2 (0.9, 1.9) 109 
TDF exposure (months)     Med (IQR)  36 (22.5, 72) 54 
Protease Inhibitor (PI) exposure N (%)  45 (39.5) 105 
Abacavir exposure                      N (%)  19 (16.7) 114 
CD4 count (cells/mm3)              Med (IQR)  565 (401, 665) 101 
Nadir CD4 count (cells/mm3)    Med (IQR) 200 (95, 298) 99 
Hepatitis B Positive                    N (%) 23 (20.2) 96 
Hepatitis C Positive     N (%) 5 (4.4) 109 
Diabetes Mellitus                       N (%) 4 (3.5) 106 
Hypertension                              N (%) 6 (5.3) 104 
Smoking                                     N (%) 36 (31.6) 104 
a. Standard deviation; b. number of patients; c. Median; d. Inter-quartile range 
  
Table 5.3 gives the distribution of adjusted KIM-1/Cr amongst the various study 
cohorts. Patients with urine PCR ≥20mg/mmol had a higher median KIM-1/Cr 
(ng/mg) levels than their comparable controls (5.9ng/mg vs. 2.7ng/mg, confidence 
interval [CI] 2.4-4.8; P = 0.0001). About 5.3% (N = 6), and 3.5% (N = 3) of the study 
cohort were hypertensive or have incident Diabetes Mellitus respectively. The 
median nadir/current CD4 count were 200 cells/mm3 (IQR 95, 298), and 565 
cells/mm3 (IQR 401, 665) respectively. The median eGFR was 85 mls/min/1.73m2 
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(IQR 75.5, 90) with 5.3% of the cross sectional study cohort having chronic kidney 
disease stage 3 (CKD3, eGFR<60). Baseline eGFR levels were significantly lower in 
males than their age-matched female counterparts (82 vs. 90 mls/min/1.73m2, 
respectively; CI 1.4-3.6; P = <0.0001). Table 5.4 gives comparative distribution of 
kidney surrogate biomarker levels amongst the various cross sectional patient 
cohorts. 
 
Table 5.3: Distribution of various adjusted KIM-1/Cr * thresholds amongst the 
DETIKI Study populations 
  
Cross-sectional 
arm (on ART) 
 
N = 104 
 
 
Cross-Sectional 
arm (off ART) 
 
N = 10 
Prospective arm 
 
N = 11 
 
 
P 
25th 
centile 
 
 
1.67 1.93 3.27 0.66 
Median 
 
 
4.14 4.69 4.01 0.015 
75th 
centile 
 
 
8.63 5.3 4.89 0.46 
* Urinary KIM-1 corrected for urinary creatinine excretion 
 
5.13.2    Prospective sub-study  
Amongst this longitudinal patient cohort (N = 11), mean age was 40 years (±7.3) 
with a median HIV duration of 3.5 years (IQR 1, 8). Median KIM-1/Cr (ng/mg) was 
4.0 (IQR 3.6, 4.8). Median CD4 count (cell/mm3), and HIV viral load (copies/ml) 
were 468 (453, 555), and 82 (27, 22700) respectively. All patients recruited to this 
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arm of the study had eGFR >60mls/min/1.73m2 with a median urine PCR of 
10mg/mmol (IQR 5, 14). 
 
Table 5.4: Comparative distribution of kidney biomarkers amongst the cross-
sectional patient cohorts (N = 114)  
 
Variables 
 
 
All patients 
 
N =114 
cross-sectional on 
ART 
N = 104 
cross-sectional off 
ART 
N = 10 
P 
KIM-1/Cr (ng/mg) 
 
 
Med  (IQR) 
4.1 (1.7, 8.3) 4.15 (1.7, 8.6) 2.7 (1.9, 5.4) 0.1 
Urine PCR1 (mg/mmol) 
 
 
Med (IQR) 
 
11 (8, 17) 11 (8, 17) 9.5 (6, 122) 0.5 
eGFR (mls/min/1.73m2) 
 
 
Med (IQR) 
85 (75, 90) 85 (75, 90) 90 (63, 90) 0.2 
1. Urine protein creatinine ratio 
 
5.13.3 Urinary KIM-1/Cr concentration and ethnicity 
Baseline KIM-1/Cr values were higher in patients of white Caucasian ethnicity 
(4.1ng/mg) compared with patients from other ethnic groups (1.1ng/mg, [CI 2.2-3.9], 
P = 0.005) figure 5.7. When stratified based on ART exposure, Caucasian patients 
either “on” or “off” ART drugs had a significantly higher baseline KIM-1/Cr 
(ng/mg) values compared to other ethnic cohorts (8.6 vs. 2.1, and 2.2 vs. 1.9 
respectively, P = 0.008). 
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Figure 5.7: Distribution of KIM-1/Cr (ng/mg) amongst various ethnic cohorts. 
Irrespective of antiretroviral therapy drug exposure, patients of white Caucasian 
ethnicity maintained higher KIM-1/Cr levels compared to other ethnic cohorts 
 
5.13.4 Antiretroviral drug exposure and kidney biomarker levels 
Table 5.5 show detailed comparison of KIM-1/Cr as a function of ART exposure. 
KIM-1/Cr is uniformly distributed across all patient cohorts regardless of ART drug 
regimen. However, when stratified according TDF exposure, patients on TDF 
regimen had a significantly higher median KIM-1/Cr than comparable cohorts 
(figure 5.8).  
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Figure 5.8: Box plot showing distribution of KIM-1/Cr (ng/mg) stratified by 
Tenofovir disoproxil fumarate exposure. HIV positive patients on TDF based 
regimen had significantly higher urinary KIM-1/Cr levels representing some degree 
of kidney impairment in this cohort of patients.  
 
Patients on ART/PI regimen had higher median urine PCR compared to those on 
alternative regimen (P = 0.02). Amongst cross sectional cohorts, patients on PI based   
regimen had higher KIM-1/Cr (5.6 ng/mg) compared to their PI-naïve counterparts 
(3.4ng/mg) but this did not reached statistical significance.  
5.13.5   Stratified protease inhibitor exposure and kidney biomarker levels  
About 32.2% of patients within the cross sectional study cohort were exposed to 
boosted PI’s (rtv boosted). The prevalence of ATV exposure was limited to about 
9.6% of total PI exposure. See table 5.6 for summary of kidney biomarkers stratified 
according to various PI sub-classes.  
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Table 5.5: Comparative distribution of kidney biomarkers stratified by antiretroviral 
therapy regimen amongst DETIKI cross sectional cohort  
 All 
patients  
 
    N = 114 
 
   ART/TDF 
 
 
N = 45 
  ART/PI 
 
N = 11 
   TDF/PI 
 
 
 N = 31 
Other 
cART 
 
N = 18 
           P 
KIM-1/Cr (ng/mg) 
Med (IQR) 
 
3.7 (1.5, 
8.2) 
3.35 (1.6, 8.2) 
 
 
5.37 (3.4, 
10.3) 
2.28 (0.48, 
6.75) 
6.17 (1.73, 
9.0) 
0.07 
Urine PCR 
(mg/mmol) 
Med (IQR 
11 (8, 17) 12 (9, 23.5) 
15 (8.0, 
67.2.) 
8 (6, 11) 
14 (8.2, 
30) 
0.02 
eGFR 
(mls/min/1.73 m2) 
Med (IQR) 
 
85 (74, 90) 82 (71, 90) 90, 77.5, 90) 82 (72.7, 90) 
89 (64.5, 
90) 
0.78 
Other ART: These include Integrase inhibitors, entry inhibitors, NNRTI’s. ART: antiretroviral therapy; TDF: 
Tenofovir; PI: Protease inhibitors P value is for group comparison between ART classes 
 
Table 5.6: KIM-1/Cr stratified by protease inhibitor (PI) exposure phenotypes  
Variables 
 
Boosted PI’S (rtv) 
 
N =37 
Atazanavir based 
regimen 
N = 11 
P 
 
 
 
 
KIM-1/Cr (ng/mg) 
Median, IQR 
 
 
5.4 (1.6, 9.1) 
 
6.2 (3.2, 12.7) 
 
 
0.23 
 
Urine PCR (mg/mmol) 
Median, IQR 
11 (6.5, 16) 11 (6, 12) 0.60 
eGFR (mls/min/1.73m2) 
Median, IQR 79 (72.5, 90) 89 (66, 90) 0.66 
Serum creatinine (mmol/l) 
 
Median, IQR 
 
82 (67.5, 94.5) 76 (67, 106) 0.93 
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5.13.6   Correlation between urinary KIM-1/Cr and traditional Markers of 
kidney injury 
There were statistically significant correlations between urinary KIM-1/Cr with age, 
total CD4 count, and urine PCR (table 5.7). When stratified into quartiles, median 
KIM-1/Cr maintained strong linear positive correlation with urine PCR (r = 0.35, p = 
0.003), table 5.8. It is noteworthy that urinary KIM-1/Cr (ng/mg) showed a positive 
correlation with urine PCR (a well-established marker of kidney injury in these 
cohorts of patients).  
Table 5.7: Correlation matrix of various co-variates as a function of KIM-
1/Creatinine (ng/mg) 
 Age 
(Years) 
TDF 
exposure 
(months) 
urine 
PCR 
eGFR Total 
CD4 
(cells/
mm3) 
CD4 
(Nadir) 
Correlation 
Coefficient # 
0.44**  0.20 -0.32** 0.11 -0.21* 
P 0.000  0.09 0.00 0.26 0.03 
Number 
available for 
analyses  
113  67 113 101 99 
Correlation 
Coefficient 
0.37** - 0.34* -0.36** -0.15 -0.24 
P 0.006 - 0.03 0.00 0.28 0.08 
Number 
available for 
analyses 
54 - 37 54 50 50 
Correlation 
Coefficient 
0.300** 0.15 -0.02 - 0.06 -0.10 
P 0.001 0.27 0.86 - 0.54 0.28 
Number 
available for 
analyses 
114 54 67 - 101 99 
Correlation 
Coefficient 
0.23* 0.05 0.27* -0.15 -.020* -0.20 
P 0.01 0.68 0.03 0.12 0.04 0.05 
  **: Statistically significant correlations; #: Spearman’s rho 
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The correlation matrix of urinary KIM-1/Cr as a function of other covariates is given 
in table 5.7. About 52% of this study population with eGFR greater than 
60mls/min/1.73m2 (and therefore normal kidney function) had KIM-1/Cr 
concentration higher the median threshold. This will suggest a degree of subclinical 
kidney injury in patients with hitherto normal eGFR (using a median KIM-1/Cr as a 
marker of kidney injury). 
 
Table 5.8: Key correlation matrix between adjusted urinary KIM-1/Cr and other 
markers of kidney function 
 
 
Variable 
 
Unadjusted KIM-1/Cr 
(ng/mg) 
 
 
Median KIM-1/Cr 
(ng/mg)  
 
 
Upper quartile KIM-
1/Cr (ng/mg)  
 
 
R 
 
P R P R P 
Serum creatinine 
(mmol/l) 
 
 
 
0.067 0.48 0.14 0.4 0.07 0.71 
eGFR (mls/min/1.73m2) 
 
-0.14 0.13 
-0.22 0.13 -0.19 0.3 
Urine PCR (mg/mmol) 
 
 
 
0.35 0.003 0.34 0.06 0.28 0.2 
R = Spearman’s correlation coefficient; significance level at <0.05 
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5.13.7   Diagnostic performance of KIM-1/Cr (ng/mg) 
I generated AUC/ROC curves to evaluate the performance of various thresholds of 
KIM-1/Cr (ng/mg), serum creatinine (mmol/l), and eGFR (mls/min/1.73m2) in 
differentiating patients with kidney injury from those with normal kidney function. 
Utilising urine PCR ≥20mg/mmol as cut-off for kidney impairment, AUC-ROC of 
KIM-1/Cr (ng/mg) was 0.68, (CI = 0.50-0.84, p = 0.04) figure 5.9.  
 
 
Figure 5.9: ROC analysis of KIM-1/Cr as a single variable. The area under the 
receiver operator curve is given (0.67) for prediction of kidney injury with 95% 
confidence interval. The higher and more leftward the KIM-1/Cr value, the greater 
its propensity to predict risk of kidney dysfunction  
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KIM-1/Cr (ng/mg) had a higher areas under the curve (AUC) compared with other 
established diagnostic markers for acute kidney injury in this population. The 
AUC’s, as well as sensitivities and specificities of other biomarkers are depicted in 
Figures 5.10-5.11.    
 
 
Figure 5.10: ROC analysis of serum creatinine (mmol/l) as a single variable. The 
higher and more leftward the serum creatinine value, the greater its ability to predict 
risk of kidney dysfunction  
5.13.8   Predictors of kidney injury  
I tested the diagnostic performance of median KIM-1/Cr (≥4.17ng/mg) as a predictor 
of kidney injury in HIV positive patients exposed to various ART drug regimen. 
Variables with P values <0.2 in univariate analyses (age, white Caucasian ethnicity, 
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TDF exposure (years), PI exposure, Abacavir exposure, eGFR, Urine PCR, Total and 
nadir CD4 count) were entered into multivariate analysis. By forward logistics 
regression (likelihood ratio), TDF exposure (per year increase) was significantly 
associated with risk of kidney injury in multivariate analyses (Odds ratio 1.4, CI 
1.02-1.82, P = 0.034), Table 5.9. 
 
Figure 5.11: ROC analysis of e-GFR as a single variable. The area under the 
receiver operator curve is given for prediction of kidney injury with 95% confidence 
interval. The higher and more leftward the eGFR value, the greater its propensity to 
predict risk of kidney dysfunction  
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Table 5.9: Univariate, and multivariate adjusted odds ratios of median urinary KIM-
1/Cr (ng/mg) 
  
Univariate 
 
Multivariate 
 
OR (CI) 
 
P 
 
 
Adjusted OR (CI) 
 
P 
Age (years) 
1.1 (1.0-1.1) 0.035 -- 
-- 
Gender (male) 
0.66 (0.28-1.5) 
0.34 
 
-- -- 
White Caucasian 
ethnicity  
0.37 (0.14-0.95) 
 
 
       0.04 
 
-- 
 
HIV duration (per year 
increase) 
1.1 (1.0-1.1) 0.051 
-- -- 
Tenofovir disoproxil 
fumarate exposure 
(years) 
1.2 (0.98-1.42) 0.08 
0.034 
1.4 (1.02-
1.82) 
HIV protease inhibitor 
exposure (months) 
0.47 (0.21-1.1) 0.074   
Abacavir (ABC) naïve 4.4 (1.1-14.5) 0.01 
-- -- 
Diabetes Mellitus 1.1 (1.3-7.6) 0.98 
-- -- 
Hypertension (mmHg) 0.98 (0.98-5.1) 0.9 
-- -- 
Smoking (Yes) 0.59 (0.25-1.3) 0.22 -- -- 
HIV RNA viral load 
(cells/mm3) 
1.0 (0.9-1.0) 0.7 
-- -- 
eGFR 
(mls/min/1.73m2) 0.97 (0.94-1.0) 0.2   
Urine PCR (mg/mmol) 
 
1.0 (0.98-1.0) 0.25 -- -- 
Current CD4 count  
 
0.9 (0.9-1.0) 0.25 
-- -- 
Nadir CD4 count  1.0 (0.9-1.0) 0.13 
-- -- 
Hepatitis C positive  
 
0.98 (0.1-7.2)              0.9 -- -- 
Hepatitis B positive 
 
0.5 (0.16-0.17) 0.3 -- -- 
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5.14   Discussion  
Traditional markers of kidney injury such as eGFR have increasingly been shown to 
detect kidney impairment later than tubular proteinuria in HIV positive patients 
exposed to ART drugs (161, 162). The increasing prevalence of ART related drug 
induced kidney morbidities meant that there is urgent need for novel surrogate 
markers that report sub-clinical level of kidney injury before routine kidney function 
tests (such as eGFR and urine ACR/PCR) become abnormal. Recently Low 
molecular weight proteinuria such as retinol binding protein (RBP) (162), KIM-1 
(163, 164, 165), neutrophil gelatinase associated lipocalin (NGAL) (174) have been 
proposed as early markers of kidney injury in both HIV positive patients on ART and 
the general population (173), (174). In this cross sectional study, I have evaluated the 
association between traditional markers of kidney injury (such as eGFR, and urine 
PCR) in HIV positive patients on ART drugs, and a novel marker KIM-1/Cr 
(adjusted for urinary creatinine excretion) that has increasingly been shown to report 
kidney tubular injury early in the general population. I observed a higher median 
urinary KIM-1/Cr levels in these cohort of HIV positive patients (4.17ng/mg, IQR 
1.68, 8.38) regardless of ART exposure compared with either healthy volunteers 
(0.097-0.39 ng/mg) (197), or patients with acute kidney injury in the general 
population (0.57925 ng/mg, IQR 0.3997-0.82972) (198). The median KIM-1/Cr for 
example in patients off ART in DETIKI study cohort was 4.6ng/mg. This may 
suggest a degree of sub-clinical kidney injury in this cohort of patients with normal 
kidney function (eGFR ≥60mls/min/1.73m2). A number of reasons may account for 
this. The natural history of HIV related kidney involvement may be associated with 
up regulation of KIM-1 synthesis in kidney tubular cells with resultant increased 
excretion of KIM-1 independent of exogenous injury (including ART drugs). This is 
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supported by data from mechanistic studies that suggests tubular injury of diverse 
aetiologies resulting in up-regulation of this putative cell adhesion molecule (KIM-1) 
(163). In addition, previous reports have shown that both glomeruli, and distal 
convoluted tubules were early target sites for the HIV virus (199) further supporting 
the role of direct effect of the virus in up regulating KIM-1 expression. Whilst the 
exact role of the natural history of HIV in KIM-1 kinetics remains a matter of 
mechanistic debate, I hypothesise that it may (in common with other yet to be 
identified factors) account for its high baseline urinary excretion of KIM-1 in HIV 
positive patients either on or off ART drugs. Utilising median KIM-/Cr as a marker 
of kidney injury, I found TDF exposure to be a strong predictor of kidney 
dysfunction in HIV positive patients on ART. TDF and PI exposures (146, 147) have 
both been independently associated with increased risk of KTD from various 
mechanistic and systematic studies. Resultant TDF induced KTD is likely to result in 
either increased up regulation of KIM-1, or its increased kinetics and excretion in 
urine. Higher median KIM-Cr values in these cohorts of patients may reflect its 
potential role both as a marker and as predictor of adverse outcomes in patients on 
these treatment regimens.  
I similarly found a high baseline KIM-1/Cr levels in patients of white Caucasian 
ethnicity compared to other cohorts. When stratified based on ART exposure, 
Caucasian patients maintained higher KIM-1/Cr values compared to other ethnic 
cohorts regardless of ART exposure. This may suggest an influence of ethnicity both 
in the expression (on kidney tubular cells), and possibly increased tubular excretion 
of KIM-1 from the kidneys. In the determination of reference urinary KIM-1 
reference intervals in healthy children, McWilliams et al found a higher urinary 
KIM-1 concentration in individuals of Caucasian ethnicity compared to African-
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American cohorts (200). Additionally, previous reports have highlighted potential 
ethnic bias in the expression and distribution of tubular proteinuria (201). In the 
women multi-agency study for example, Black ethnicity was associated with 
significant albuminuria as well as an independent risk factor for increased excretion 
of tubular biomarker proteins including interleukin-8 (IL-8), neutrophil gelatinase 
associated lipocalin (NGAL), α-1 microglobulin (A-1M) in HIV positive patients on 
ART (201). A probable explanation for this observation might be the role of genetics 
in influencing the adverse effects of ART on the kidneys, as well as expression and 
kinetics of these low molecular weight proteins. TDF induced kidney tubular 
dysfunction for example has a higher prevalence in white Caucasian males compared 
with other gender matched ethnic cohorts (107, 108, 109, 144, 149). Although 
association between TDF exposure and risk of KTD remains speculative, recently 
both mechanistic and pharmacogenetic studies have increasingly implicated the role 
of single nucleotide polymorphisms (SNP) of genes encoding proteins involved in 
the bio-disposition of TDF (107, 108, 110). It is probable that there might be an 
ethnic bias in the genes associated with synthesis and expression of KIM-1 on 
tubular cells. SNP of these genes therefore accounting for either increased or 
decreased expression of this putative glycoprotein on kidney tubular cells. The exact 
underlying mechanism for the increased urinary KIM-1 excretion in Caucasian 
population is still unknown, and will need exploration by further mechanistic work in 
this area. 
I also observed a significant positive correlation between advancing age, white 
Caucasian ethnicity, and high urine PCR levels with KIM-1/Cr. In HIV-positive 
patients, higher urine PCR levels have always been associated with and utilised as a 
point-of-care marker of kidney dysfunction in these cohort of patients on ART (162). 
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The positive correlation reported by this study supports a potential role of KIM-1/Cr 
(a potential alternative marker of kidney dysfunction this cohort of patients).  It is 
noteworthy that in this report urine KIM-1/Cr kinetics maintained an inverse 
relationship with eGFR. The latter is a well-established surrogate marker of kidney 
injury in both HIV positive cohorts and the general population, with lower levels 
associated with worsening kidney impairment. This will additionally support a 
possible role for urinary KIM-1/Cr as a potential marker of kidney injury in HIV 
positive patients exposed to ART drugs. In addition, I have shown that a significant 
number of patients in this study cohort with hitherto normal kidney function (eGFR 
(>60mls/min/1.73m2) had median KIM-1/Cr (ng/mg) concentration significantly 
above diagnostic thresholds (for KIM-1) for kidney injury in the general population. 
This may suggest some degree of subclinical kidney injury that has been masked or 
not reported by kidney function as determined by the four variable eGFR. The 
novelty of this approach is the identification of these patients with significant 
diagnostic values of KIM-1/Cr (>4.17ng/mg) even when eGFR in these patients were 
reported as normal.  
Serum creatinine and eGFR have remained the main diagnostic markers of acute 
kidney injury in both the general population and HIV positive patients. Despite this, 
KIM-1/Cr (ng/mg) had a comparatively higher significant AUC (0.68, P = 0.04, CI 
0.5-0.84) compared to these established kidney markers in this study. This may 
additionally suggest a potential diagnostic role for KIM-/Cr in these cohorts of 
patients, and perhaps its ability to identify kidney injury earlier in these cohorts of 
patients than traditional markers of kidney injury. The higher proportion of 
proteinuria (urine PCR >20mg/mmol) in older cohort of patients in this study appears 
consistent with findings from the general population. Similarly, analyses of this study 
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cohort also showed a reciprocal relationship between eGFR and advancing age, 
another matrix that mirrors findings in the general population.  
5.14.1   Study limitations  
Admittedly, a number of limitations evident in this study including its relatively 
small sample size and cross-sectional design meant that causality could not be 
established with certainty based on its findings. This will require subsequent 
validation by large sample sized prospective studies. I will therefore advise caution 
in interpretation and application of these findings.  
5.14.2   Conclusion  
I have demonstrated that in HIV positive patients on ART, TDF exposure 
significantly predicts the risk of kidney injury as defined by median KIM-1/Cr 
(>4.17ng/mg). Additionally, HIV positive patients regardless of ART drug exposure 
had urinary KIM-1/Cr values well above diagnostic thresholds for either normal 
volunteers, or patients with AKI in the general population. This suggests a probable 
role for median KIM-1/Cr (>4.17ng/mg) as an early diagnostic biomarker in these 
cohorts of patients. Further exploitation/utility of this threshold (KIM-1/Cr 
>4.17ng/mg) at point for care (as a diagnostic marker of kidney injury) in these 
cohorts of patients will however need validation by a larger cohort of prospectively 
recruited patient population. 
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CHAPTER 6 
FINAL DISCUSSION 
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6.1   Epidemiological perspectives of ART drug related adverse effects 
Patient’s socio-economic status have been shown to significantly impact on the 
reporting of ART drug related toxicities (68). This is in common with other factors 
such as study setting, as well as tools/algorithms adopted in the adjudication of 
adverse events (68). These factors wholly or in common account for marked 
variability in reported prevalence rates of ART drug related ADR’s (68). Even with 
clear recommendation by different national and international ADR grading and 
reporting guidelines (70), this variability in prevalence rates have remained the same 
(70). The CONSORT statement (72), and its further extension (73) were aimed at 
improving the robustness and effectiveness of reporting of ADR’s from systematic 
studies across a broad range of morbidities including HIV positive patients. What 
impact this has made to the reporting of ADR’s is still unknown. But by far the 
Naranjo ADR probability scale represents the most robust and validated adverse 
events assessment tool currently in use both in clinical practice as well as research 
settings (71). Additionally, proven efficacy and safety in randomised controlled 
clinical trials have been employed as part of the benchmark for incorporation of 
various ART drugs into national and internationally sanctioned treatment guidelines 
(18). Therefore, the phenotype of drug related adverse effects reported from these 
studies and the populations they study do contribute significantly to the totality of the 
adverse events morbidity associated with these drugs. Nevertheless, post-marketing 
surveys (phase IV) captures other components of adverse effects morbidity not 
reported or limited by the relatively short observational period of systematic studies. 
I have explored this in Chapter three of this thesis with a descriptive analysis of the 
MHRA database.  
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Despite these efforts, the observation that industry funded RCT’s tended to report 
almost all spectrums of ADRs (mild, moderate or severe), in contrast to non-profit 
studies that have emphasized on reporting serious adverse events does suggests some 
outstanding lopsidedness in the reportage of overall ADR epidemiological burden 
(69).   
Amongst the various ART drug related clinical toxicity syndromes thus far 
described, TDF related kidney injury is increasingly becoming a subject of clinical 
concern over the past few years. In this thesis, I have examined the prevalence, 
pattern, as well as genetic, and non-genetic determinants of TDF induced kidney 
injury in these cohorts of patients.  
6.1.1   Tenofovir induced kidney tubular dysfunction (KTD)  
Despites its well-established efficacy and safety (144), recently TDF have been a 
subject of increasing concerns regarding its propensity to cause kidney related 
adverse effects (145). In a recent EUROSIDA report for example, a 10-year exposure 
to TDF was associated with about 16% risk of decline in eGFR (146). The magnitude 
of eGFR decline in this report was highest in patients on ATV/r regimen (22%), 
compared to other PI based regimen (8% and 11% for LPV/r and Indinavir 
respectively) (146).  Patients on ART regimen containing both PI/TDF had a faster 
rate of decline (41%) in kidney function in the study (146). Despite these reports, the 
exact clinical phenotype, diagnostic markers, and mechanism of TDF related kidney 
injury remains a matter of unresolved mechanistic and epidemiological debate. A 
number of recent reports have suggested kidney tubular dysfunction (KTD) and its 
extreme form (Fanconi syndrome) as the predominant clinical and laboratory 
phenotypes of TDF related kidney injury (144, 145). The reported prevalence of 
clinically significant TDF related kidney injury is variable, but it has been estimated 
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to range between 2-11% (147, 148, 149). The long-term effects of TDF on kidney 
function however still remain unknown. Analyses of the five and ten year Gilead 
follow-up studies (GS934, and GS903E respectively) have shown that long-term 
eGFR stabilises despite initial decline (202, 203, 204, 205).  
6.2.0   The Role of ABCC2 and ABCC10 genetic polymorphisms, and risk of 
kidney tubular dysfunction following exposure to TDF: A systematic review and 
Metanalysis 
Single nucleotide polymorphisms (SNPs) of genes encoding transport proteins 
involved in the bio-disposition of TDF have been examined in recent studies, 
especially their potential association with increasing risk of kidney injury in these 
cohorts of patients (107, 108, 110, 115). The discordant outcomes reported by these 
various studies meant that uncertainty remains as to the exact role of these SNP’s in 
the pathogenesis of TDF related kidney toxicity. Most notably are SNP of genes 
encoding transport proteins such as ABCC2 24CC (MRP2), and ABCC10 (MRP7) in 
HIV positive patients on ART. In this report, we have evaluated current evidence by 
carrying out a systematic review, and metanalysis of studies examining the role of 
ABCC2 (MRP2), ABCC4 (MRP4), ABCC10 (MRP7), and ABCB1 (p-glycoprotein) 
SNP’s and risk of TDF induced KTD in HIV positive patients on ART. This is with 
the view to establish if an association exist, as well as its magnitude and potential 
utility in triage of these cohorts of patients before commencement of treatment.   
We found significant association between possession of the ABCC10 SNP 
(rs9349256), and risk of TDF induced KTD in HIV positive patients on ART. This is 
consistent with the seminal report by Pushpakom et al (110) who first established 
MRP7 as a putative TDF transporter, and subsequently confirmed association 
between SNP’s of its gene (ABCC10, rs9349256, rs2125739) and risk of TDF 
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induced KTD. Conversely, we found no significant association between the multiply 
studied ABCC2 24CC genotype (rs717620, MRP2) and risk of KTD. This is hardly 
surprising, because as was exhaustively expounded in other sections of this thesis, 
MRP2 (encoded by ABCC2) have not been shown to be a putative TDF transporter. 
Additionally, whilst initial reports such Rodriquez-Novoa et al (107) have suggested 
its association with increased risk of KTD, subsequent reports (115) have failed to 
demonstrate any significant association. It is probable that the various modes of 
adjudication of kidney function (eGFR, diagnostic criteria for Fanconi syndrome 
etc.) adopted by the studies included in the review, as well as their small sample size 
may have accounted for the discrepancy of these reports.  
6.2.1   Strengths of the study 
This review represents the first attempt at comprehensive evaluation of current 
evidence of association between SNP’s of genes encoding TDF transport proteins 
and risk of kidney injury in HIV positive patients. Despite its relatively small size 
(borne out of small sample size of constituent studies), it has provided a signal 
potentially invaluable in the design of future prospective pharmacogenetic studies 
especially as it pertains to the role of the intronic ABCC10 (MRP7, rs9349256) SNP.  
6.2.2   Limitations 
A major imitation of this study is the relatively small size of its constituent studies. 
Additionally the lack of agreement in the definition of what constitutes kidney 
tubular dysfunction in the constituent studies may have confounded the true 
homogeneity/heterogeneity of our pooled data, and by implication reported 
association. Consequently, it is difficult to definitely establish causality between 
possessions of these SNP’s and risk of KTD following TDF exposure with certainty. 
Despite this however, it provides the first attempt at comprehensive assessment of 
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current evidence, which will be invaluable in the design of future prospective 
pharmacogenetic studies.  
6.2.3   Conclusion and future perspectives 
The intronic ABCC10 (MRP7, rs9349256) SNP was consistently associated with 
increased of TDF induced KTD in HIV positive patients on ART.   
6.3.0   The pattern and phenotype of TDF induced kidney injury 
Since the first reported association between TDF exposure and the risk of kidney 
injury, uncertainty remains as to its true pattern as well as clinical/laboratory 
phenotypes that define it (107, 144, 149). Without a thorough understanding of these 
two key variables (pattern of injury and laboratory/clinical phenotype), it becomes 
impossible to accurately identify patients at risk and therefore reduce further harm by 
opting for an alternative ART regimen and or ensuring more robust 
clinical/laboratory monitoring.  Most of the initial reports in this area derive from 
trial cohorts of HIV positive patients exposed to TDF (145, 146). How much of the 
hospital observational kidney toxicity phenotype mirrors “real-life” experience of 
TDF in these cohorts of patients outside of clinical trial environment remains a 
matter of epidemiological debate (144). This study represents the first attempt at 
exploration of an observational database (the MHRA yellow card records) to 
ascertain the pattern of kidney injury in HIV-positive persons exposed to TDF. Over 
a 9-year observational period, I identified about 106 patients who satisfied criteria for 
the definition of acute kidney injury (33%), Fanconi syndrome (17%), and kidney 
tubular dysfunction (50%). This was out of a total of 407 yellow cards reviewed of 
patients who developed suspected ADR on TDF and had yellow cards submitted to 
MHRA. The higher percentage of KTD representing the milder form of TDF related 
kidney injury in this study population is in agreement with what has thus far been 
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reported from previous studies (107, 108, 110). The median duration of TDF 
exposure was 316 (IQR 120,740) days, with those having the extreme kidney toxicity 
phenotype (Fanconi syndrome) having the highest duration of exposure to TDF of 
(419 days, IQR 246, 1000). However, the relationship between duration of TDF 
exposure, and the development of the most extreme phenotype of TDF induced KTD 
is still uncertain.   
I found a higher number of reported TDF related ADRs from 2005 to 2006, and then 
followed by a gradual decline thereafter. This perhaps reflects initial periods of 
increasing awareness of TDF related ADR’s, resulting in increased monitoring, and 
perhaps a probable subsequent clinical caution with the use of TDF. I could not 
accurately estimate the impact of protease inhibitor (PI) exposure on the pattern of 
TDF-related injury in this cohort because of missing data on PI exposure in the study 
population. About four patients out of the entire study cohort had data on PI 
exposure. All patients on boosted Atazanavir (n = 2) had KTD, whilst those on 
boosted Lopinavir and Indinavir had Fanconi syndrome and KTD respectively. 
Despite this relative paucity of PI-exposure data, association of all PI’s in this study 
cohort with varying degrees of KTD (including Fanconi syndrome) perhaps reflects 
and agrees with the totality of evidence thus far reported from most observational 
and clinical trial cohorts (154, 153, 171, 191). The role of PI exposure in the 
pathogenesis of TDF-related injury has continued to be a subject of intense 
mechanistic and therapeutic debate (144). In the recent analyses of the Swiss HIV 
study cohort database, contemporaneous administration of TDF with boosted 
Atazanavir or Lopinavir was associated with a greater initial rate of decline in e-GFR 
compared to TDF/EFV regimen (189). Additionally, Cao et al (190) recently 
reported a greater rate of decline in kidney function in a cohort of Chinese patients 
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on TDF+PI/r based ART regimen compared to those on non-TDF regimen at 48 
weeks. Amongst suggested mechanisms for the role of PIs in the TDF-related kidney 
injury includes but not limited to PI-mediated increase in plasma concentration of 
TDF (191). Patients classified as Fanconi syndrome had the highest frequency of 
hospitalization (55.6%) compared to other patient’s cohorts. As alluded to in earlier 
sections of this thesis, Fanconi syndrome represents the most extreme phenotype of 
TDF related kidney toxicity, and will probably explain its association with the 
highest morbidity seen in this cohort. Additionally, I also found complete restoration 
of kidney function in about 50% of this study cohort. This mirrors what has been 
reported by a number of systematic studies exploring TDF related kidney morbidity. 
I also found all reported deaths in this study cohort to be due other HIV related 
complications and not progressive kidney disease or TDF exposure.  
6.3.1   Strengths of the study  
This study represent the first attempt at interrogation of such a observational data 
scheme in order to address the uncertainty regarding the pattern of TDF related 
kidney injury. Having an observational cohort perspective to what has thus far been 
established from RCT’s will prove invaluable in the design of future prospective 
studies aimed at exploring other outstanding clinical/mechanistic themes in regards 
to TDF related kidney injury.  
6.3.2   Study limitations 
This study is limited by previously identified impediments encountered in the course 
of exploring such observational data schemes. Its descriptive design for example, as 
well as difficulties with accurately estimating the prevalence of TDF related kidney 
injury suggests caution in the application of this study outcomes and limits any 
ability to estimate true incidence of TDF-related kidney injury. Additionally, issues 
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of under reporting of yellow card records suggest caution in establishing definite 
causality between TDF exposure and risk of kidney injury in these cohorts of 
patients. Furthermore, been a developing field, the absence of a universally accepted 
validated definition of what constitutes tubular dysfunction in HIV-positive patients 
on TDF makes objective adjudication of the Yellow Card reports difficult. Despite 
this however, this study outcome fits within the framework and narrative of the 
phenotype of TDF related KTD thus far expounded by systematic studies.  
6.3.3   Future perspectives  
Whilst this study may have provided an epidemiological perspective of the pattern of 
this evolving morbidity, however in order to accurately characterise the exact pattern 
and phenotype of TDF induced KTD, there will be need for further studies designed 
to explore other observational databases with the view to compliment and support 
data from systematic studies.   
6.4.0   Association between ABCC2 and ABCC10 single nucleotide 
polymorphisms, and risk of kidney injury following Tenofovir Disoproxil 
Fumarate (TDF) exposure: A candidate gene study 
This study represents the first attempt at exploring the association between thresholds 
of novel kidney markers such retinol binding protein (corrected for urinary creatinine 
excretion [RBPCR >17μg/mmol]), and SNP’s encoding transport proteins involved 
in the bio-disposition of TDF (such as ABCC2, ABCC4, ABCC10, OAT1, and OAT3) 
in these cohorts of patients. I found possession of genotype CC at position 24 of the 
ABCC2 gene to confer protection against risk of KTD in HIV positive patients 
exposed to TDF. This study is the first report suggesting a protective role for 
possession of this SNP’s in HIV positive patients on TDF and therefore at risk of 
KTD. Previous reports have either reported increased risk of KTD with this SNP, or 
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have shown no effect depending on the method of adjudication of kidney function 
(107, 108, 109, 115). Most notably, studies utilising eGFR as marker of kidney 
dysfunction have shown no association between possession of the ABCC2 24CC 
genotype and risk of KTD in HIV positive patients on TDF-based ART regimen. 
This is probably expected given that tubular dysfunction rather than glomerular 
injury has been suggested as the underlying pathogenetic mechanism for TDF related 
kidney injury. The evident discordance in the outcomes of these studies (107, 108, 
110, 115, 116) may be due to a number of factors; firstly, differences in outcomes 
measures (e.g. eGFR, LMWP, urine PCR etc.) utilised to evaluate kidney function 
may have accounted for either under, or over reporting of kidney impairment. 
Certainly, from most reports, eGFR tends to under report early stages of TDF related 
kidney impairment (162). Secondly, all of the pharmacogenetic reports thus far 
exploring SNP’s of genes encoding TDF transport proteins and risk of KTD have 
been relatively small sample sized studies significantly underpowered to robustly 
report any definitive causality between possession of ABCC2 24CC genotype and 
risk of KTD. Additionally, I found no significant association between other evaluated 
SNP’s such as ABCC4, OAT1, and OAT3, and the risk of TDF induced KTD. 
6.4.1   Strengths of the study 
Despite its novelty, this study represent the first attempt at exploring the relationship 
between possession of ABCC2 24 CC genotype, and risk of KTD in HIV positive 
patients exposed to TDF (by utilising a RBPCR as a marker of kidney injury). What 
has hindered utility of previous surrogate markers such as the previously reported 
diagnostic criteria of KTD and Fanconi syndrome (107) is their impracticability as 
point of care assays. Conversely, LMWP (RBP, KIM-1, NGAL, etc.) are 
increasingly been shown to be potential markers of KTD supported by their 
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additional ease of point of care assay. Nonetheless, urine ACR/PCR and eGFR for 
now remains the standard laboratory makers of kidney dysfunction in HIV positive 
patients or ART until validation of these LMWP by future prospective studies  
6.4.2   Limitations of the study 
This study is limited partly by its relatively small sample size, which makes robust 
association of causality difficult. Secondly, it’s utility of a surrogate marker of 
kidney dysfunction (RBPCR) still undergoing evaluation as a point of care assay, and 
extraction of DNA from serum (rather than whole blood) suggests caution in the 
interpretation of these findings. Nevertheless, these findings are consistent with some 
of the earlier pharmacogenetic reports in this area and may not have been 
significantly confounded by these limitations.  
6.4.3   Future perspectives 
A large prospective pharmacogenetic study encompassing various ethnic populations 
and utilising currently validated markers of kidney dysfunction in these cohorts of 
patients is required to robustly and conclusively address the remaining uncertainty 
regarding the role of genetics in the pathogenesis of TDF induced KTD. Such study 
will be enhanced by incorporation of key pharmacogenetic questions proposed by 
Jorgenson et al (182) in its design to avoid the pit falls that has been the theme of 
previous pharmacogenetic reports in this area. 
6.5.0   Association between KIM-1/Creatinine and risk of kidney dysfunction 
following exposure to ART drugs 
The limitations of traditional markers of kidney injury such as eGFR and urine 
ACR/PCR in the diagnosis of ART-related kidney dysfunction are well established 
(162). This is more so with TDF induced kidney injury, which has been characterised 
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as tubular, rather than glomerular injury. This study has explored the correlation and 
probable diagnostic utility of KIM-1/Cr in HIV positive patients “on” and “off” 
various ART regimen. Previous studies in HIV population have explored relationship 
between thresholds of KIM-1, and kidney dysfunction/survival in pregnant women 
(201). Adopting a separate cross-sectional and prospective design, I explored the 
relationship (including potential diagnostic utility of this biomarker) in a cohort of 
HIV positive patients with varied morbidities and on various ART regimen. I found a 
higher baseline median (≥4.17ng/mg urinary KIM-1/Cr levels in HIV positive 
patients both “on” and “off” ART drugs compared to either non-HIV positive normal 
volunteers (0.39 ng/mg) (197), or those with acute kidney injury in the general 
population (0.57 ng/mg) (198). This may suggest a degree of sub-clinical kidney 
injury in this cohort of HIV positive patients with “normal” functioning kidneys 
(eGFR ≥60mls/min/1.73m2). It is still unclear why these cohorts of patients have a 
higher baseline KIM-1/Cr concentration. HIV/AIDS associated kidney morbidities 
including possibly HIV associated nephropathy (HIVAN) might be associated with 
up regulation of KIM-1 synthesis in kidney tubular cells with resultant increased 
excretion of KIM-1 independent of exogenous injury (including ART drugs). This is 
supported by data from mechanistic studies, which showed that tubular injury of 
diverse aetiologies results in up-regulation of this putative cell adhesion molecule 
(KIM-1) (163). In addition, previous reports have shown that both glomeruli, and 
distal convoluted kidney tubules were early target sites for the HIV virus (199), 
further supporting the role of direct effect of the virus in up regulating KIM-1 
expression. Whilst the exact role of the natural history of HIV/AIDS in KIM-1 
kinetics remains a matter of mechanistic debate, I hypothesised that it may (in 
common with other yet to be identified factors) account for its high baseline urinary 
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excretion in HIV positive patients either “on” or “off” ART drugs. Mechanistically, 
it is important to assess KIM-1 kinetics different from changes in eGFR as the latter 
has been suggested to report predominantly glomerular injury. Conversely, kidney 
tubular injury has been the hallmark of a number of ART drugs, most notably TDF. 
Additionally, I found a statistically significant correlation between urinary KIM-1/Cr 
with age, white Caucasian ethnicity, and urine PCR. Urine PCR is a well-established 
marker of kidney injury in both HIV positive patient cohorts as well as the general 
population. Its significant positive correlation with a threshold of KIM-1/Cr may 
suggest a probable diagnostic role for this biomarker in these cohorts of patients. I 
have already shown significant urinary levels of KIM-1/Cr in patients with normal 
eGFR. About 52% of this study population with “normal” kidney function (eGFR 
greater than 60ml/min/1.73m2) have KIM-1/Cr values higher the median threshold 
(reported by manufacturers or the general population). This will suggest a degree of 
subclinical kidney injury in patients with hitherto normal eGFR. I further assessed 
agreement between KIM-1/Cr, and a current diagnostic benchmark of TDF induced 
kidney injury (urine PCR >20mmol/L) by ROC analysis. Utilising urine 
PCR>20mg/mmol as a marker of kidney injury, I found KIM-1/Cr (ng/mg) having a 
higher AUC 0.67 compared to either serum creatinine (0.64), or eGFR (0.31) in 
diagnosing patients with kidney injury.  
6.5.1   Strength of the study 
This study is amongst the first to explore the utility of novel LMWP such as KIM-
1/Cr as potential surrogate markers of kidney dysfunction in a population of HIV 
positive patients on ART, whose pattern of kidney toxicity appears to be under 
diagnosed by other more established traditional markers of kidney dysfunction. This 
study established significant correlation between a novel marker of kidney 
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dysfunction (KIM-1/Cr) with other traditional markers of kidney injury such as urine 
PCR. 
6.5.2   Limitations of the study 
This study is limited by its relatively small sample size, and cross-sectional design. 
This meant that causality could not be established with certainty based on its 
findings. A further validation of these findings will be required by prospective 
studies adequately powered to explore these findings. I will therefore advise caution 
in interpretation and application of these findings. 
6.5.3   Future perspectives 
Whilst this study may have provided an epidemiological perspective of the pattern of 
this evolving morbidity, however in order to accurately characterise the exact pattern 
and phenotype of TDF induced KTD, there will be need for further studies designed 
to explore other observational databases with the view to compliment and support 
data from systematic studies.   
A large prospective pharmacogenetic study encompassing various ethnic populations 
and utilising currently validated markers of kidney dysfunction in these cohorts of 
patients is required to robustly and conclusively address the remaining uncertainty 
regarding the role of genetics in the pathogenesis of TDF induced KTD. Such study 
will be enhanced by incorporation of key pharmacogenetic questions proposed by 
Jorgenson et al (182) in its design to avoid the pit falls that has been the theme of 
previous pharmacogenetic reports in this area. For now, traditional markers of kidney 
function such as eGFR, urine PCR/ACR continue to serve as the point-of-care assays 
for the determination of kidney injury in all cohorts of HIV positive whether “on” or 
“off” ART drugs.  
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Additionally, adequately powered cross sectional and prospective studies are needed 
to robustly address both association, and agreement between novel kidney 
biomarkers such as KIM-1, and RBPCR with other traditional markers of kidney 
dysfunction. This is important as LMWP (such as KIM-1 and RBPCR) are 
increasingly evolving as early diagnostic markers of kidney injury in the general 
population. Their utility in ART drug related kidney injury cohort would be 
invaluable to the early detection and management of this rising morbidity. Having 
robust data attesting to their agreement with traditional markers (such as eGFR and 
urine PCR) will no doubt enhance their reliability, and acceptance as point of care 
assays for monitoring of HIV positive patients on ART drugs.  
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APPENDICES 
APPENDIX A: Study Collaborators 
Principal investigator’s 
 
Hospital/University site 
Dr. Frank Post 
 
King’s College Hospital London 
Collaborated on TDF candidate SNP study (Chapter 
Four) 
Ms. Lucy Campbell  King’s College Hospital London 
 Collaborated on TDF candidate SNP study (Chapter 
Four) 
Professor Joseph V Boventre Renal Division, Department of Medicine, Brigham and 
Women’s Hospital, Harvard Medical 
School, Boston, Massachusetts, USA 
Collaborated on the KIM-1 association study 
(Chapter Five) 
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APPENDIX B: Case Record Form 
 
 Defining the prevalence and pattern of kidney injury in HIV-infected patients 
exposed to antiretroviral therapy (ART) drugs 
 
Case Record Form: Cross sectional study/Prospective study 
 
Date of 
assessment 
Subject 
initials 
Subject 
code 
Date of Birth Study number 
 
 
    
 
Patient Information leaflet given to subject   Yes  No 
  
Consent Form signed      Yes  No 
Eligibility          
                                                                                                                  Yes No
        
Age >18 years           
Hiv-positive patients ”on” or ”off” Tenofovir      
Any CD4 count or viral load         
Able to give consent          
          
Patient History……………………………………………… 
Gender  Male        Female  
Ethnic group White  Black  Asian  Other  
Past Medical History__________________ Date __ /__ /__ 
Weight _________ kg   Date __ / __ / __ 
Height _________ m    Date __ / __ / __ 
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Anti-retroviral Drug History        
Please list current and all previous HIV drugs in regimens  
Regimen HIV drugs in Regimen  
(Dose not required) 
 
 
Start date Stop date Date/time 
last ARV 
taken 
1     
2     
3     
4     
5     
6     
 
Is patient currently taking any medication other than anti-retroviral therapy?  
 No  Yes   
If YES please specify 
Drug Date started 
  
  
  
 
Medical History    Current eGFR (date): 
Urine dipstick     Urine PCR (date): 
Urine ACR (date): 
Past medical history: Hypertension/ Diabetes Mellitus / Smoker 
Co-infection: Hepatitis B/ Hepatitis C 
When CKD 1st diagnosed: 
Relationship with ARVS: Definite              Probable      Possible           Unlikely 
If not related to ARVs, give likely cause: 
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APPENDIX C: DNA concentration 
Extracted DNA concentration as estimated by spectrophotometry (NanoDrop®) 
 
Sample ID DNA Concentration (ng/μl) 
GS18001 47.8 
GS18002 8.6 
GS18003 4.6 
GS18004 6.2 
GS18005 8.8 
GS18006 4.8 
GS18007 7.9 
GS18008 9.1 
GS18009 7.4 
GS18010 4.6 
GS18011 6.6 
GS18012 8 
GS18013 3.9 
GS18014 3.2 
GS18015 4.8 
GS18016 3.9 
GS18017 2.1 
GS18018 4 
GS18019 5.7 
GS18020 10.9 
GS18021 7.6 
GS18022 6.5 
GS18023 4.7 
GS18024 18.1 
GS18025 9.8 
GS18026 6.9 
GS18027 13.1 
GS18028 13.1 
GS18029 12.1 
GS18030 16.3 
GS18031 8 
GS18032 7.7 
GS18033 4.2 
GS18034 5.4 
GS18035 5.2 
GS18036 4.5 
GS18037 5.1 
GS18038 4.2 
GS18039 6.1 
GS18040 6.5 
GS18041 7.4 
GS18042 5.6 
GS18043 2.7 
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GS18044 5.4 
GS18045 5 
GS18046 8.6 
GS18047 4.6 
GS18048 10.1 
GS18049 6.8 
GS18050 7.3 
GS18051 4 
GS18052 4.4 
GS18053 5.9 
GS18054 4.6 
GS18055 5.9 
GS18056 6.6 
GS18057 5.6 
GS18058 6 
GS18059 7.6 
GS18060 7.3 
GS18061 4 
GS18062 6.5 
GS18063 3.8 
GS18064 7.2 
GS18065 5.6 
GS18066 8.3 
GS18067 7.7 
GS18068 4.8 
GS18069 6 
GS18070 6.2 
GS18071 11.4 
GS18072 1.2 
GS18073 5.9 
GS18074 5.5 
GS18075 12.1 
GS18076 7.4 
GS18077 66.4 
GS18078 3.1 
GS18079 6.9 
GS18080 7.2 
GS18081 4.1 
GS18082 1.8 
GS18083 6.5 
GS18084 18.2 
GS18085 1.3 
GS18086 18 
GS18087 1.2 
GS18088 1.7 
GS18089 19.9 
GS18090 0.8 
GS18003 47.8 
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GS18004 8.6 
GS18005 4.6 
GS18006 6.2 
GS18007 8.8 
GS18008 4.8 
GS18009 7.9 
GS18010 9.1 
GS18011 7.4 
GS18012 4.6 
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Appendix D 
PCR raw data including amplifications plots and reaction plate samples  
 
 
ABCC2_24_CC_GS18057_GS18112
Well Group X Content Y Content
B2 Mutant
B3 Mutant
B4 Mutant
B5 Heterozygous
B6 Mutant
B7 Mutant
B8 Mutant
B9 Mutant
B10 Heterozygous
B11 Mutant
C2 Mutant
C3 Mutant
C4 Mutant
C5 Heterozygous
C6 Mutant
C7 Mutant
C8 Mutant
C9 Mutant
C10 Mutant
C11 Mutant
D2 Mutant
D3 Heterozygous
D4 Mutant
D5 Mutant
D6 Heterozygous
D7 Mutant
D8 Heterozygous
D9 Mutant
D10 Mutant
D11 Heterozygous
E2 Blank
E3 Mutant
E4 Mutant
E5 Heterozygous
E6 Mutant
E7 Mutant
E8 Mutant
E9 Mutant
E10 Mutant
E11 Wild
F2 Mutant
F3 Mutant
F4 Heterozygous
F5 Mutant
F6 Mutant
F7 Mutant
F8 Mutant
F9 Mutant
F10 Mutant
F11 Mutant
G2 Mutant
G3 Mutant
G4 Mutant
G5 Mutant
G6 Heterozygous
G7 Heterozygous
G9 Blank
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ABCC4_A3463G (rs1751034)
Well Group X Content Y Content
B2 Wild
B3 Wild
B4 Heterozygous
B5 Wild
B6 Heterozygous
B7 Wild
B8 Wild
B9 Heterozygous
B10 Mutant
B11 Heterozygous
C2 Wild
C3 Wild
C4 Mutant
C5 Wild
C6 Wild
C7 Wild
C8 Wild
C9 Heterozygous
C10 Wild
C11 Wild
D2 Wild
D3 Heterozygous
D4 Wild
D5 Mutant
D6 Wild
D7 Heterozygous
D8 Wild
D9 Heterozygous
D10 Heterozygous
D11 Heterozygous
E2 Heterozygous
E3 Heterozygous
E4 Heterozygous
E5 Heterozygous
E6 Wild
E7 Wild
E8 Wild
E9 Heterozygous
E10 Heterozygous
E11 Heterozygous
F2 Wild
F3 Heterozygous
F4 Wild
F5 Wild
F6 Wild
F7 Mutant
F8 Heterozygous
F9 Wild
F10 Wild
F11 Heterozygous
G2 Wild
G3 Wild
G4 Heterozygous
G5 Wild
G6 Heterozygous
G7 Wild
G9 Blank
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ABCC4_669_C_T (rs899494)
Well Group X Content
B2 Heterozygous
B3 Wild
B4 Heterozygous
B5 Wild
B6 Wild
B7 Wild
B8 Wild
B9 Wild
B10 Heterozygous
B11 Wild
C2 Wild
C3 Wild
C4 Heterozygous
C5 Wild
C6 Heterozygous
C7 Blank
C8 Wild
C9 Wild
C10 Heterozygous
C11 Heterozygous
D2 Wild
D3 Wild
D4 Heterozygous
D5 Wild
D6 Wild
D7 Heterozygous
D8 Wild
D9 Heterozygous
D10 Heterozygous
D11 Heterozygous
E2 Wild
E3 Wild
E4 Heterozygous
E5 Wild
E6 Wild
E7 Wild
E8 Heterozygous
E9 Wild
E10 Wild
E11 Wild
F2 Wild
F3 Mutant
F4 Heterozygous
F5 Heterozygous
F6 Heterozygous
F7 Wild
F8 Wild
F9 Heterozygous
F10 Heterozygous
F11 Wild
G2 Wild
G3 Heterozygous
G4 Wild
G5 Heterozygous
G6 Heterozygous
G7 Wild
G9 Blank
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ABCC10_(rs9349256) _GS18001_GS18056
Ancestral Allele   = GG FAM = G
Mutant                  = AA VIC   = A
Heterozygous      = AG
Well Group X ContentY Content
B2 Mutant
B3 Heterozygous
B4 Heterozygous
B5 Mutant
B6 Blank
B7 Mutant
B8 Wild
B9 Mutant
B10 Mutant
B11 Mutant
C2 Mutant
C3 Mutant
C4 Mutant
C5 Mutant
C6 Heterozygous
C7 Mutant
C8 Mutant
C9 Wild
C10 Mutant
C11 Wild
D2 Wild
D3 Heterozygous
D4 Mutant
D5 Mutant
D6 Mutant
D7 Heterozygous
D8 Mutant
D9 Heterozygous
D10 Heterozygous
D11 Heterozygous
E2 Mutant
E3 Mutant
E4 Mutant
E5 Wild
E6 Mutant
E7 Mutant
E8 Mutant
E9 Mutant
E10 Blank
E11 Mutant
F2 Mutant
F3 Mutant
F4 Wild
F5 Mutant
F6 Mutant
F7 Mutant
F8 Heterozygous
F9 Mutant
F10 Mutant
F11 Heterozygous
G2 Mutant
G3 Heterozygous
G4 Mutant
G5 Heterozygous
G6 Mutant
G7 Mutant
G9 Blank
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SLC22A6 453A (G>A)
Well Group X Content Y Content
B2 Heterozygous
B3 Heterozygous
B4 Wild
B5 Wild
B6 Wild
B7 Wild
B8 Wild
B9 Heterozygous
B10 Heterozygous
B11 Wild
C2 Wild
C3 Heterozygous
C4 Heterozygous
C5 Wild
C6 Wild
C7 Wild
C8 Wild
C9 Wild
C10 Heterozygous
C11 Wild
D2 Wild
D3 Heterozygous
D4 Heterozygous
D5 Wild
D6 Wild
D7 Wild
D8 Heterozygous
D9 Wild
D10 Wild
D11 Wild
E2 Wild
E3 Wild
E4 Wild
E5 Wild
E6 Wild
E7 Heterozygous
E8 Wild
E9 Wild
E10 Wild
E11 Wild
F2 Wild
F3 Wild
F4 Wild
F5 Heterozygous
F6 Heterozygous
F7 Wild
F8 Heterozygous
F9 Heterozygous
F10 Wild
F11 Wild
G2 Wild
G3 Wild
G4 Wild
G5 Heterozygous
G6 Wild
G7 Wild
G9 Blank
